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Conjugation of targeting, imaging and drug molecules to 
nanoparticles has been a developing area of interest over the last 10-15 
years.  Although great strides have been made, characterization and 
activity of functionalized nanoparticles is still incomplete.  More work 
needs to be done to allow generalized predictions to be made about the 
impact of size, amount loading and the best synthetic approaches to utilize 
nanoparticles to their fullest potential.   
Imaging agents such as fluorophors and chelated metals have 
been attached to the surface of dendrimers and studied as profusion or 
targeted imaging agents.  One important target, the translocator protein 
(TSPO, formerly named peripheral benzodiazepine or PBR), has not been 
targeted with a nanoparticle.  The translocator protein is a mitochondrial 
membrane protein that spans the lipid bi-layer and mediates cholesterol 
transport across the mitochondrial membrane.  Two cell lines that have 
high expression of TSPO are MDA-MB-231 human breast cancer and C6 
rat glioma cell.  The first portion of this dissertation describes the 
synthesis, characterization and imaging capabilities of a TSPO targeted 
dendrimer with fluorescence, MRI and EM capabilities. 
Matrix metalloproteinases (MMPs) are another target for 
substantiating the role of nanoparticles in biology.  MMPs are a class of 
zinc dependant enzymes that have been found to degrade the extra 
cellular matrix.  Several MMPs have been discovered and studied, but 
MMPs 2, 7 and 9 are most interesting for their high expression associated 
with the proliferation in certain types of tumor cells1-2.  Although 
pharmacological inhibitors have been unsuccessful in treating MMP 
associated cancers, other approaches utilizing the enzymes have been 
successful.  For example, small peptide sequences that are selectively 
cleaved by a specific MMP(s) have been developed and used in 
molecularly activated fluorescence probes and prodrug.  The second 
portion of this dissertation describes the incorporation of dendrons to 
develop MMP-9 activated delivery of doxorubicin or paclitaxel to cancer 
cells.    
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1 
CHAPTER I 
 
 
 
BACKGROUND AND INTRODUCTION 
 
 
 
 
1.1 Dissertation Overview 
Nanoparticles that target, image and deliver therapeutics to disease 
through non-toxic and non-immunogenic processes have been a major goal of 
interdisciplinary research in the last 10-15 years.  The exponential development 
of imaging methods and instrumentation, nanoparticles and discovery of 
molecular targets has opened numerous options for improving diagnostic 
imaging, drug delivery and efficacy monitoring.  One area lagging behind in the 
quest for ideal agents in imaging and therapeutic efficacy quantification is the 
development of “smart” molecules designed for specific diseases and targets.  
Although great strides have been made in creating new nanoparticles, their 
functionalization and subsequent chemical and biological characterization 
remains a challenge.  Determining which combination(s) of targeting modalities, 
imaging agents and therapeutics is most effective is another factor that must be 
addressed when developing smart agents.  Also, more work needs to be done to 
allow generalized predictions to be made about the impact of size, loading 
amount and the best synthetic approaches so that nanoparticles can be utilized 
to their fullest potential.  In the work I present for my dissertation, both imaging 
and therapeutic applications of dendrimeric structures were studied.  First, as 
shown in Chapter 1, I developed a TSPO targeted dual-modality imaging agent 
2 
from a PAMAM dendrimer backbone.  Second (Chapter 2), with the knowledge 
about the synthesis and characterization of dendrimeric scaffolds learned from 
the PAMAM project, I designed a new modular system of dendrimer based 
multifunctional nanoparticles and developed the therapeutic piece of that system, 
which incorporated two different drugs and two different peptides.  Finally 
(Chapters 3, 4 & 5) the efficacy of these systems were evaluated in vitro 
(Chapters 3, 4, & 5) and finally the results are discussed based on their 
contribution to the overall modular system and their future use in this project 
(Chapter 6).   
 
 
1.2 Molecular Imaging (MI) 
Molecular Imaging (MI) is the process of detecting and studying specific 
molecules (genes, proteins, etc.) in vivo through the use of molecular probes, 
detection technologies and/or imaging strategies 3-5.  MI is used in magnetic 
resonance (MR), optical imaging, X-ray, ultrasound and with radionuclides to 
detect and study disease 3-4.  Each of these techniques has advantages and 
disadvantages as highlighted in Table 1.1.  Expansion of the currently available 
imaging agents (both dendrimeric and non-dendrimeric) is essential in further 
detecting disease, understanding biology and treating disease.  MI is in its 
infancy as a clinical tool with fluorodeoxy glucose positron emission tomography 
(FDG PET) being widely practiced, but has experienced an exponential growth 
as a research tool and has the potential to transform medicine.  Yet for MI to be 
used in personalized medicine improvements are needed to the chemistry of the 
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Table 1.1: Summary of various imaging techniques available.   
Imaging Technique 
Portion of EM 
Radiation 
Spectrum 
Used in 
Image 
Spatial 
Resolution Depth
Temporal 
Resolution Sensitivity Cost Advantages Disadvantages
Positron Emission 
Tomography (PET) γ-rays 1 - 2 mm
no 
limit
10 sec to 
minutes 
10-11 to  
10-12 
mole/L 
$$$$
High sensitivity, 
unlimited depth, 
isotopes 
substitute 
naturally 
occuring atoms, 
quantitative 
translational 
research 
Cyclotron 
needed, 
nontrivial 
chemistry 
relatively low 
spatial 
resolution, 
ionizing 
radiation, 
expensive 
Single Photon 
Emission Computed 
Tomography 
(SPECT) 
γ-rays 1 - 2 mm no limit minutes 
10-10 to  
10-11 
mole/L 
$$$ 
Many probes 
available, 
multiple reporter 
imaging, 
adaptable to 
clinic 
Relatively low 
spatial 
resolution, 
ionizing 
radiation, 
expensive 
Magnetic 
Resonance Imaging 
(MRI) 
Radiowaves 10 - 100 μm 
no 
limit
minutes to 
hours 
10-3 to   
10-5 
mole/L 
$$$$
Highest spatial 
resolution, 
combines 
morphological 
and functional 
imaging 
Relatively low 
sensitivity, 
long scan and 
post-
processing 
time, may need 
mass quantity 
of probe 
Optical 
Bioluminescence Visible light 3 - 5 mm
1 - 2 
cm 
seconds to 
minutes 
10-15 to  
10-17 
mole/L 
$$ 
Highest 
sensitivity, 
quick, easy, low-
cost, relatively 
high-throughput, 
lack of ionizing 
radiation 
Low spatial 
resolution, 
relatively 
surface-
weighted, 
limited 
translational 
research, 
limited depth 
Optical 
Fluorescence 
Imaging 
Visible light 
or near 
infrared 
2 - 3 mm < 1 cm 
seconds to 
minutes 
10-9 to   
10-12 
mole/L 
$ - $$
High sensitivity, 
quick, easy, low-
cost, multiple 
reporter 
imaging, lack of 
radiation, 
relatively high-
throughput, real-
time monitoring 
Relatively low 
spatial 
resolution, 
surface-
weighted, 
limited depth 
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agents to be uses for MI and targeted intervention. One avenue to improving MI 
and molecularly targeted therapy is through the use of dendrimeric scaffolds.  
However, most MI studies performed with dendrimers have utilized commercially 
available chemistries such as PAMAM™ and DAB™ (PPI) 6-8 rather than more 
unique structures with controllable functionalities.    
Dendrimers have been most often been used in MI as MRI contrast 
agents.  Based on the same principles as nuclear magnetic resonance (NMR) 
spectroscopy, MRI measures the relaxation rate of the hydrogen nuclei of water 
to realign with an applied magnetic field following a radiofrequency pulse.  Two 
types of signal can be observed: T1 (longitudinal relaxation, return of the net 
magnetization to its maximum length in the direction of the magnetic field) and T2 
(spin-spin relaxation, occurs when the spins in the high and low energy state 
exchange energy but do not loose energy to the surrounding lattice) relaxation.  
Signal from T1 relaxation corresponds to the energy released as the water 
molecules realign with the magnetic field; while, T2 relaxation relates to the 
precession of the spin vector about the plane perpendicular to the ground state 
and is affected by the mobility of the water molecule (protons).  MR signals are 
obtained from the differences in relaxation of water molecules that are rapidly 
exchanging with the inner and outer sphere orbitals of an inorganic molecule or 
atom.  Profusion agents used in development of better MI techniques and 
instrumentation, such as Gd chelated DOTA (1,4,7,10-Tetraazacyclododecane-
1,4,7,10-tetraacetic acid) and DTPA (Diethylenetriamine- N,N,N',N',N"-
pentaacetic acid, N,N-Bis(2-(bis-(carboxymethyl)amino)ethyl)-glycine pentetic 
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acid) increase MR contrast when chelating a paramagnetic ion such as Gd3+, 
which changes the relaxation time of associated water molecules due to the 
coordination of the water molecule with the gadolinium ion.  Contrast agents with 
multiple paramagnetic particles increase the differences in relaxation times 
between water molecules which are exchanging coordination with a metal 
(typically gadolinium) and those which are not.  Since macromolecules rotate 
slower than small molecules, the rate of exchange is slower in larger molecules, 
producing longer T2 relaxations.  The most commonly studied dendrimer MR 
agents are PAMAM™ dendrimers surface functionalized with Gd-DOTA or Gd-
DTPA 9. 
Optical Imaging techniques using fluorescence or bioluminescence have 
been reported 3-5, 10 for MI.  Molecules that absorb and emit light in the near 
infrared (NIR) range of the spectrum (650-900 nm) are ideal for biological 
applications because in this region of the electromagnetic spectrum, tissue 
relatively transparent with low light scatter and absorption by water and 
hemoglobin.  Numerous small organic dyes have been developed have desirable 
optical characteristics, with some being commercially available.  Among these 
are indocyaninie green (ICG), IRDye800CW (LI-Cor), and Alexaflur680 
(Molecular Probes).  Several of these dyes have been conjugated to molecular 
targets and used to study disease both in vitro and in vivo10.   
Multivalent NIR fluorescence is difficult to accomplish by attaching multiple 
organic dyes to a backbone as with MRI due to self-quenching of the fluorophors.  
This quenching, caused by small stoke shifts (eg. significant overlap between the 
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absorption and emission spectra), has been utilized to make fluorescent switches 
11-13. In reported switches, several dyes are attached to a polymer backbone via 
a peptide linker which diminishes the fluorescence signal due to a high local 
concentration.  After the peptide is proteolytically cleaved the dyes are released, 
activating fluorescence 12-14.  Forester resonance energy transfer (FRET) is 
another method used to make biochemical switches where quenching dye pairs 
are attached in close proximity (20-60Α) such that one is cleaved through a 
biological process (i.e. proteolytically, or through another biological process) 
inducing fluorescence 15-16.  A biochemical fluorescent switch can be made into a 
targeted imaging agent by making the cleavage process specific for a single 
biological event.  This approach provides the advantage of targeting (and thus 
being able to study) a specific biological molecule or event. 
Development of clinically relevant agents to image disease or biological 
processes is essential in MI.  These chemistries generally contain two 
functionalities or components: a targeting moiety (ligand, protein, antibody, etc.) 
to provide selectivity and a signaling modality (fluorophor, MR agent, radioligand, 
etc.) to produce a signal 17-20.  Recently, multimeric imaging agents, in which 
several imaging and/or targeting agents are covalently attached to a biologically 
compatible backbone, have been developed 21-24.    
Increasing the signal to background for detecting diseased tissues can be 
accomplished by numerous strategies so that the diseased tissues can be easily 
detected.  Targeting can be accomplished with a molecule which will bind a 
receptor (small organic ligand, protein, antibody, etc.) or through the use of a 
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protease as in the fluorescent switch described above.  Several proteins and 
enzymes have been identified as good targets for both therapeutics and imaging 
agents; including: vascular endothelial growth factor (VEGF), matrix 
metalloproteinases (MMP), translocator protein (TSPO), δ2-dopamine, and 
somatostatin-23.  These proteins and enzymes are typically overexpressed in 
diseased tissue (compared to normal), so in theory when these agents are 
delivered they target or label diseased cells with enhanced selectively.  The 
Bornhop group has developed a number of MI agent that target TSPO 25-30.   
Targeting can be accomplished with a molecule which will bind a receptor 
(small organic ligand, protein, antibody, etc.) or through the use of a protease as 
in the fluorescent switch described above.  Several receptors have been 
identified as good targets for both therapeutics and imaging agents.  Most of the 
receptors are up-regulated in diseased tissue compared to normal tissue.   
 
1.3 Translocator Protein (TSPO) 
TSPO is a mitochondrial membrane protein that spans the lipid bi-layer 
and mediates cholesterol transport across the mitochondrial membrane (Figure 
1.1). Expression of TSPO is important in processes such as steroidogenesis and 
apoptosis.  Although TSPO is ubiquitous, it is expressed more in steroid-
producing cells such as testis, ovarian, placenta and brain 31-32.  TSPO has been 
shown to be a good target for molecular imaging because it has been found to be 
over expressed in diseased cells and there are several small molecules known to 
bind the protein (Figure 1.2).  The 11C, 3H and 18F analogs of several TSPO 
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binding ligands have previously been used in PET for in vivo imaging and to 
study TSPO activity 33-35.  Although these ligands are powerful imaging  
 
 
 
 
 
agents, they are limited by complex and expensive synthesis, short half lives and 
low resolution.  Figure 1.2 displays several of the known, high affinity TSPO 
ligands: Alpidem, Ro5-4864, PK11195, FGIN-1, DAA1106, DAA1097 and 
SSR180575.  Although PET analogs have been made of all these compounds, 
there are few examples of conjugating these ligands to non-radioactive imaging 
agents.  Conjugation of these ligands to imaging modalities requires additional 
chemistry which can lower the binding affinity for TSPO.  A derivative of 
PK11195 has been synthesized to provide a conjugable analog, ClPhIQ (Figure 
1.3).  In the process of synthesizing the amine terminated molecule with a six 
1
2
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Figure 1.1.  TSPO’s structure and location in the mitochondrial membrane. 
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carbon linker, another conjugable form of PK11195 was produced, the carboxylic 
acid derivative (ClPhIQ Acid) 36-37.  
The development of ClPhIQ (ostensibly a conjugable form of a TSPO ligand) has 
facilitated the construction and evaluation of many new targeted imaging agents 
(ClPhIQ-molecular imaging agent). For example by appending organic 
fluorophors, lanthanide chelates both optical and MR imaging has been shown to 
be possible and by using a copper chelate for PET becomes an imaging option 
(Figure 1.3) 36.  Also, ClPhIQ has been attached to derivatives of the well known  
 
 
 
 
 
metal chelate 1,4,7,10-tetraazacyclododecane (cyclen) which can lead to a 
unique optical agent, MR or even a PET imaging agents.  The fluorescence 
analog used for optical imaging synthesized in the Bornhop laboratory contains 
N
N
Cl
Cl
O
N
Alpidem
N
N
O
Cl
Cl
Ro5-4864
N
N
O
Cl
PK11195
H
N
F
N
O
FGIN-1
F N
O
O
O
O
DAA1106
OCl
N
O
O
DAA1197
N
N
N
Cl
O
N
O
SSR180575  
 
Figure 1.2.  High affinity TSPO ligands. 
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an antenna for light harvesting and two phosphonate esters for metal chelation38.  
Europium was then chelated to the macrocycle giving the desired compound. 
The cyclen derivative DO3A was also used to chelate Gd3+ (for MRI) and 64Cu 
(for PET). Preliminary in vitro and in vivo experiments have shown that these MI 
agents target disease26, 39-40.  Although the monomeric agents are extremely 
useful and have shown great utility, only one imaging agent can be attached to a 
single TSPO ligand, thus limiting limited because they contain a single imaging 
agent and a single targeting ligand.  
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Figure 1.3.  Structures of select TSPO targeted imaging agents. 
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While bi-functional agents described above are valuable, the ability to 
couple multiple ligands together could afford large increases in binding 
(improving targeting); incorporation of multiple imaging agents and can lead to 
increased signal.  The potential for multi-modal imaging or monitoring the 
delivery of therapeutics can not be realized with traditional targeted imaging 
agents, but can be with nanoparticles.   
 
1.4 Nanoparticals 
 Nanoparticle development has exploded in the last couple of decades.  
With nearly as many different nanoparticle structures as there are uses.  A few of  
 
 
 
 
 
the most commonly studied nanoparticles are polymers, micelles, dendrimers, 
viruses, DNA/RNA, lipids, drug nanocrystals, ceramic-based, albumin, 
nanoemulsions, nanogels, metal oxides, proteins, liposomes, quantum dots, gold 
nanoparticles, carbon nanotubes, nanowires, as well as various hybrid systems 
such as metal cored dendrimers.  Some of these systems are graphically 
Polymers Micelles DNA/RNA Dendrimers LipidsViruses  
 
Figure 1.4 Representaions of select nanoparticle structures. 
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represented in Figure 1.4.  Each of these systems has a variety of different 
chemical structures which have strengths and weaknesses as shown in Table 
1.241-46.      
 Polymers offer the advantages of being easily synthesized, water-soluble, 
nontoxic, biodegradable, conjugable and can be in surface modified (i.e. 
pegylated).  Furthermore, they can accumulate and be retained in tumor tissue 
(EPR effect).  However, since some polymer structures are easily degraded in 
vivo, they can produce undesirable metabolites, do not easily encapsulate 
molecules and have undefined architecture in solution42-43, 47.  Micells are 
suitable carriers for water-insoluble drugs, biocompatible, self-assembling and 
biodegradable; however, have limited stability, may require surfactant 
concentrations of 20% or higher, and can be immunogenic with growing diversity 
in amino acids 42-43, 47.  Dendrimers can be tuned for improved solubility and 
biodristrubution, contain high structural and chemical homogeneity, are easily 
functionalized, can have high ligand density, controlled degradation and 
multifunctionality.  If not careful a positive charge on the dendrimer surface may 
lead to toxicity and immunogenicity42-43, 47.  As a final example of strengths and 
weaknesses in nanoparticles, liposomes are amphiphilic, biocompatible, easily 
modified and have targeting potential, but the preparation steps have to be 
carefully controlled in order to achieve reproducible properties such as size and 
entrapment efficiency42-43, 47.  
The major two uses of nanoparticles in biotechnology are imaging and 
therapeutic delivery.  Some systems are simple and contain multiple copies of a  
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Table 1.2 Characteristics of some Nanoparticles for Imaging and Therapy 
Nanoparticle Advantages Disadvantages  
Liposomes 1) Amphiphilic  
2) Biocompatible 
3) Easily modified 
4) Targeting Potential 
1) Careful synthetic 
control required for  
reproducibility 
Polymers 1 ) Water-soluble 
2) nontoxic 
3) Biodegradable 
 
 
1) May produce 
undesirable metabolites 
Micelles 1) Carries water-insoluble 
drugs 
2) Biocompatible 
3) Self-assembling 
4) Biodegradable 
 
 
1) Limited stability  
2) Possible toxic 
monomers 
3) Possible immune 
response 
4) May produce 
undesirable metabolites 
5) May require 20% 
surfactant  
Dendrimers 1) Biodistribution 
can be tuned 
2) High structural 
homogeneity 
3) Easily functionalized 
4) High ligand density 
5) Controlled degradation 
6) Multifunctional 
1) Positive charge may be 
toxic 
2) Immunogenicity 
Viral 
Nanoparticles 
1) Bioconjugable 
2) Multivalent 
3) Targeted 
4) Multifunctional 
5) Defined geometry  
6) Uniform 
 
1) Genetic Alteration 
2) May require additional 
regulatory oversight 
3) Liposomes and 
Dendrimers may be better 
Carbon 
Nanotubes 
1) Water-soluble 
2) Biocompatible through 
chemical modification 
(organic functionalization) 
3) Multifunctional 
1) Solublility issues 
2) Toxicity problems 
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single imaging or drug molecule while other nanoparticles are more complex.  
Nanoparticles have properties optimal for incorporating multiple signatures or 
functions by the incorporation of multiple imaging modalities, drugs, targeting 
molecules, solubilizing molecules, etc. into a single particle.  To date very few  
examples of more than two modalities have been reported, however the field is 
rapidly moving in this direction43, 46.   
 Nanoparticles have been applied to every modality of molecular imaging 
including: light microscopy, optical microscopy, photoacoustic imaging, X-ray, 
computed tomography X-ray, PET, SPECT, and MRI48-49.  MRI is currently one of 
the most benefitted modalities from nanoparticles.  Due to its low sensitivity, the 
molecular structures of nanoparticles can increase signal in the MRI to near PET 
or SPECT resolution.  This is accomplished with additional Gd3+ ions as well as 
through altering the T1 and T2 relaxations time due to the increased size (and 
thus slower rotation) of the nanoparticle48.  Other examples of nanoparticles for 
imaging include hybrid nanoparticles such as quantum dots with PEG polymers 
attached to the surface.  These QD-PEG hybrids have been conjugated with 18F 
labeled RGD peptides for improved PET imaging and targeting ability as well as 
having a fluorescence signal49.   
 Nanoparticle aided therapeutic delivery has been extensively studied with 
agents being used daily in the clinic 50.  Nanocarrier systems offer the advantage 
of fewer doses, improved delivery by protecting metabolically fragile molecules, 
increased drug efficacy and shorted patient recovery time51-53.  Patient comfort is 
also increased with nanoparticle delivery systems due to their ability to delivery 
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drugs to the desired site, leaving healthy tissues unaffected and reducing or 
eliminating off target (systemic) toxicity54.  One use of nanoparticles in drug 
delivery is the development of smart polymers.  These polymers are designed to 
degrade in acidic conditions, delivering their therapeutic load to specific cells or 
parts of the cell.    For example, Murphy et. al. reported poly(acrylic) polymers 
that disrupt red blood cell (RBC) membranes and distribute their drug specifically 
into the cytosol46, 55.    
 
1.5 Prodrugs 
Drug therapy has long been used as one of the major methods for 
treatment of disease.  The diagnosis of a new disease leads rapidly to the search 
for therapeutic treatments that cure, improve the quality of life or lengthen the life 
(for life threatening diseases) for patients with the disease.  Classic drugs suffer 
from many shortcomings including: high toxicity, instability, inefficient solubility, 
undesirable methods of introduction, poor pharmacodynamics, non-specificity 
and bad smell and taste56-58.  Drug research involves more than drug discovery, 
but also researching 1) methods to discover drugs quicker (i.e. high throughput 
screening), 2) properties that improve drug absorption, distribution, metabolism 
and excretion (ADME) and 3) reducing systemic toxicity and improving 
therapeutic efficacy56,58.  One method for improving the ADME properties, reduce 
systemic toxicity and improve efficacy of therapeutic agents is through the 
development of prodrugs.  Prodrugs are inactive derivatives of the parent drug 
molecule which becomes activated either by enzymes or under spontaneous 
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conditions.  Prodrugs incorporate pieces that are designed to improve delivery of 
a drug to the active site by manipulating the physiochemical properties of the 
system in such a way that the lipophilicity, permeability, stability and/or tissue 
specificity of the active drug is modified56, 59.  
 Several approaches to release of active drug from the prodrug have been 
explored, including enzyme activation or cleavage, intramolecularly activated and 
changes in chemical properties.  Activation by enzyme cleavage is the most 
common type of prodrug and typically accomplished with ester, carbamate or 
amide linkages which can be hydrolyzed by caroxyesterases (ubiquitous in 
tissue) or other enzymes (for specificity)60.  Intramolecularly activated prodrugs 
occur through cyclization reactions which either cyclize to form the active drug or 
are released as a leaving group in the cyclization reaction.  A third kind of 
intramolecularly activate prodrug is referred to as a two step reaction in which the 
drug is released after cyclization that was initiated by enzyme activation. 
Enzyme-mediated cancer imaging and therapy (EMCIT) has been utilized 
to deliver drugs and imaging agent to solid tumors specifically.  Coupling of 
chemotherapy agents to polymers has provided better drug solubility, stability, 
specificity and controlled release.  Other strategies in which doxorubicin (DOX) 
was coupled to an enzyme selective cleavable peptide and released solely in the 
tumor environment have show success in animal studies61.  Cyclization of 
precursors to form benzoxazolones is anexample of prodrug cyclization that 
results in the active drug.  With these drugs, alcohol and carbamate 
functionalities are ortho to each other on a benzyl ring.  Upon activation, the 
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alcohol attacks the carbonyl followed by loss of a leaving group to provide the 
benzoxazolone therapeutic agent58.   
 
1.6 Dendrimers 
Dendrimers are spherical macromolecules, developed simultaneously in 
the laboratories of Newkome 62 and Tomalia 63-66 in the mid 1980’s, which contain 
an inner core followed by successive layers of branching.  As dendrimers 
become larger (higher generations), the diameter and number of terminal groups 
increase exponentially.  The spherical architecture of dendrimers and ease of 
synthesis is an attractive alternative to linear polymers leading to numerous 
applications of dendrimers and modifications to dendrimers 23, 67.  The most 
widely used dendrimers are polyamido amine (PAMAM™) dendrimers (Figure 
1.5).  The PAMAM™ dendrimer consists of an ethylene diamine (or ammonia) 
inner core with branching amide and amine linkages separated by two carbons.  
PAMAM™ dendrimers are attractive scaffolds because they are physically 
robust, water soluble and commercially available with amines (full generation), 
esters (half generation) or alcohols at the termini.  
Although PAMAM™ dendrimers are attractive scaffolds for biological 
applications; there are some inherent weaknesses in the structure and synthesis 
of these molecules.  PAMAM™ dendrimers are synthesized by a divergent 
method, which begins with a central core and builds towards the periphery by 
adding successive layers to form higher generations (Figure 1.6).  Divergent  
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synthesis consists of performing a few reactions iteratively to obtain higher 
generations.  Although divergent synthesis allows for rapid production of high 
generation dendrimers, the products have imperfections caused by incomplete 
and side reactions, becoming more frequent in successive generations.  The 
surface of traditional divergent dendrimers is uniform, limiting control over 
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Figure 1.5 Fourth generation PAMAM dendrimer 
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functional group locations.  In general each functional group will be randomly 
distributed over the surface, with other conformations unobtainable 68.   
An alternative approach to the divergent preparation of dendrimers is through 
convergent synthesis; which consists of synthesizing dendrons or “arms” of the 
dendrimer first, followed by attaching them (dendrons) to a central core to form 
the final structure (Figure 1.7).  Convergent synthesis of dendrimers consists of a 
variety of different reactions and is more labor intensive, but generally produces  
 
 
 
 
 
more homogeneous molecules.  By changing a few synthetic steps, the core, 
middle or periphery of the dendron can be adjusted so that the final structure 
contains sections with different functionality.  With convergent synthesis, the 
locations of functional groups can be controlled and modified as needed 
expanding applicability.  However, convergent synthesis is more costly and time 
consuming. 
 
Figure 1.6 Schematic representation of divergent dendrimer synthesis  
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Surface functionalized dendrimers are created by attaching ligands, etc. to 
the reactive terminal endgroups 68.  Numerous agents have been functionalized 
onto the surface of dendrimers, including: therapeutic agents69-81, targeting 
moieties (peptide, proteins, antibodies and small molecules)70, 76-78, 80, 82-87,  
 
 
 
 
 
imaging agents (fluorescent compounds, chelated metals, sensors, 
radioligands80, 88-92, solubilizing agents (PEG)69, and carbohydrates68, 85, 93-96, 
amongst others.  Dendrimers can be functionalized homogeneously or 
heterogeneously.  Homogenous functionalization is characterized by the entire 
periphery of the dendrimer being functionalized with the same functional group.  
A perfect example of homogenous functionalization is the first use of dendrimers 
for use as MRI probes.  In these studies, PAMAM dendrimers were completely 
functionalized with DTPA or DO3A chelated Gd3+ 91, 97-98.  Heterogeneous 
 
Figure 1.7 Schematic representation of convergent dendrimer synthesis 
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functionalized dendrimers contain two or more different functional groups on the 
surface.  Heterogeneous functionalization can be either random or controlled 
(through the manipulation of the terminal groups). One example of 
heterogeneous functionalization comes from the Baker group which has 
synthesized a series of heterogeneously functionalized dendrimers that contain 
folate for targeting, fluorescent dyes for imaging and various therapeutics for 
disease elimination78, 99-102.   
Dendrimers have been used to encapsulate molecules for imaging, drug 
delivery, studying ionic properties, and much more103.  One dendrimer design of 
hydrophobic interiors with hydrophilic exteriors makes dendrimers ideal for non-
covalently incorporating drug molecules, while other dendrimer structures are 
perfect for encapsulating metals.  Metals inside a dendrimer structure have been 
used as catalysts, for PET, SPECT, MRI, fluorescence and CT imaging86, 104-107, 
for photodynamic therapeutic108-109 and for light harvesting agents110-111.   
The convergent approach to synthesizing dendrimers can be used to 
make dendrons with differing functionalities (either orthogonal protecting groups, 
or pre-functionalized) which can be attached to a core in a “mix and match” 
fashion to provide a variety of dendrimers.  This chemistry is highly tunable, 
allowing for rapid re-routing if the dendrimer does not prove biologically 
compatible.  The “mix and match” dendrimers being developed in Chapters 2-5 
are capable of: 1) Therapeutic delivery targeted to the site of disease; 2) a 
biochemical switch capable of monitoring both the cleaved dendrimer location 
and therapeutic delivery; 3) solubility agents for tuning the molecule; and 4) a 
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locator beacon for following the molecule from the site of injection.  Presented 
here are studies using PAMAM™ dendrimers to demonstrate that multi-modal, 
targeted imaging agents can be synthesized to improve the current capabilities of 
imaging agents.  Following the data obtained with PAMAM™ dendrimers, 
convergent dendrons which can be attached pre or post functionalization to 
provide “mix and match” functional nanoparticles containing imaging agents, 
therapeutics, sensors, solubility enhancers or any number of other modalities are 
possible.     
 
1.7 Characterization of Dendrimers 
 The unique properties and structures of both surface functionalized and 
encapsulated dendrimers, as well as the diversity of research on dendrimers is 
reflected in the number of methods for characterizing the various characteristics 
of dendrimers.  These methods include: atomic force microscopy (AFM), 
scanning tunneling microscopy (STM), optical tweezers (OTW), dynamic static 
light scattering (DLS and SLS), gel electrophoresis (GE), ethidium bromide 
intercalation assay (EBIA), fluorescent dye intercalation assay (FLIA), zeta 
potential (ZP), isothermal titration calorimetry (ITC), circular and linear dichroism 
(CD and LD), melting profiles (MeltP), differential scanning calorimetry (DSC), 
fluorescence quenching (FLQ), electron paramagnetic resonance (EPR), 
synchrotron X-ray diffraction (SXRD), cross-polarized microscopy (CPM), 
stopped-flow fluorescence and circular dichroism (SFF, SCD), fourier-transform 
infrared (FTIR) spectroscopy, small angle X-ray scattering (SAXS), optical 
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microscopy (OM),  molecular simulations (M-S), nuclear magnetic resonance 
(NMR), UV-vis, matrix assisted laser desorption ionization mass spectrometry 
(MALDI-TOF MS), fluorescence, elemental analysis, gel permeation 
chromatography (GPC), size exclusion chromatography (SEC), reverse phase 
HPLC, and potentiometric titration95, 100-101, 107, 112-116.  Even with the vast number 
of methods, characterizing dendrimers is not always trivial as many of these 
characterization methods only work due to specific properties of the dendrimer.  
In particular when working with heterogeneously functionalized dendrimers it is 
often difficult to determine that the different moieties are attached and to quantify 
how many of each are present.   
 
1.8 Dendrimers as Imaging Agents 
 MRI dendrimer imaging agents have progressed over the last decade from 
blood pool agents containing several Gd3+ ions to targeted contrast enhancing 
agents.  The original MRI dendrimer agents were based on the simple design to 
increase the signal.  This was done by increasing the number of ions per 
molecule and by capitalizing on slower rotation of the large macromolecule thus 
decreasing the rate of exchange of water.  Recently, targeted MRI dendrimers 
have been reported with polysaccharides, oligopeptides, proteins, antibodies, 
oligo-nucleotides, folic acid and biotin-avidin 117-118. 
 While building MRI agents has been the focus of most dendrimeric 
research efforts, the use of metals such as 111In or 153Gd radiotracers have been 
incorporated into scaffolds for PET imaging86.  Also, several examples of 
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fluorescence imaging in vitro and small animal in vivo imaging have been 
reported45, 89, 119, including a dual-modality MRI-fluorescence probe118.  In further 
research, dendrimers have been used to develop fluorescent sensors based on 
quenching dye pairs14-16, 120.    
 
1.9 Dendrimers as Therapeutics 
 Several delivery mechanisms utilizing dendrimers have been developed 
using dendrimers, including conjugating or encapsulating drugs, photodynamic 
therapy, boron neutron capture therapy and photothermal therapy121.  Drugs 
encapsulated into dendrimers have been shown to exhibit an increase in 
solubility and toxicity, compared to unloaded dendrimers.  The type of dendrimer 
scaffold employed uses effects of encapsulation and delivery that are not always 
intuitive.  For example, hydrophobic cores are not always necessary for 
encapsulation of hydrophobic drugs such as the encapsulation of paclitaxel into 
poly(glycerol) dendrimers, which is not fully understood121.   
 Therapeutics that are covalently attached to dendrimers are generally 
incorporated with a method of detachment to reactivate the therapeutic; while 
some drug molecules are designed to remain toxic while still attached to the 
dendrimer.  Various drugs have been attached to dendrimers including 
methotrexate, paclitaxel, doxorubicin, cis-platnin, and ibuprofen86, 121-122. These 
therapeutic dendrimers have been found to have lower systemic toxicity and give 
higher accumulation in solid tumors with slower release profiles86.  Furthermore, 
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the dendrimer scaffold also plays a role in the delivery and therapeutic efficacy of 
the drug121. 
 Photodynamic therapy relies on activation via light (visible or NIR) and has 
been enhanced by the incorporation of multiple porphyrin sensititizers (needed 
for therapy) and 5-aminolaevulinic acid (ALA, needed for tumor uptake and 
selectivity)122 into a dendrimer.  In Boron neutron capture therapy, 10B is 
irradiated with low-energy thermal neutrons to produce high energy α-particles 
and 7Li nuclei.  Given that the α-particles pathlength is only 10 μm, the toxicity of 
the α-particles are limited to the cells containing 10B.  PAMAM dendrimers have 
been utilized to deliver large doses of 10B to diseased tissue via targeting 
moieties121-123.  
  
1.10 Matrix metalloproteinases (MMPs) 
MMPs are zinc dependant proteases found to partake in tumor 
progression with their ability to degrade the basement membrane and 
components of the extracellular matrix 124.  Twenty four human MMPs have been 
discovered and studied, but MMPs 2, 7 and 9 are found to be expressed in high 
concentration and are associated with certain cell types in the tumor 
microenvironment including tumor cells, tumor associated fibroblasts, endothelial 
cells and various cells of the myeloid and lymphoid classes 1, 125-126.   
MMP Inhibitors (MMPI) were developed to phase III clinical trials and 
found to fail as treatments.  One reason for this potential failure is the complex 
role MMPs play in tumor development and metastasis.  Current research 
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indicates that MMP9 contributes to the establishment and early survival of 
metastatic tumors, but have an ever-changing role at later stages of tumor 
development 127-128.  Thus introducing MMPIs during late stage metastatic 
development would not effectively eradicate the cancer.  Another possibility that 
could explain the success of MMPIs in mouse models and not in clinical trials is 
the type of studies completed.  The mouse models primarily used in preclinical 
MMPIs studies were xenograft models126, 128.  Recently, more complex genetic 
models have been developed because these models more accurately mimic the 
multistage progression of tumor progression and thus they better represent 
human tumors.  
 
1.11 Matrix Metaloproteinase 9 (MMP9) 
 Gelatinase B, also known as MMP9, plays an important role in tumor 
metastasis.  MMP9, a type IV collagenase, has been found to be a prognostic 
indicator in breast cancer patients2.  This protease is important in degrading the 
basement membrane of tumors, which is a key role in tumor metastasis.  
Interestingly, MMP9 is not found exclusively in tumor cells, but also in 
inflammatory cells that surround the tumor environment 126.  Studies have shown 
MMP9 contributes to tumor metastasis and early development by degrading the 
basement membrane and promoting angiogenesis at the metastatic site among 
other mechanisms2.  Subsequently, MMP9 has not been shown to have an effect 
on growth of the tumor following establishment of tumors in the lung124.   
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1.12 MMP9 Cleavable Peptides 
Several small peptide sequences that are selectively cleaved by a specific 
MMP(s) have been developed.  These selectively cleavable peptides have been 
used in molecularly activated fluorescence molecular probes14-16, 19, 129.   Pro-
drugs using an MMP cleavable peptide have also been created by attaching the 
peptide to doxorubicin (DOX), auristatins or CBI-TMI130.  The peptide was 
cleaved between the Gly-Leu bond in the presence of the enzyme, followed by a 
cascade reaction to liberate the active drug from the remaining amino acids 61.  
Studies have also shown that a few amino acids attached to DOX do not 
significantly affect the efficacy of the chemotherapeutic 131.  The sequence 
AVRWLLTA has been shown to be cleaved by MMP9 and MMP2, however at 
very different rates.  MMP9 cleaves AVRWLLTA more rapidly, making it capable 
of being used to specifically target MMP9.   
 
1.13 MMP9 Associated Cell Lines 
 Although specific mouse models are ideal to mimic human tumor 
progression, in vitro studies are useful in deciphering mechanisms and effect of 
perturbation of the system.  For cell studies, it is helpful to have both null and 
positive expressing cell lines.  One positive expressing cell line for MMP9 is 
derived from the mouse mammary tumor virus–driven polyoma viral oncogene 
(MMTV-PyVT) transgenic mouse model.  The MMTV-driven polyoma virus 
middle T antigen transgenic mouse, developed by Muller and colleagues in 1992 
[51], is routinely used in the Matrisian laboratory for studies of breast cancer 
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metastasis to the lung.  MMTV-PyVT animals develop multifocal mammary gland 
tumors that can affect all 10 glands with an average latency of 34 + 6 days in 
females. Metastatic disease to the lung occurs in 100% of animals.  A recent 
study has demonstrated that PyVT tumors develop through 4 distinct stages that 
are comparable to human disease both morphologically and by expression of 
biomarkers, indicating that this is a very relevant model for human breast 
cancer132. The Matrisian laboratory isolated and characterized a series of cell 
lines from a single primary tumor in an MMTV-PyVT FVB mouse. A highly 
aggressive PyVT antigen/E-cadherin-positive cell strain, now referred to as 
PyVT1, formed compact, rapidly growing unifocal tumors in the mammary fat pad 
of syngeneic FVB mice with a morphology consistent with the poorly 
differentiated component within MMTV-PyVT mammary tumors, and form 
colonies in the lung within 5 weeks when injected via the tail vein126. These cells 
have been labeled with Luciferase using the modified retroviral vector pMSCV for 
in vivo imaging (PyVT-R221A-luc)126.   
 Two further cell lines, derived from Lewis Lung Carcinomas (LLC), have 
been developed with MMP9 positive and null versions.  The LLC-RSV and LLC-
MMP9 have undetectable and high levels of MMP9 respectively.  These cells 
were made from LLC cells by incorporating an empty vector (LLC-RSV) and an 
MMP9 vector (LLC-MMP9) into the cells.  A fourth cell line that is useful in 
studying therapeutic effects in vitro is the MDA-MB-231 human breast cancer cell 
line.  Although this cell line is not specifically linked to MMP9, it is the benchmark 
cell line for translation into human tumor behavior.  By using all four cell lines, a 
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comprehensive estimation of which molecules will be best to move forward into in 
vivo experiments can be established.   
 
1.14 Doxorubicin (DOX) 
A major challenge in drug development is selectively delivering a 
therapeutic dose to the site of disease.  Targeted delivery will ideally result in the 
reduction of systemic activity, increased therapeutic index and increased efficacy 
of the drug.  For example, many cancer drugs are limited as a therapeutic due to 
cardiotoxicity and myelosuppression, however modifications to the molecule 
have resulted in a compound that is activated in the tumor 131. 
DOX, an anthracycline chemotherapeutic agent, is effective for treatment 
of acute leukemia, malignant lymphomas and solid tumors (including small cell 
lung carcinoma).  Toxicity of DOX is caused by effecting ribosomal RNA 
precursor synthesis and DNA synthesis 133.  Unfortunately, the drug is also 
known for its systemic toxicity, primarily cardio toxicity and myelosuppression 
and becoming resistant to the cancer cells134 which limit the use of DOX for 
treating malignant disease.  Several attempts have been undertaken to make a 
prodrug form of DOX.  These include attaching small protease cleavable peptide 
chains to the terminal amine134-135, dangling DOX off of nanoparticles 43, and 
structure modification133.  Although some modifications have proven to inactivate 
DOX, others have been shown to retain activity and still other modifications are 
debated as to whether the activity remains as will be discussed in Chapter 3.   
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1.15 Paclitaxel (PXL) 
 Paclitaxel (Taxol™) is one of the most prescribed chemotherapeutic 
agents currently in use, primarily being used to treat breast, lung, ovarian and 
head and neck malignancies136-137.  Isolated from the bark of the Pacific Yew 
tree, paclitaxel super stabilizes microtubules by binding to the hydrophobic 
pocket within the central domain of the polymerized microtubule138.  The 
mechanism of action of other microtubule inhibitors, such as colchicine or vica 
alkaloids, is to bind the dimers and prevent polymerization that assembles the 
microtubules.  However, paclitaxel bound microtubules enhance polymerization 
so much that polymerization can occur without GTP present and 
depolymerization is resistant to Ca2+, cold temperatures and dilution.  The 
mechanism of paclitaxel action is concentration dependent; at high 
concentrations paclitaxel increases polymer mass and induces microtubule 
bundle formation in interphase cells while at low concentrations paclitaxel 
suppresses microtubule dynamics without altering polymer mass137.  Two 
disadvantages of paclitaxel are the development of resistance and 
hypersensitivity.  Resistance is believed to be caused by either hypostable 
microtubules that shift the equilibrium towards the dimer rather than the 
polymer137, 139-140 or an equilibrium that shifts the dynamics of the microtubules 
toward being more dynamic rather than rigid 137, 141-143.  The problem of 
hypersensitivity is believed to be caused by the solvent emulsion used to 
administer paclitaxel rather than the drug itself.  Due to poor solubility, paclitaxel 
is often administered in Cremophor EL, a caster oil emulsion, but has recently 
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been administered as an albumin bound molecule, nab-paclitaxel144-145.  Albumin 
non-covalently binds paclitaxel and transports it into the tumor environment, 
providing an increased concentration of paclitaxel in the tumor environment.  
Overall, albumin bound paclitaxel is less hypersensitive, produces increased 
survival in patients, is better tolerated and is able to be given in higher doses144.  
Given the success of nab-paclitaxel other delivery mechanisms for paclitaxel are 
being developed, including the use of covalently bound paclitaxel 100.       
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CHAPTER II 
 
 
 
PAMAM DENDRIMER AS AGENTS FOR TARGETING DISEASE 
 
 
 
 
2.1 Background and Introduction 
Development of clinically relevant molecular probes to image diseases or 
biological processes is essential for the advancement of personalized medicine.  
A variety of biomarkers specific to cancer and other diseases have been 
identified and used for therapy and/or imaging10, 46, 80.  Proteins have been 
targeted using antibodies146, complementary proteins44, small molecules29-30, 36, 
nanoparticles147-149 and dendrimers6, 80, 150.  Attachment of multiple and/or 
different species to a single dendrimer has produced a single molecule which 
targets, images and/or delivers a therapeutic dose to the site of disease151-152.  
The advantages of using dendrimers include a) multiple moieties or multiple 
copies of the targeting agent on a single particle, b) biocompatibility, c) size 
solubility and d) tunability. However the challenges of using dendrimers include, 
a) the difficulty in characterization of functionalized molecule, b) nonuniform 
distribution of the adduct(s), c) complexity in determining the optimum size and d) 
insuring that the targeting moiety retains activity after attachment to the 
dendrimer.  It is clear that macromolecules will play an important role in 
personalized medicine; however, the current synthetic scaffolds are particularly 
ineffective in targeting intra-cellular receptors. 
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The translocator protein (TSPO, previously known as the peripheral-type 
benzodiazepine receptor or PBR), spans the mitochondrial membrane and has 
become an attractive receptor for therapeutics and targeted imaging153.  TSPO is 
associated with a number of biological processes including cell proliferation, 
apoptosis, steroidogenesis, and immunomodulation, yet, its exact physiological 
role is still not fully defined153-155.  Over expression of TSPO has been shown in 
numerous types of cancer including brain, breast, colorectal, prostate and 
ovarian cancers, as well as astrocytomas, hepatocellular and endometrial 
carcinomas154.  Two well characterized cell lines with high TSPO expression are 
C6 Rat Glioma cells35 and MDA-MB-231 human breast cancer cells156.  Several 
small, high binding, selective molecules have been developed for TSPO and 
made into positron emission tomography (PET), magnetic resonance (MR) and 
optical imaging agents157-158,28, 36, 159. While attractive, macromolecules targeting 
TSPO have not been reported, possibly due to difficulty in internalizing large, 
synthetic molecules.  
Dendrimers can be adapted to coupling technologies allowing them to be 
used with emerging targets, therapeutics and imaging strategies. Multiple 
attachment points can provide increased therapeutic efficacy, reduced drug side 
effects, increased signal to background for improved imaging detection limits.  
Methods of targeting include attaching several copies of a binding molecule 
(small molecules, peptides, proteins or antibodies) to the surface of the 
dendrimer to capitalize on polyvalency, or the enhanced permeability and 
retention (EPR) effect were tumor accumulation occurs due to the particle size 
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and the increased vasculature of the tumor160-161.  Imaging with dendrimers is 
possible through the attachment of small molecule fluorophors (for optical), metal 
chelates (for fluorescence, MRI, PET and SPECT) or with a switch activated by a 
physiological process for enhanced tissue characterization13, 162.  Dendrimers can 
serve as effective prodrug scaffolds with the drug molecules being attached 
through a linkage which activates the drug in vivo once they reach the delivery 
site.  Cleavage from the scaffold can occur through a change in pH, enzyme 
reaction or slow degradation of the macromolecule13.   
While internalization of large nanoparticles through the cellular membrane 
has been shown; targeting of specific organelles has scarcely been reported163-
164.  Here I present the synthesis, characterization, cellular internalization and 
mitochondria labeling of a dendrimer nanoparticle.  Although fluorescence is 
useful for in vitro studies of biological processes, in vivo and clinical analysis is 
difficult.  In order to produce detectable in vivo signal, the fluorescence must be 
in the near infrared (NIR) region of the electromagnetic spectrum.  An added 
complication with nanoparticles that use NIR dyes is the potential for 
fluorescence quenching at high local concentration of the dyes, limiting the 
number of dyes that can be attached per molecule.  Metal chelates provide more 
imaging options (through being able to chelate different metals to the same 
chelate) for both clinical and academic arenas. 
One research tool, electron microscopy (EM), has been used to probe 
many questions in biology165-166.  Cellular organelles are visually distinguishable 
from each other in an EM image (resolution of 1-2 nm) while they are not in a 
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fluorescence image (resolution of 200 μm). Information related to specific cellular 
structures requires additional probes in fluorescence microscopy.  Current 
techniques in EM include dosing and staining the samples post fixation to label 
the structure(s) and/or protein(s) of interest.  Few reports of labeling live cells 
prior to fixation and EM imaging have been reported to date167.  Labeling the cells 
before fixation offers the advantage of being able to directly study the effect a 
probe has on the biological system.  Using dendrimers, targeting moieties, 
fluorescent dyes and electron dense metals incorporated into the same molecule 
it is demonstrated here that the ClPhIQ functionalized dendrimers enter the cell 
unperturbed and are imaged via fluorescence (live or fixed) and/or EM (fixed).   
Here, the ability of PAMAMs as targeted, multi-modal imaging agents was 
substantiated through demonstrating the synthesis, characterization and 
biological utility of a TSPO targeted dendrimer.  Binding studies demonstrate the 
affinity for TSPO was maintained.  Studies with fluorescent cellular imaging show 
the potential of this agent to target high expressing TSPO cells.  We further 
demonstrate that live cells can be labeled in vitro and subsequently imaged via 
thin section EM for TSPO specificity.  The TSPO targeted dendrimers are useful 
for fluorescence, MRI and EM imaging because of their ability to enter cells 
under physiological conditions and label mitochondria specifically in diseased 
tissue.  The combined body of work on the TSPO targeted dendrimers provides 
proof that PAMAM dendrimers can be used to target intracellular structures in 
living, diseased cells.  The ability to deliver a dendrimer in an intracellular fashion 
to live, diseased cells will have an impact on both detection and treatment of 
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diseases.  Highlighted in this chapter is a fourth generation (G(4)-PAMAM) 
dendrimer particle which targets an internal cellular receptor (TSPO) and binds 
that target by passing through the cellular membrane under normal physiological 
conditions and without the external perturbation of the cellular membrane can be 
prepared, characterized and imaged. 
 
2.2 Synthesis of ClPhIQ-PAMAM-Liss 
The TSPO targeted dendrimer was synthesized using 1-(2-
chlorophenyl)isoquinoline-3-carboxylic acid (ClPhIQ Acid) a precursor of the 
conjugable TSPO targeted molecule previously reported36.  ClPhIQ Acid  
 
 
  
 
 
(Scheme 2.1) was activated with benzotriazol-1-yloxytris(dimethylamino)-
phosphonium hexafluorophosphate (BOPCl), in pyridine and dimethyl sulphoxide 
 
 
Scheme 2.1: Synthesis of ClPhIQ-PAMAM. 
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(DMSO) to a solution of G(4)-PAMAM dendrimer in DMSO.  An average of 12 
and 23 ClPhIQ Acids were attached by reacting G(4)-PAMAM dendrimer with 15 
and 30 molar equivalents of the activated TSPO ligand respectively to obtain two 
ClPhIQ-PAMAM compounds, 1 and 2 (Scheme 2.1).  Excess ClPhIQ Acid and 
coupling agent were removed by diafiltration with a molecular weight cut off 
(MWCO) of 5 kDa.  Both ClPhIQ-PAMAM molecules were characterized with 
nuclear magnetic resonance (NMR) and matrix assisted laser desorption 
ionization time of flight mass spectrometry (MALDI-TOF-MS). 
 
2.3 Characterization of ClPhIQ-PAMAM-Liss 
The average number of TSPO ligands per dendrimer was estimated using 
NMR integrations. It was shown from proton NMR spectra of the PAMAM and 
ClPhIQ pieces individually that the aromatic proton signals are exclusively from 
the ClPhIQ Acids attached (7.0-7.9 ppm) to the particle (Figure 2.1); while the 
interior PAMAM methylenes are the only signal observed from 2-4 ppm (Figure 
2.2) and the amides are found from 8.4-9 ppm (Figure 2.2).  By calculation there 
are approximately 930 methylene protons in a G(4)-PAMAM dendrimer and 9 
protons (all aromatic) per ClPhIQ Acid molecule. To determine the average 
number of ClPhIQ Acids per dendrimer, the integral from 7.0-8.2 was calibrated 
to 9 and the resulting integral from 2-4 ppm was divided into 930.  As shown in 
Figure 2.3, we find 23 ClPhIQ Acids attached to the dendrimer when the 
dendrimer was reacted with 30 equivalents of ClPhIQ Acid.  NMR spectra 
indicate that 12 ClPhIQ acids are attached when 15 equivalents of ligand are 
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reacted with the dendrimer (Figure 2.4).  The amount of ClPhIQ that binds to the 
dendrimer nearly doubles (from 12 to 23) with doubling the amount of ClPhIQ in 
the reaction (from 15 to 30).   
 
 
 
 
 
MALDI-TOF MS was also utilized to confirm the average number of 
ClPhIQ Acids attached to the dendrimer.  First a MALDI-TOF spectrum was 
 
 
 
Figure 2.1.  1H NMR of G(4)-PAMAM Dendrimer. 
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acquired of the G(4)-PAMAM with the average molecular weight (MW) found to 
be 13,244 Daltons (Figure 2.5), significantly lower than the 14,215 Daltons of a 
G(4)-PAMAM without any of the widely reported structural defects168.  These 
defects include incomplete reactions, making one arm of the dendrimer  
consistently a generation behind, and side reactions that stop the expansion of 
that branch of dendrimer altogether.   The ClPhIQ-PAMAM (1) has an average 
MW of 16,513; and thus, by calculation has 12 ClPhIQ Acid molecules per 
PAMAM (Figure 2.6).  This result is consistent with the NMR data; as was the 
number of ClPhIQ Acids per PAMAM for ClPhIQ-PAMAM (2) with 23 ClPhIQ 
ligands attached (Figure 2.7).  Additionally, it was calculated that ClPhIQ-
PAMAM, 2, to have approximately 24 ClPhIQ Acids per PAMAM, consistent with 
NMR data.  
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Figure 2.2: 1H NMR of G(4)-PAMAM. 
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Figure 2.3: 1H NMR of 23 ClPhIQ Acids attached to G(4)-PAMAM (ClPhIQ23-
PAMAM). 
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Figure 2.4: MALDI-TOF spectum of G(4)-PAMAM. 
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Figure 2.5. Characterization and determination of the average number of 
ClPhIQ per Dendrimer by MALDI-TOF MS.  MALDI-TOF spectrum of 
ClPhIQ12-PAMAM (1). 
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2.4 Synthesis of TSPO-PAMAM-Liss 
After characterizing the ClPhIQ-PAMAM molecules with NMR and MALDI-
TOF-MS, the dendrimer was further functionalized by reacting it with Lissamine 
rhodamine B sulfonyl chloride™ (Lissamine or Liss) in dimethyl formamide (DMF) 
overnight to give 1 or 2 Lissamine dyes per dendrimer (Scheme 2.2).    The DMF 
was removed in vacuo and excess dye was removed by diafiltration (MWCO = 
5,000) in water.  UV-Vis and fluorescence were employed to characterize the 
optical imaging agent.  Attaching the dye to the dendrimer produced a compound 
 
Figure 2.6. Characterization and determination of the average number of 
ClPhIQ per Dendrimer by MALDI-TOF MS.  MALDI-TOF spectrum of 
ClPhIQ23-PAMAM (2). 
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with an absorbance maximum at 500 nm (versus 550 nm for free dye) and a 
slightly red shifted emission at 586 nm (versus 583 nm for free dye) as displayed 
in Figure 2.8.  The broadening of the absorbance spectra is due to the large 
amount of ClPhIQ modalities attached and the PAMAM absorbing as high as 380 
nm and the strong signal due to the large number of bonds absorbing; both 
broadening the UV-Vis spectrum.  A control compound (PAMAM-Liss), the  
 
 
 
 
 
agent absent of the targeting moiety, was synthesized similarly to the targeting 
agent by reacting G(4)-PAMAM dendrimer with Lissamine™ (Scheme 2.2). The 
 
 
Scheme 2.2: Attachment of Lissamine dye to PAMAM. 
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PAMAM-Liss (4) conjugate was also purified by diafiltration in which the first low 
molecular weight fraction was slightly pink (from dye) and subsequent washing 
resulted in lighter color until no color was present.  A minimum of three colorless 
washing in the low molecular weight fraction was completed to provide pure 
ClPhIQ-PAMAM-Liss with no unreacted lissamine dye.  A molecular weight 
difference for the PAMAM and PAMAM-Liss of 500 – 600 amu was observed in 
the MALDI-TOF MS spectrum, consistent with an average of 1 dye per 
dendrimer.  
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Figure 2.7.  The absorbance and emission spectra of ClPhIQ-PAMAM-Liss. 
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2.5 Imaging of TSPO-PAMAM-Liss 
To evaluate the biological activity of the imaging agent, C6 rat glioma cells, 
shown to express a high concentration of TSPO169-170, were incubated with  
 
 
 
 
A B
C D
 
Figure 2.8.  Live cell images of C6 rat glioma cells. Panal A: Red fluorescence 
of ClPhIQ-PAMAM-Liss (3) dosed cells; B: DIC image of ClPhIQ-PAMAM-Liss 
(4) dosed cells; C: DIC image of PAMAM-Liss dosed cells; D: Red 
Fluorescence image of PAMAM-Liss dosed cells. 
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ClPhIQ-PAMAM-Liss (3) or PAMAM-Liss (4) for 12 hours in collagen coated 
MatTek™ dishes and visualized by fluorescence microscopy.  Live cell imaging 
was preformed immediately after rinsing the cells with PBS or saline to remove 
media and unbound or un-internalized imaging agent.  A Nikon Eclipse TE2000-
U fluorescence microscope (Lewisville, TX) equipped with Texas Red and FITC 
filter sets was employed for the in-vitro imaging.  As shown in Figure 2.8, the 
ClPhIQ-PAMAM-Liss labels the cell, while the control (PAMAM-Liss) does not 
produce fluorescence.  As another control, cells were incubated with Lissamine 
and again no fluorescence was observed.  The imaging experiments were 
performed in triplicate with observations being consistent with respect to 
absorbance and fluorescence intensity and the absence of fluorescence in the 
controls.  We hypothesize that the dendrimer with the TSPO binding ligand 
(ClPhIQ-PAMAM-Liss, 3) produced bright, localized, cellular fluorescence due to 
its ability to pass through the cellular membrane and bind to the target protein 
TSPO (Figure 2.9).  Since ClPhIQ Acid conjugated dye is known to bind TSPO, 
glioma cells overexpress TSPO and it is an organellular protein, we believe that 
the dendrimer labels the mitochondria by binding to TSPO.  In the labeling 
experiment where the dendrimer without the targeting ligand (compound 4) was 
used, no fluorescence was found in the cell at exposure times as long as 5 
seconds.  Taken together these results indicate that the ClPhIQ moiety is 
necessary for cellular uptake of the dendrimer at labeling concentrations of 1 μM 
and equilibration times of 6-12 hours. 
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Figure 2.9.  Selected montage of red fluorescence images of ClPhIQ-PAMAM-
Liss (4) dosed cells from the z series.  Panel A: slice 10; B: slice 15; C: slice 
20; D: slice 21; E slice 22; F: slice 23; G: slice 24, H: slice 325; I: slice 30; J: 
slice 35; K: DIC Fluorescence overlay.  
 
50 
To further confirm that the agent was intracellular, a series of z stacked 
images (pseudo-confocal) were obtained allowing different regions of the cells to 
be viewed (Figure 2.10).  These z stacked images were accomplished by 
changing the lens position incrementally, moving the focal planes of the 
microscope through cells and collecting the images by viewing fluorescence.  In 
the center focal planes there is a dark hole, consistent with the nucleus as shown 
in the fluorescence-DIC overlay (Figure 2.10 panel K).  This observation 
suggests that the agent undergoes internalization, passive or active, and does 
not just label the membrane due to lipophilic nature of the ClPhIQ moiety.  Since 
only a small amount of out-of-focus light is observed in the membrane slices of 
the z stacked images, labeling of the membrane appears to be negligible. 
Furthermore, fluorescence signal is observed through the cell to the entire 
nuclear membrane, but not in the nucleus, indicating uptake of the dendrimer by 
the cells but not the nucleus.  Previously reported small molecule agents have 
not labeled the nucleus, even though low concentrations of TSPO are present 
there28.  The reported macromolecular agent behaved as expected and targeted 
the mitochondria and was not up-taken into the nucleus as indicated in Figure 
2.10.  
To further explore that ClPhIQ-PAMAM-Liss was targeting the 
mitochondria, a co-incubation experiment was preformed.   This was 
accomplished by first incubating C6 rat glioma cells with ClPhIQ-PAMAM-Liss as 
described above for the live cellular imaging, followed by fixation using 
paraformaldehyde, and then treatment of the cells with Mitotracker Green™  
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(MTG) according to the manufacturer’s guidelines.  The cells were then imaged 
using a Texas Red filter set to interrogate the Lissamine (red) fluorescence and a 
FITC filter set to detect the MTG (green) fluorescence.  Figure 2.11 shows C6 rat 
glioma cells incubated with either ClPhIQ-PAMAM-Liss or the control, PAMAM- 
 
 
 
 
 
Liss.  The DIC images in Figure 2.11A and 2.11G are present to indicate the 
location of the cells relative to fluorescence signal of ClPhIQ-PAMAM-Liss 
 
 
Figure 2.10.  Fluorescence Images of fixed C6 rat glioma cells.  Panal A: DIC 
of ClPhIQ23-PAMAM-Liss (2) and MTG dosed cells; B: Red fluorescence of 
ClPhIQ23-PAMAM-Liss (2) and MTG dosed cells; C: Green fluorescence of  
ClPhIQ23-PAMAM-Liss (2) and MTG dosed cells; D: Red and Green 
fluorescence overlay of ClPhIQ23-PAMAM-Liss (2) and MTG dosed cells; E: 
DIC, Red and Green fluorescence overlay of ClPhIQ23-PAMAM-Liss (2) and 
MTG dosed cells; F: DIC, Red and Green Fluorescence overlay of PAMAM-
Liss (4)and MTG dosed cells; G: DIC of PAMAM-Liss (4) and MTG dosed 
cells; H: Green fluorescence of PAMAM-Liss and MTG dosed cells; and I: Red 
fluorescence of PAMAM-Liss (4) and MTG dosed cells. 
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(Figure 2.11A) and PAMAM-Liss dosed cells (Figure 2.11G).  Fluorescence from 
the imaging agent is displayed in red (Figure 2.11B) and fluorescence from the 
MTG as green (Figure 2.11C).  As demonstrated above with live cell imaging, the 
ClPhIQ-PAMAM-Liss (2) agent labels the fixed cells principally perinuclear 
(Figure 2.11B).  The MTG labels the mitochondria of cells, as shown by 
numerous investigators171-172, particularly when used in low concentrations as 
those employed here (25nM).  MTG was used in low concentration (25 nM) to 
ensure that it primarily labeled only the mitochondria.  More careful interrogation 
of the fluorescence signals allow an insight about where the species are within 
the cell.  Figure 2.11 panels D and E display co-registration of ClPhIQ-PAMAM-
Liss (2) and MTG with yellow indicating areas of overlap while red and green 
indicate areas where ClPhIQ-PAMAM-Liss (2) (red) and MTG (green) are not 
coincident.  It is encouraging to see that most of the red and green converge to 
yellow, indicating that the majority of ClPhIQ-PAMAM-Liss (2) is in the same 
location of the cell as the MTG.  This good co-localization is further evidence that 
ClPhIQ-PAMAM-Liss (2) is labeling the mitochondria and not other parts of the 
cell.  As demonstrated in Figure 2.11 panels F – I and in the live cell imaging 
(Figure 2.9), fluorescence from the dendrimer is only detected if ClPhIQ Acid is 
incorporated into the dendrimer.  In other words, images from cells inoculated 
with the control agent (PAMAM-Liss) exhibit no fluorescence (Figure 2.11I).  
MTG fluorescence was not affected (Figure 2.11C, F&H) by the presence or 
absence of dendrimer agent and the cellular membrane was not perturbed by 
non-physiological chemical or physical processes prior to or during the incubation 
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with ClPhIQ-PAMAM-Liss.  Excess imaging agent was removed prior to fixation 
in all experiments.  Taken together, the fluorescence images in Figure 2.11 
indicate that the ClPhIQ-PAMAM-Liss is targeting the mitochondria and that the 
ClPhIQ ligand is necessary for this mitochondrial labeling to occur.  The z 
stacked images and co-incubation experimental results indicate that the imaging 
agent is internalized into the cell through normal cellular functions.  Although no 
quantitative binding studies were performed, the agent binds with high enough 
affinity to remain in the cell after fixation, washing and treatment with MTG.    
Further evidence of the utility of ClPhIQ-PAMAM-Liss (2) was 
demonstrated by labeling MDA-MB-231 human breast cancer cells, an 
aggressive human cancer cell line.  Like the C6 rat glioma cells, the MDA-MB-
231 human breast cancer cells have been shown to over express TSPO 156.  The 
cells were incubated with ClPhIQ-PAMAM-Liss (2) following the same 
procedures as with the C6 rat glioma cells, fixed and treated with MTG for co-
registration investigations.  The individual red and green fluorescence of ClPhIQ-
PAMAM-Liss (2) and MTG respectively in fixed MDA-MB-231 cells is 
demonstrated in panels A and C of Figure 2.12; while, panels E and F show the 
lack of red fluorescence in the PAMAM-Liss treated cells.  Association between 
the red and green (shown in yellow) is evident in the overlays of panels B and D 
indicating co-localization of the ClPhIQ-PAMAM-Liss (2) and MTG.  These 
additional results represent further evidence that ClPhIQ-PAMAM-Liss (2) is able 
to label TSPO rich mitochondria in cancer cells. 
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Figure 2.11.  Microscope images of MDA-MB-231 cells.  Panal A: Red 
fluorescence of ClPhIQ23-PAMAM-Liss (2)  and MTG dosed cells; B: Red and 
Green Fluorescence overlay of ClPhIQ23-PAMAM-Liss (2) and MTG dosed 
cells; C: Green fluorescence of ClPhIQ23-PAMAM-Liss (2) and MTG dosed 
cells; D:Red and Green Fluorescence and DIC overlay of ClPhIQ23-PAMAM-
Liss (2) and MTG dosed cells; E: Red fluorescence of PAMAM-Liss (4) dosed 
cells; F: DIC image of PAMAM-Liss (4) dosed cells.  
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2.6 Synthesis and Characterization of ClPhIQ-PAMAM-Gd-Liss 
The ClPhIQ-PAMAM-Liss-Gd dendrimer was synthesized starting with 
ClPhIQ-PAMAM and reacting 1,4,7,10-Tetraazacyclododecane-1,4,7-tris(t-butyl 
acetate)-10-succinimidyl acetate (tri-T-butyl-DO3A-NHS) in DMSO to give 
ClPhIQ-PAMAM-tBuDO3A (5).  Unreacted tri-T-butyl-DO3A-NHS and other low 
molecular weight byproducts were removed by diafiltration with a 5 kDa. MWCO. 
NMR and MALDI-TOF MS were used to characterize the number of tri-T-butyl-
DO3A molecules attached to the dendrimer.  The integration of the t-butyl methyl 
peak at 1.4 ppm was compared to the aromatic protons from the ClPhIQ ligands 
attached to the dendrimer to determine the ratio of TSPO ligand (as 
characterized above) to the metal chelate.  Typically, reacting a dendrimer with 
23 ClPhIQ ligands with 30 equivalents of tri-T-butyl-DO3A resulted in an  
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Scheme 2.3: Synthesis of G(4)-PAMAM TSPO targeted MRI and Fluorescence 
agent. 
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average attachment of 23 metal chelates per dendrimer.  Next, in two steps, the 
t-butyl groups were removed by treatment with trifluoroacetic acid (TFA) and the 
resulting carboxylates on the DO3A were chelated with gadolinium by reaction 
with gadolinium trichloride in water.  Characterization with NMR (pre-chelation) 
and MALDI-TOF MS (pre and post chelation) verified the desired reactions were 
completed.  The MALDI-TOF MS of ClPhIQ-PAMAM-DO3A prior to chelation 
displays and average mass of 26,500 amu (Figure 2.13).  This is consistent with 
the attachment of 18 chelates per PAMAM.   
Finally, Lissamine was reacted with dendrimer 2 in DMF to produce a 
TSPO targeted molecule with dual imaging modalities (MR and Fluorescence).  
The fluorophore attachment was observed through characterization with MALDI- 
 
 
 
Mass (m/z)
26,500
 
Figure 2.12.  MALDI-TOF Spectrum of ClPhIQ-PAMAM-DO3A.  
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TOF MS (31,000 a.m.u.), UV-Vis (max absorbance at 551 nm) and fluorescence 
(ex. 551 nm, em. 586 nm) spectroscopy.  As a control molecule, PAMAM-Gd was 
synthesized as described with ClPhIQ-PAMAM-Gd (6), by stating with 
unfunctionalized G(4)-PAMAM. 
 
2.7 Fluorescence Imaging of ClPhIQ-PAMAM-Gd-Liss 
Cellular internalization studies were first accomplished with fluorescence 
microscopy.  Both MDA-MB-231 and C6 rat glioma cells were imaged with 
ClPhIQ-PAMAM-Gd-Liss.  Fluorescence microscopy images were taken on a 
Nikon Eclipse TE2000-U fluorescence microscope (Lewisville, TX) equipped with 
Texas Red and FITC filter sets.  The fluorescence samples were prepared by 
incubating the dendrimer with either C6 rat glioma or MDA-MB-231 human breast 
cancer cells for 6-18 hours in microscopy bottomed MatTek™ dishes, followed by 
removal of excess imaging agent by 3 - 4 washings with saline.  In the first 
experiment, MDA-MB-231 cells were imaged live.  As seen in Figure 2.14, the 
TSPO targeted imaging agent labels MDA-MB-231 cells.  The overlay of the 
fluorescence and DIC images indicate that the imaging agent is perinuclear 
(Figure 2.14, panels A & B); as expected since TSPO is primarily located on the 
mitochondria.  No perturbation of the cellular membrane was performed, 
indicating that the imaging agent is labeling the mitochondria via normal 
biological processes.  A series of Z-stacked images (data not shown) show 
fluorescence from the dendrimer in the cell on several planes and not solely on  
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the cell surface.  The control compound, PAMAM-Liss (4), did not label the cells 
at higher fluorescence integration times and higher concentrations of molecule 
(Figure 2.14, panels C & D).  As with the ClPhIQ-PAMAM-Liss (4) molecule, the 
indication is that the ClPhIQ moiety is necessary for the labeling and 
internalization of the imaging agent into the cell. 
   
 
 
 
Figure 2.13.  Cellular images of MDA-MB-231 cells dosed with ClPhIQ-
PAMAM-Gd-Liss (7) and PAMAM-Liss.  Panel A: Red Fluorescence image of 
ClPhIQ-PAMAM-Gd-Liss (7); Panal B: DIC and Red Fluorescence overlay of  
ClPhIQ-PAMAM-Gd-Liss (7); Panal C: Red Fluorescence image of PAMAM-
Liss (4); Panal D: DIC image of PAMAM-Liss (4). 
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   Further cellular fluorescence studies were completed in C6 rat glioma cells 
with commercially available Mitotracker Green™ (MTG).  The cellular labeling 
was completed using the procedure described for the MDA-MB-231 cells, but 
 after incubation, the cells were fixed with 4% para-formaldehyde and treated 
with 25 nM MTG immediately before imaging.  MTG is a commercially available 
small molecule known to label mitochondria and has fluorescence properties (ex. 
490 nm & em 516 nm) complementary to ClPhIQ-PAMAM-Gd-Liss (7) and our 
microscope.  The ClPhIQ-PAMAM-Gd-Liss (7) was imaged using a Texas Red 
filter set while the MTG was imaged with a FITC filter set.  Fluorescence bleeding 
was tested with cell plates that were dosed with either MTG or ClPhIQ-PAMAM-
Liss-Gd (7) and imaged using both filter sets.  No signal bleed-through was seen 
for either molecule when images with the improper filter set.   
In Figure 2.15 panel A displays the MTG (FITC filters) fluorescence and 
panel B displays the ChPhIQ-PAMAM-Liss-Gd (7) (Texas Red filters) 
fluorescence in C6 rat glioma cells.  Figure 2.15, Panel C is an overlay of panels 
A & B; coincident fluorescence from the MTG and the fluorescence from the 
ClPhIQ-PAMAM-Liss-Gd (7) appear yellow and non-coincident fluorescence is 
red (ClPhIQ-PAMAM-Liss-Gd) (7) or green (MTG).  Very little green or red is 
seen and yellow dominates the image.  The co-incubation evidence suggests 
that the ClPhIQ-PAMAM-Liss-Gd (7) and MTG are located in the same 
intracellular location as seen with the ClPhIQ-PAMAM-Liss (2).  Since TSPO is 
found on the mitochondria and MTG is designed to bind mitochondria, this 
observation suggests that ClPhIQ-PAMAM-Liss-Gd (7) is binding to the 
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mitochondria.  Since the ClPhIQ-PAMAM-Gd-Liss (4) was shown to bind TSPO, 
which is located on the mitochondrial membrane; mitochondria labeling was 
expected as confirmed in the fluorescence images.  The culmination of all the 
fluorescence data provides strong evidence that the ClPhIQ-PAMAM molecules 
are internalized into cells by normal biological processes and bind to the  
 
 
 
 
 
 
Figure 2.14:  Cellular co-localization in C6 Rat Glioma cells and co-incubation 
with Mitotraker Green.  Panel A: Fluorescence of MTG.  Panel B: Fluorescence 
of ClPhIQ-PAMAM-Gd-Liss (7).  Panel C: Fluorescence overlay of MTG and 
ClPhIQ-PAMAM-Gd-Liss (7) fluorescence.  Yellow indicates co-registration.  
Panel D: The fluorescence overlay of MTG and ClPhIQ-PAMAM-Gd-Liss (7) 
onto the DIC image. 
61 
mitochondria.  To further examine the utility of the ClPhIQ-PAMAM molecules 
binding affinity to TSPO, T1 and T2 relaxation (for Gd3+ containing molecules) 
and EM studies were completed.   
 
2.8 Binding studies of ClPhIQ-PAMAM-Gd to TSPO 
A radioligand binding study of the ClPhIQ-PAMAM-Gd (6) was completed 
by Mingfeng Bai performing a competition assay using the tritiated ligand 
[3H]PK11195 as the competitor.  The [3H]PK11195 ligand was used because it 
has the most similar structure to ClPhIQ. PK11195 is the best previously 
characterized ligand27-28, 36 to compete with ClPhIQ binding. Displacement  
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Figure 2.15.  The IC50 curve of the competitive binding assay ClPhIQ-
PAMAM-Gd (6) (left) and Ac-amnohexyl ClPhIQ (right) with radiolabled 
PK11195.  
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studies using increasing concentrations of ClPhIQ-PAMAM-Gd (6) were 
performed in the presence of 15 nM [3H]PK11195 to obtain the IC50 curve (Figure 
2.15).  Radiobinding assays were also performed on an acetate capped 
aminohexyl ClPhIQ (Ac-aminohexyl ClPhIQ) compound.   The ClPhIQ-PAMAM-
Gd was found to have a Ki of 510 nM per ClPhIQ ligand while the Ac-aminohexyl 
ClPhIQ has a binding affinity of 1.5 μM.  These results indicate that having 
several molecules attached to a dendrimer improves the binding capabilities of 
ClPhIQ 3 fold. 
 
2.9 MR studies of ClPhIQ-PAMAM-Gd 
Having Gd3+ chelated to the TSPO targeted dendrimer allows for two new 
imaging methods to be utilized: MRI and EM.  Previous studies have found 
increased rates of relaxation in both T1 and T2 experiments using nanoparticles,  
 
 
 
 
Table 2.1 Relaxivities of PAMAM-Gd compounds. 
Compound T1 
Relaxation 
per Gd3+ 
(mM-1s-1) 
T1 
Relaxation 
per PAMAM 
(mM-1s-1) 
T2 
Relaxation 
per Gd3+ 
(mM-1s-1) 
T2 
Relaxation 
per PAMAM 
(mM-1s-1) 
Magnevist™ 4.8±0.044 - 5.6±0.13 - 
PAMAM-Gd  7.8±0.65 180 7.7±0.27 177 
ClPhIQ-
PAMAM-Gd (6) 
7.7±0.76 177 8.0±1.2 184 
ClPhIQ-
PAMAM-Gd-
Liss (7) 
4.0±1.04 92 3.8±0.40 87 
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including dendrimers 91, 98, 117.  To explore the utility of ClPhIQ-PAMAM-Gd (6) 
and ClPhIQ-PAMAM-Liss-Gd (7) and MRI agents, T1 and T2 relaxivities were 
determined.  The TSPO targeted dendrimer was tested for its ability to increase 
relaxation of water molecules compared to Magnevist™ using a Maran 0.5T 
NMR scanner.  Samples were diluted to five different concentrations in Gd3+ with 
saline and placed in disposable NMR/MR tubes.  The T1 and T2 relaxation rates 
of each sample were measured three times per sample.  The samples were 
cooled between trials to ensure consistent temperature.  The ClPhIQ-PAMAM-
Gd (6), ClPhIQ-PAMAM-Gd-Liss (7), PAMAM-Gd and Magnevist were all 
measured at five concentrations (20 – 100 μM in Gd).  Table 2.1 provides the 
relaxation rates for each of these molecules.   
The T1 relaxivitiy of PAMAM-Gd and ClPhIQ-PAMAM-Gd (6) is greater 
than that of Magnevist™ by a factor 1.6 on per Gd3+ or by 37 on a per molecule 
basis. The ClPhIQ-PAMAM-Gd-Liss (7) has a lower relaxivity than Magnevist™ 
per Gd3+.  The difference between ClPhIQ-PAMAM-Gd (6) and ClPhIQ-PAMAM-
Liss-Gd (7) is the presence of 1-2 dyes attached to the dendrimer.   
T2 relaxivity was not increased as significantly as with T1 but was still 1.4 
and 33 times better than Magnevist™ on average based on a per molecule and 
per Gd3+ ion basis respectively.  These values are consistent with recently 
published PAMAM-Gd molecules when the amount of Gd3+ and generation of the 
dendrimer are taken into account98.  Again, the relaxation rate of ClPhIQ-
PAMAM-Liss-Gd (7) was lower than the other samples, even Magnevist™.   
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Lissamine is a zwitter ion and charged molecules have been shown to reduce 
relaxivity, this is most likely the cause of the reduced relaxivity.  In order to test 
the charged molecule theory on the PAMAM system, a series of dye and Gd3+ 
functionalized PAMAM molecules were synthesized and T1 and T2 relaxivities 
were acquired.  The four reactions completed were 1) Cy5.5 attachment to 
PAMAM-Gd; 2) Lissamine attachment to PAMAM-Gd; 3) PAMAM-Gd reacted 
under the conditions of dye conjugation without dye present and 4) Gd chelated 
to PAMAM-Liss.  The T1 and T2 results are all lower with dye attached to the 
scaffold than without dye attached (Table 2.2).  Although Cy5.5™ does not affect 
the relaxivity as much as Lissamine in either T1 or T2, the rates are still faster 
than without the dye: 5.56 versus 7.33 for T1 and 5.95 versus 7.19 for T2.   Liss- 
 
 
 
 
Table 2.2 Relaxation rates of Dye-PAMAM-Gd compounds obtained on a 
Maran 0.5T NMR scanner. 
Compound T1 
Relaxation 
per Gd3+ 
(mM-1s-1) 
T1 
Relaxation 
per PAMAM 
(mM-1s-1) 
T2 
Relaxation 
per Gd3+ 
(mM-1s-1) 
T2 
Relaxation 
per PAMAM 
(mM-1s-1) 
Magnevist™ 4.8±0.044 - 5.6±0.13 - 
Cy5.5-PAMAM-Gd  5.56±0.10 128 5.95±0.17 137 
Liss-PAMAM-Gd 
(Gd attached first) 
4.34±0.24 100 4.04±0.33 93 
PAMAM-Gd 
(reacted under dye 
conjugation 
conditions) 
7.33±0.25 169 7.19±0.18 165 
Liss-PAMAM-Gd 
(Liss attached first) 
5.83±0.79 134 6.10±0.86 140 
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PAMAM-Gd (T1 = 4.34 and T2 = 4.04) has relaxation rates close to ClPhIQ-
PAMAM-Liss-Gd (T1= 4.0 and T2 = 3.8) suggesting that the extra crowding 
associated with the ClPhIQ ligand with more attached to the dendrimer does not 
effect the relaxation rate.  By reacting PAMAM-Gd under the reaction conditions 
(stirred the compound with DMF), and having the molecule maintain the 
relaxation rate prove that the reaction conditions do not effect the integrity of 
Gd3+ to the dendrimer or otherwise change the molecule.  Interestingly, the order 
of addition does affect the relaxivities since Lissamine conjugated to the 
dendrimer first has slower relaxation rates than Gd added first.   Overall, the 
relaxation experiments confirm 1) increased relaxivities present with PAMAM-Gd 
compounds compared to Magnevist™; 2) the ClPhIQ ligand does not significantly 
effect the relaxation of the Gd ions; 3) the zwitterionic dyes do effect the 
relaxation rates of the PAMAM-Gd molecule; 4) the effect of the dyes on the 
PAMAM-Gd is dependent on which dye is used and the order of attachment to 
PAMAM and 5) PAMAM-Gd is stable to the dye conjugating conditions.     
 
2.10 Summary of EM studies 
An added advantage of having electron dense metal ions directly 
incorporated into the dendrimer allows the molecule to produce contrast in a 
transmission electron microscope (TEM) independent of heavy metal staining.  
Since the gadolinium dendrimers were shown via fluorescence to label 
mitochondria on cells overexpressing TSPO, EM experiments were performed by 
Dr. Bernard Anderson.  High TSPO concentration C6 rat glioma cells were plated 
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in 4 cm cellular culture dishes, dosed with ClPhIQ-PAMAM-Gd (6) and prepared 
for EM as described in the experimental section.  The cells were free of any lead 
or uranium salts, which are commonly employed for improved contrast of 
organelles in biological samples173.  A set of cells not dosed with ClPhIQ-
PAMAM-Gd served as the control.  Figure 2.16 illustrates typical TEM images of 
C6 cells labeled with ClPhIQ-PAMAM-Gd and unlabeled control.  The differences 
between the labeled and control cells at 2,650X magnification are apparent as 
numerous individual mitochondria in the labeled sample (Figure 2.16A) have 
enhanced contrast over the surrounding cellular area whereas little contrast 
difference is visible between the mitochondria and the intracellar material in the 
control sample (Figure 2.16D).  Magnification of the mitochondrial regions by 
7650X and 25,000X for both samples further illustrates their differences (Figure 
2.16 B, C, E & F).  The mitochondria for those cells treated with ClPhIQ-PAMAM-
Gd (6) have become very dark compared to control.   
The enhanced contrast of ClPhIQ-PAMAM-Gd (6) treated cells compared 
to control cells was initially attributed to the accumulation of the high-Z, electron 
dense Gd3+ chelated to the dendrimer.   The elemental composition of these 
electron dense regions was analyzed using Energy Dispersive X-ray Analysis 
(EDX), and it was determined that the enhanced contrast of the mitochondria 
was due to osmium and not gadolinium.  It was concluded that osmium tetroxide, 
a strong oxidizer, used in the EM sample preparation as a secondary fixative,174 
reacted with receptor-bound ClPhIQ-PAMAM-Gd (6) forming large, polymeric 
osmium structures.  Osmium tetroxide is known to coordinate nitrogen, (ClPhIQ-
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PAMAM-Gd has ~238 nitrogens) and oxidize the surrounding material175 creating 
areas of increased contrast anywhere there is a build-up of dendrimer.  Although 
this data suggests osmium causes the increase in mitochondrial  
 
 
 
 
 
contrast and not Gd3+, further experiments provided evidence that osmium 
reacted with the dendrimer. Plus, the control cells without dendrimer did not have 
 
 
Figure 2.16.  TEM images of ClPhIQ-PAMAM-Gd dosed (A-C) and undosed 
cells (D-F).  A: ClPhIQ-PAMAM-Gd dosed cell at 2650x magnification. B: 
ClPhIQ-PAMAM-Gd dosed cells at 7100x magnification.  C: ClPhIQ-PAMAM-Gd 
dosed cell at 25,000x magnification.  D: Undosed cell at 2650x magnification.  
E: Undosed cell at 7100x magnification. F: Undosed cell at 25,000x 
68 
the increased contrast on the mitochondria.  The collective data indicate that the 
ClPhIQ-PAMAM molecules target the mitochondria. 
 
2.11 Conclusions 
The work described in this chapter expanded on previous work completed 
in the Bornhop laboratory to synthesize new imaging agents that target TSPO.  
The previous agents were exclusively small molecules that could incorporate 
only a single imaging agent per ligand.  Incorporating dendrimers as scaffolds for 
TSPO targeting has allowed expansion to dual-modality imaging and for EM 
experiments to be performed.   
First, a TSPO targeted imaging agent was synthesized using a G(4)-
PAMAM backbone, ClPhIQ acid and Lissamine™ (ClPhIQ-PAMAM-Liss, 3).  
Second, the imaging agent was characterized with MALDI-TOF-MS and NMR 
and third imaged in C6 rat glioma and MDA-MB-231 human breast cancer cells.  
To our knowledge this is the first example of a TSPO-targeted dendrimer and 
among the few dendrimeric compounds that are internalized into the cell under 
normal physiological conditions.  Cellular experiments demonstrate the ability for 
a large, synthetic molecule (conjugated PAMAM) to be internalized into the cell 
and target a specific protein (TSPO).  Overall, this first set of imaging agents 
based on ClPhIQ-PAMAM moves the research a step closer to understanding 
biological events at the molecular level and ultimately enabling personalized 
medicine.  Co-localization of the ClPhIQ-PAMAM-Liss and MTG indicates that 
the compound binds to the mitochondria. 
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The second half of this project focused on the synthesis of a dual-imaging 
TSPO targeted dendrimer.  The original ClPhIQ-PAMAM-Liss was expanded to 
include a Gd3+ ion that can be utilized for MRI or EM studies. The ClPhIQ, Gd3+ 
and Lissamine functionalized dendrimers were then found to label cells with high 
TSPO concentrations analogous to the ClPhIQ-PAMAM-Liss (3) molecule.  As 
with the ClPhIQ-PAMAM-Liss (3), the ClPhIQ-PAMAM-Gd-Liss (7) was found to 
only label the cells if the ClPhIQ ligand was attached to the dendrimer. Again, the 
cells were labeled perinuclear, not found in the membranes and entered the cell 
without perturbing the membrane.  Co-incubation of ClPhIQ-PAMAM-Gd-Liss (7) 
with MTG yielded significant overlap between the mitochondrial binding dye 
(MTG) and the dendrimer indicating that the TSPO targeted dendrimer was on 
the mitochondria.  ClPhIQ-PAMAM-Gd (6) was shown to bind to TSPO with a 
510 nM binding affinity in a radiobinding study completed by Mingfeng Bai. These 
molecules also provide increased relaxation compared to Magnevist™.  Due to 
the Gd3+ loaded within the dendrimer, EM studies were performed by Dr. Bernard 
Anderson.  EM studies confirmed that the ClPhIQ-PAMAM compounds are 
labeling the mitochondria by only producing contrast on mitochondria of cells 
dosed with ClPhIQ-PAMAM-Gd (6).  Through developing TSPO targeted 
dendrimers, the fields of dendrimer functionalization, characterization of 
functionalized dendrimer products, fluorescence and MRI imaging, TSPO 
targeting and biological EM have been advanced.   
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2.11 Experimental Procedures 
General Methods:  
 G(4)-PAMAM™ dendrimer in a 10% w/w solution of methanol was 
purchased from Fischer Scientific and pipetted into a pre-weighed vial 
immediately before use.  The methanol was evaporated under a stream of Ar(g) 
and the resulting viscous oil was dissolved in water, frozen and lyophilized to 
give a fluffy white powder.  The mass of the dendrimer was determined by re-
weighing the vial and calculating the mass difference.  1-(2-
chlorophenyl)isoquinoline-3-carboxylic acid ClPhIQ Acid was synthesized in our 
laboratory as previously reported36-37.  All 1,4,7,10-Tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) and DOTA derivatives were purchased form 
Macrocyclics and used as arrived.  All other chemicals were purchased from 
Fischer Scientific and used as is unless otherwise indicated.   
MALDI-TOF MS were obtained on a PerSeptive Biosystems Voyager-DE 
STR mass spectrometer.  Freshly recrystalized trans-indole acrylic acid (IAA) 
was used as the matrix in a 10 mg/mL solution of DMSO.  The plate was spotted 
with 1 μL of a 10:1 solution of matrix to analyte.  NMR spectra were obtained on 
a 400 MHz Bruker AV-400 instrument with a 5 mm Z-gradient broadband inverse 
probe.  NMR spectra were obtained in d6-dimethyl sulphoxide. UV-vis spectra 
were obtained on a Shimadzu 1700 UV-vis spectrophotometer.  Fluorescence 
spectra were obtained using a ISS PCI spectrofluorometer at room temperature.  
MR relaxivities were obtained using a Maran 0.5T NMR scanner.   
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ClPhIQ-G(4)-PAMAM™ (1): 
 First, ClPhIQ Acid (152.9 mg, 540 μmoles) and benzotriazol-1-
yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOPCl, 288.1 mg, 
651 μmoles) were dissolved in 2 mL of DMSO each.  Triethyl amine (Et3N, 100 
μL) was added to the ClPhIQ Acid solution.  The BOPCl solution was added to 
the ClPhIQ Acid solution.  The mixture was stirred for 5-10 minutes (sometimes a 
change from clear to bright orange would occur) and was then added to a stirred 
solution of G(4)-PAMAM™ dendrimer (252.2 mg, 18 nmoles) in DMSO (5 mL).  
The reaction was stirred at room temperature overnight.  Unreacted ClPhIQ Acid 
was removed by diluting the solution 4 fold with water and placing the solution in 
an Amicon Centrifugation molecular weight filter (molecular weight cut off = 5 
kDa.) and concentrating the solution to approximately 500 μL via centrifuging at 
3000 revolutions/minute (1419 x g) for 1 hour.  The solution was diluted and re-
concentrated three times with water to wash any unreacted materials away.  
Finally, the solution was lyophilized to give 441.2 mg (100 % yield) of a slightly 
yellow powder.  The same procedure was followed for synthesizing the 
(ClPhIQ)12-PAMAM using fewer equivalents of ClPhIQ Acid and BOPCl.  
ClPhIQ30-G(4)-PAMAM:  MALDI-TOF MS 19,500 a.m.u.  1H NMR (300 MHz, 
CDCl3) δ 8.8 (1H, s), 8.6 (1H, s), 8.2-8.5 (5H, m), 7.5-8.0 (9H, multi), 2.9 (3H, bs) 
and 3.1-3.5 (28H, m) ppm.  
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ClPhIQ-G(4)-PAMAM™-Lissamine (2): 
 G(4)-PAMAM™ (9 mg, 400 nmoles) with or without ClPhIQ Acid was 
dissolved in 2 mL of dimethylformamide (DMF). Next, 23 μL of a 17.3 mM 
solution of lissamine sulphonyl chloride™ was added to the stirred dendrimer 
solution.  The reaction was stirred overnight followed by purification in Amicon 
Centrifugation filters as described above and lyophilized to give 5.6 mg (61% 
yield) of a pink fluffy solid.  The presence of the fluorophor was confirmed with 
UV-vis (max absorbance at 551 nm) and Fluorescence (ex 551 nm, em. 586 nm) 
spectroscopies.  Specific conditions and yields provided above were for 
ClPhIQ23-G(4)-PAMAM, but UV-vis and fluorescence spectra were identical for 
ClPhIQ12-PAMAM and PAMAM-Liss.   
 
ClPhIQ-G(4)-PAMAM™-DOTAtBu (3):  
 ClPhIQ-G(4)-PAMAM™ (202 mg, 9 μmoles) and DOTAtBu (179 mg, 97 
μmols) were dissolved in 2 and 1 mL of DMSO respectively.  The 1,4,7,10-
Tetraazacyclododecane-1,4,7-tris(t-butyl acetate)-10-acetic acid mono(N-
hydroxysuccinimide ester) (DOTAtBu-NHS) solution was added dropwise to a 
stirring solution of ClPhIQ-G(4)-PAMAM™ over a 10 minute period.  The reaction 
was stirred overnight and purified with the Amicon Centrifugation filters (5kDa. 
MWCO) following the procedure used for ClPhIQ-G(4)-PAMAM™ purification 
and lyophilized to give 163.2 mg (100% yield) of ClPhIQ-G(4)-PAMAM™-
DOTAtBu.  The molecular weight was determined using MALDI-TOF MS to be 
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31,000 a.m.u.  1H NMR (300 MHz, CDCl3) δ 8.8 (1H, s), 8.6 (1H, s), 8.2-8.5 (20H, 
m), 7.5-8.0 (9H, multi), 2.9 (3H, bs) and 3.1-3.5 (208H, m), 1.4 (108, s) ppm. 
 
ClPhIQ-G(4)-PAMAM™-DOTA (4): 
 ClPhIQ-G(4)-PAMAM™-DOTAtBu (256.0 mg, 9 μmoles) was dissolved in 
3 mL of neat trifluoroacetic acid (TFA) and stirred overnight.  The solution was 
diluted 10 fold with water and purified with Amicon Centrifugation filters (5kDa. 
MWCO) following the procedure used for ClPhIQ-G(4)-PAMAM™ purification 
and lyophilized to give 120 mg (100% yield).  The molecular weight was 
determined using MALDI-TOF MS to be 27,000.  1H NMR (300 MHz, CDCl3) δ 
8.8 (1H, s), 8.6 (1H, s), 8.2-8.5 (5H, m), 7.5-8.0 (20H, multi), 2.9 (3H, bs) and 
3.1-3.5 (73H, m) ppm. 
 
ClPhIQ-G(4)-PAMAM™-DOTA-Lissamine (5): 
 ClPhIQ-G(4)-PAMAM™-DOTA (4.8 mg, 148 nmoles) was dissolved in 1 
mL of dimethylformamide (DMF). Next, 12.8 μL of a 17.3 mM solution of 
lissamine rhodamine B sulfonyl chloride™ (221 nmoles) was added to the stirred 
dendrimer solution.  The reaction was stirred overnight followed by purification in 
Amicon Centrifugation filters (5kDa. MWCO) as described above and lyophilized 
to give 2.8 mg (57% yield) of a pink fluffy solid.  The presence of the fluorophor 
was confirmed with UV-vis (max absorbance at 551 nm) and Fluorescence (ex 
551 nm, em. 586 nm) spectroscopies.   
 
74 
ClPhIQ-G(4)-PAMAM™-DOTAGd3+(6): 
 ClPhIQ-G(4)-PAMAM™-DO3A (22 mg, 679 nmoles) was dissolved in 
water. Next, 1 mL of a 9.1 mg/mL solution of GdCl3 (9.1 mg, 25 μmoles) was 
added to the dendrimer solution.  The reaction was stirred at room temperature 
for 24 hours and purified with Amicon Centrifugation filters (5kDa. MWCO) 
following the procedure used for ClPhIQ-G(4)-PAMAM™ purification and 
lyophilized to give 24.7 mg (100% yield).  The molecular weight was determined 
using MALDI-TOF MS to be 30,500 Da.   
 
ClPhIQ-G(4)-PAMAM™-DOTAGd3+-Lissamine (7): 
 ClPhIQ-G(4)-PAMAM™-DOTAGd3+ (5.3 mg, 145 nmoles) was dissolved 
in 1 mL of dimethylformamide (DMF). Next, 12.7 μL of a 17.3 mM solution of 
lissamine rhodamine B sulfonyl chloride™ (220 nmoles) was added to the stirred 
dendrimer solution.  The reaction was stirred overnight followed by purification in 
Amicon Centrifugation filters (5kDa. MWCO) as described above and lyophilized 
to give 3.7 mg (69% yield) of a pink fluffy solid.  The presence of the fluorophor 
was confirmed with UV-vis (max absorbance at 551 nm) and Fluorescence (ex 
551 nm, em. 586 nm) spectroscopies.   
 
G(4)-PAMAM™-Lissamine: 
 G(4)-PAMAM™ dendrimer (5.5 mg, 393 nmoles) was dissolved in 3 mL of 
DMF and 22 μL of 17.3 mM lissamine rhodamine B sulfonyl chloride™  in DMF 
was added to the stirred dendrimer solution.  The reaction was stirred overnight 
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followed by purification in Amicon Centrifugation filters (5kDa. MWCO) as 
described above and lyophilized to give 4.0 mg (70% yield) of a fluffy pink solid.  
 
Cell Internalization Experiments 
 G(4)-PAMAM™-Lissamine derivatives: Either 20,000 C6 rat glioma or 
40,000 MDA-MB-231 breast cancer cells were plated into collagen coated glass 
bottom microscopy (MatTeck™) dishes and allowed to grow for two days in cell 
media. After two days, the cells had good morphology and were attached, 
however were not confluent. G(4)-PAMAM™-Lissamine compounds (with or 
without other moieties) were diluted to 1 μM with media from a 10 mg/mL stock 
solution in DMSO. The media over the cells was replaced with the media 
containing the fluorophor and incubated for 6-12 hours. The media was then 
poured off and the cells were carefully rinsed 3-4 times with Dulbecco’s 
Phosphate Buffered Saline (DPBS). The cells were imaged live. Both white light 
and fluorescence pictures were obtained. 
For fixed cells, the rinsed cells were incubated at room temperature for 30 
minutes with a 4% Para formaldehyde solution.  The cells were carefully washed 
4 times with DPBS and stored under DPBS at 4 C until imaged (not longer than 
1 week, typically overnight).  Immediately before imaging, the fixed cells were 
incubated with a 25 nM solution of mitotracker green (MTG) for 10 minutes.  
Excess MTG was removed by 4 washings with DPBS and the cells were imaged. 
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Radiobinding Assay:  
 To complete this assay, C6 rat glioma cells (cultured in Dulbecco’s 
modified Eagle medium (DMEM)-F12 medium (Gibco/Invitrogen) supplemented 
with 0 5% FBS and 2.5% horse serum (HS) at 3.7% CO2) were scraped from 150 
mm culture dishes into 5 mL of phosphate buffered saline (PBS), dispersed by 
trituration, and centrifuged at 500 xg for 15 min. Cell pellets were resuspended in 
PBS and assayed to determine protein concentration. The binding studies with 
[3H]PK11195 on 30 μg of protein from cell suspensions were performed as 
previously described 176.  The data was analyzed using PRISM software (vs 4.0, 
GraphPad, Inc., San Diego, CA).  In PRISM, the one binding site competition 
assay wizard was used, which incorporates the equation: Y=Bottom + (Top-
Bottom)/(1^10(X-LogEC50)).  For the ClPhIQ-PAMAM-Gd dendrimer, the IC50 
was found to be 510 nM on a per ClPhIQ ligand basis with a goodness to fit error 
of 0.9394. 
 
Preparation of TEM Samples:  
 C6 cells were plated in a 4 cm culture dish, allowed to propagate to near 
75% confluency and treated with a 32 μM ClPhIQ-PAMAM-Gd solution in 
Dulbecco’s Modified Eagle Medium.  After incubation at 37 °C for 10 hours, the 
C6 cells were then washed three times with a 0.1 M solution of sodium 
cacodylate buffer to remove any extracellular ClPhIQ-PAMAM-Gd.  The cells 
were subsequently fixed for one hour using a 4% paraformadehyde solution.  
The fixed cells were post-fixed using a 1% Osmium Tetroxide solution, 
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dehydrated using ethanol, pelletized and sliced into 80 nm thick sections.  The 
sections were placed on a 300 mesh copper grid and imaged on a Phillips CM-12 
Electron Microscope.   
 
Relaxivity of Gd Dendrimers:   
 Samples were prepared at 5 concentrations (in Gd) from 1 μM to 1 mM, 
depending on the availability of sample.  Pre-written pulse sequences were used 
to obtain the relaxation at each concentration for both T1 and T2 which varied the 
time intervale between the pluse and detecting the population that had relaxed.  
The data was graphed and fitted to a three parameter exponential rise to max 
curve to give the relaxation at each concnetration.  Each sample was run 3 times 
with 15 minute intervals between trials.  The relaxivity was determined by 
graphing the relaxation versus concentration and fit to a line.  The slope of the 
line is the relaxivity.   
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CHAPTER III 
 
 
 
ATTEMPTED DELIVERY OF DOX WITH MMP-9 TARGETED DENDRONS 
 
 
 
3.1Introduction 
 Although there is a plethora of research being done in cancer, science still 
has left many questions about the cause, progression and best therapeutic 
strategy unanswered.  Of the different angles being developed, “smart systems” 
are an imperative branch to be developed.  These systems are usually based on 
a large MW scaffold and are designed to selectively target disease leaving 
healthy cells and tissue unaffected.  Smart systems can be designed to also to 
image the location(s) of diseased tissues while subsequently delivering therapy 
50, 121.  Although there are a few smart systems undergoing clinical trials 177, 
many opportunities exist toward improving clinical outcomes for cancer patients. 
Matrix metalloproteinases (MMPs) represent an attractive target for smart 
system approaches to treating and diagnosing cancer.  Specific MMPs have 
been associated with the microenvironment of tumors and are found in 
increasing levels of concentration through all stages of tumor progression, 
making them good targets for prodrug therapy.  In addition, several short peptide 
sequences have been identified that are cleaved selectively by a specific MMP or 
specific groups of MMPs.  One such sequence, AVRWLLTA, is known to be 
cleaved by MMP9 between the tryptophan and leucine residues with good 
selectivity178.  Although pharmacological inhibitors have been unsuccessful in 
79 
treating MMP associated cancers, other non-inhibitor approaches utilizing MMP 
enzymes as targets have been successful120, 179-180.  The goal of this part of the 
project is to develop a modular system for therapeutic, efficacy monitoring, 
molecule tracking and tenability based on a dendrimeric scaffold.  The modular 
system will be explored by making an MMP-9 cleavable peptide for therapeutic 
delivery to the primary tumor site of cancerous tissue as well as micrometastatic 
lesions while leaving healthy tissue unaffected by the drug.   
The development of improved scaffolds for imaging and drug delivery is 
being extensively investigated.  Scaffolds allowing the attachment of a variety of 
different modalities to a single nanoparticle for targeting, imaging, drug delivery 
and controlling circulation time have been reported; however no modular systems 
in which pieces of nanoparticles can be synthesized individually and “mix and 
matched” together have been reported.  One challenge with this type of system 
is characterization of both the precursor scaffolds and the functionalized product.  
The modular system being developed here includes the therapeutic (as 
described in this and the following chapter), a beacon for monitoring MMP 
cleavage, a tracer for monitoring the location of the scaffold before and after 
cleavage and room for one more modality.  The fourth modality could be an 
agent to increase circulation time (such as PEG), target specific tumor receptors 
(small molecule ligands, antibodies, proteins, etc.), or a second therapeutic as 
well as a number of other agents.   
In this chapter I report the synthesis and characterization of a prodrug 
component of a modular system based on polyester backbones.  The prodrug 
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contains the doxorubicin (DOX), modified for attachment and an MMP9 cleavable 
peptide for inactivation of the drug until released.  The DOX was then attached to 
a dendron scaffold and chemical characterization of the molecule was completed 
to determine the exact number of drug molecules per dendron.  Finally, 
preliminary cellular studies were performed which indicate this DOX-peptide-
Dendron is not a viable candidate to move forward into animals or for 
combination with the other pieces of the modular system.  The goal of this part of 
the project (Chapters 3, 4 & 5) is to develop a MMP-9 cleavable peptide to 
deliver therapy to the primary tumor site of cancerous tissue as well as 
micrometastatic lesions while leaving healthy tissue unaffected by the drug.   
 
3.2 Synthesis of H2N-Gly-Dendron 
In the construction of the MMP-9 cleavable peptide-dendron scaffold, Boc-Gly (2-
(tert-butoxycarbonylamino)acetic acid) was first attached to the dendron (8, 2- 
 
 
 
 
 
Scheme 3.1.  Synthesis of H2N-Gly-Dendron. 2-(benzyloxycarbonyl)-2-
methylpropane-1,3-diyl bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) 
(H2N-Gly-Dendron, 9).   
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 (benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis(3-hydroxy-2-(hydroxymethyl)-
2-methylpropanoate) reported by Hult et. al.181 for easier conjugation of the 
peptide since primary amines are more reactive than alcohols.  This was 
accomplished by reacting dendron 8 with excess Boc-Gly using 1-ethyl-3-(3'- 
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Figure 3.1 ESI MS of Boc-Gly-Dendron. 
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dimethylaminopropyl)carbodiimide (EDCI) as the coupling agent and 
diisoproplyethyl amine (DIEA) in dimethyl formamide (DMF) under anhydrous 
conditions.  The crude product was purified with the Biotage SP1™ system (silica 
gel with a hexane/ethylacetate gradient) to give Boc-Gly-Dendron (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-((2-
amino acetate)-methyl)-2-methylpropanoate) in 31% yield.  The Boc-Gly-
Dendron was characterized with both 1H NMR and ESI+ MS.  The MS gave the 
product ion peak at 1,085 (Figure 3.1).  The NMR provided all the expected 
peaks, including carbamate NHs at 8.0, aromatic benzyl peaks at 7.3, benzyl CH2 
peak at 5.2, Gly and interior dendron methylenes from 3.7-4.4 and methyl peaks 
from the Boc protecting groups and dendron interior (Figure 3.2).  There was also 
a small amount of DMF still present in the product even after extensive 
concentration and chromatography as seen at 2.9 ppm in the NMR.  
The Boc groups were removed with TFA, either neat or in 50% methylene 
chloride, to give H2N-Gly-Dendron (9, 2-(benzyloxycarbonyl)-2-methylpropane-
1,3-diyl bis[3-(2-amino acetate)-2-((2-amino acetate)-methyl)-2-
methylpropanoate).  The H2N-Gly-Dendron was characterized with MS and NMR.  
The MS provided the expected product ion peak at 685.40 (Figure 3.3).  
Extensive NMR characterization studies were performed, including 1H, HSQC  
(1H-13C) and HMBC (1H-13C) spectra to obtain the exact assignments of each  
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peak for later evaluation after Fmoc-[Ahx]-AVRWLLTA-[Ahx] was coupled to 
H2N-Gly-Dendron (9).  The proton peaks were mostly assigned using the proton 
NMRs (Figure 3.4) of the starting materials and confirmed with the HSQC and 
HMBC spectra (Figures 3.5 and 3.6).  Again, the 1H NMR provided the expected 
peaks at 8.5 (amines), 7.3 (Aromatic Benzyl protons), 6.3 (Benzyl methylene), 
4.3 (interior dendron methylenes), 3.8 (Gly methylenes) and 1.2 (interior dendron 
methyls).  The Gly methylene peak was confirmed by looking at the HSQC and 
HMBC data where HSQC shows protons coupled to carbon by 1 bond (proton 
 
 
Figure 3.2 NMR of Boc-Gly-Dendron. 
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directly bonded to that carbon) and HMBC shows protons coupled by 2 bonds 
(the proton is coupled to the carbon alpha to it).  In the HSQC  
 
 
 
 
 
spectra, the peak at 3.8 ppm is coupled to the carbon at 40 ppm, indicating that 
the carbon at 40 ppm is the glycine methylene carbon.  The ester carbonyl 
between the glycine and dendron scaffold was assigned as 168 pmm because in 
the HMBC, 3.8 ppm is coupled with 168 ppm (Figure 3.6).  These assignments 
LS-vi-70-1 #1-25 RT: 0.03-0.82 AV: 25 NL: 8.53E6
T: + p Full ms [50.00-2000.00]
200 400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
685.40
742.33
628.40
343.27 1368.93764.47595.47 1536.87940.33472.33311.27199.20 1099.27 1203.33 1798.00 1884.87
LS-vi-70-1 #1-25 RT: 0.03-0.82 AV: 25 NL: 8.53E6
T: + p Full ms [50.00-2000.00]
665 670 675 680 685 690 695 700 705 710 715
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
685.40
686.33
676.47
687.40 707.47
677.53
708.40688.27 698.47678.40670.47 713.27666.47 715.27673.20 696.40 700.53
R
el
at
iv
e 
A
bu
nd
an
ce R
el
at
iv
e 
A
bu
nd
an
ce
 
 
Figure 3.3.  ESI MS of H2N-Gly-Dendron. 
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were used later to determine whether the peptide (Fmoc-[Ahx]-AVRWLLTA-
[Ahx]) was attached to the H2N-Gly-Dendron scaffold.  
 
 
 
 
 
 
Figure 3.4.  1H NMR data of H2N-Gly-Dendron.  
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3.8 ppm
40 ppm
 
 
Figure 3.5  HSQC of H2N-Gly-Dendron. 
3.8 ppm
168 ppm
 
 
Figure 3.6 HMBC NMR spectra of H2N-Gly-
Dendron (9).
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3.3 Synthesis and Characterization of Fmoc-Pep-dendron 
The peptide sequence AVRWLLTA has been shown by Chen et. al. to be 
cleaved specifically by MMP9 178.  Therefore, this sequence was chosen to be 
used in constructing an MMP9 cleavable therapeutic scaffold.  The peptide was 
attached to the dendron by activating the carboxylic acid of Fmoc-[Ahx]-
AVRWLLTA-[Ahx] with 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDCI)  
 
 
 
 
 
and N,N-Diisopropylethylamine (DIEA) in anhydrous DMF under Ar(g) for 30 
minutes.  After activation of the peptide, H2N-Gly-Dendron (9) in anhydrous DMF 
was added to the reaction.  The reaction was stirred until complete (by HPLC) 
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Scheme 3.2.  Conjugation between the Gly-Dendron and Fmoc-[Ahx]-
AVRWLLTA-[Ahx] 
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and then concentrated and purified with high pressure liquid chromatography 
(HPLC) to give Fmoc-Pep-Dendron (10).    
The reaction was monitored by HPLC using a BioBasic 120 SEC column.  
Initially a reverse phase C18 column was used, but deciphering what new peaks 
were generated throughout the course of the reaction were was impossible 
without another means of characterization.  At the time no MALDI-TOF MS 
conditions could be found to give product ion peaks, making identification by MS 
impossible as well.  With SEC the peaks elute in order of relative size; providing 
a starting point for characterizing the product(s) from small molecular weight 
biproducts.  As shown in Figure 3.7, the dendron (black) is eluted at 21 minutes  
(E) and the Fmoc-[Ahx]-AVRWLLTA-[Ahx] peptide spiked with EDCI (blue) at 19 
minutes (D).   The coupling reaction (red) gives several peaks at 14 (A), 16 (B), 
18 (C), 19 (D, shoulder), 23 (F) and 28 (G) minutes.  The reaction was purified by 
collecting the peaks off the HPLC and concentrating each individually.  By the 
nature of SEC chromatography, peaks A, B and C at 14, 16 and 18 minutes 
respectively in the reaction trace are larger molecules than any of the 
components in the reaction mixture.  Peak D in the trace is the peptide and the 
shoulder of one of the peaks in the reaction.  For characterization purposes, the 
shoulder in the reaction trace (Figure 3.7, red) was carefully separated from peak 
C by collecting 3 fractions: C, C & D, and D.   The ESI+ MS of this shoulder (peak 
D) is consistent with that of the peptide.  Peaks A, B and C were expected to be 
conjugation products, given that larger molecules elute earlier in SEC.  No side  
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reactions that produce larger molecules were expected, but to be sure peaks A, 
B and C were further characterized to determine coupling efficacy.     
Although SEC provided evidence that the coupling occurred, this was not 
strong enough evidence for peptide attachment, nor did it provide information 
about how many peptides had been attached to each dendron.  Since initial 
attempts at MALDI-TOF MS failed, two other methods were developed to 
characterize the coupling reaction and to determine the number of peptides 
attached to each dendron.  Peak A was characterized for the formation of the 
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Figure 3.7.  SEC Traces of Fmoc-[Ahx]-AVRWLLTA-[Ahx] with EDCI (Blue), 
Gly-Dendron (black) and the coupling reaction between the two components 
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bond between the carboxyl terminal of the peptide(s) and the primary amine(s) of 
the dendron using 2 dimensional (2D) NMR techniques.   Then peaks A, B, C 
and D were analyzed with a ninhydrin assay for quantifying the amine content 16, 
leading to the number of peptides attached to the dendron.   
 
 
 
 
 
The NMR experiments were meant to determine that a bond formed 
between the carboxylic acid of the Fmoc-[Ahx]-AVRWLLTA-[Ahx] peptide and the 
amine(s) on the dendron.   To obtain the needed information, 1H, HSQC (Figure 
3.8) and HMBC (Figure 3.9) NMRs from the individual pieces (dendron and  
2.1/ 34 ppm
1.5/ 24 ppm
1.2  /26 ppm
3.0/ 38 ppm
 
 
Figure 3.8.  HSQC NMR of Fmoc-[Ahx]-AVRWLLTA-[Ahx]. 
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Fmoc-[Ahx]-AVRWLLTA-[Ahx]) were assigned.  The Fmoc-[Ahx]-AVRWLLTA- 
[Ahx] peptide peaks were assigned by finding the five carbon methylene chains 
present at either end of the peptide (Ahx groups).  The specific proton and  
 
 
 
 
 
carbon signals for the carboxy terminal methylene chain were assigned by 
locating the carboxylic acid carbon at 175 ppm.  Then the HMBC and HSQC 
2.1/ 175 ppm
2.1/ 24 
ppm
 
 
Figure 3.9 HMBC NMR of Fmoc-[Ahx]-AVRWLLTA-[Ahx]. 
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spectra were assigned by working from the peak at 2.1 ppm that was coupled to 
175 ppm in the HMBC spectra, therefore 2.1 ppm was assigned as  
 
 
 
 
 
the methylene protons alpha the carboxylic acid terminus.  HSQC indicated that 
the carbon peak at 34 ppm was the carbon alpha to the carboxylic acid by 
association with the 2.1 ppm 1H peak.   The peak at 2.1 ppm was coupled to both 
175 and 24 ppm in the HMBC spectra.  Thus, the peak at 24 ppm was assigned 
to the carbon in the beta position from the carboxylic acid.  HSQC then provided 
the coupling signal between 24 ppm and 1.5 ppm to indicate that the 1H peaks at 
 
 
Figure 3.10 Proton and carbon assignments from the proton, HSQC and 
HMBC NMR spectra 
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1.5 ppm were on the beta carbon.  The remaining peaks were assigned using 
these techniques.  The peak assignments are shown in Figure 3.10.  
 To determine coupling between Fmoc-[Ahx]-AVRWLLTA-[Ahx] and H2N-
Gly-Dendron (10), HMBC NMR was used to prove that the methylene proton of 
the glycine methylene (3.8 ppm) on the H2N-Gly-Dendron is coupled to the 
carbonyl carbon (173 ppm) on the peptide.  Further confirmation that the carbon 
at 173 ppm was the carboxylic acid carbon from the peptide came from the peak 
between 173 ppm and 2.1 ppm (the methylene protons on the peptide chain).  An 
HSQC was also used to monitor any shifts in the proton and carbon spectra that 
occurred due to coupling (Figures 3.8, 3.9 and 3.11).  Fortunately, the peak at 
3.8 ppm did not shift significantly nor did any other proton peak shift to overlap 
this methylene.  This system is a rare example for using NMR to determine 
coupling, since often with larger synthetic products peaks overlap too much to be 
assigned.  
 Since no information regarding the coupling efficiency was obtained with 
NMR, a ninhydrin assay to quantify the concentration of the primary amines in 
each sample was completed.  The primary amine concentration was then used to 
back calculate the number of peptides attached to the dendron.  Ninhydrin assay 
was performed by reacting samples with a DMSO ninhydrin standard in boiling 
water for 10 minutes followed by cooling and addition of ethanol.  A series of 
standard leucine samples from 10 nM to 1 mM were reacted along with known 
94 
3.8, 41 ppm
3.8, 173 ppm 2.1, 173ppm
 
 
 
 
 
Figure 3.11.  The HMBC (blue) and HSQC (red) NMR spectra of FmocPep-
Dendron (10).  Top: full spectra; Bottom: zoom in of the peak at 3.8 and 173 ppm. 
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samples like the peptide and the Gly-Dendron and the unknown samples (peaks 
eluted from the SEC column) at 0.1 mg/mL.  The amine concentration of each 
sample was determined from the linear relationship of the leucine standards.  All 
four primary amines on the dendron reacted with the ninhydrin while the peptide 
did not react significantly with the ninhydrin, as expected since no primary 
amines are present.  To determine the number of free amines present in the 
unknown samples, the amine concentration of 1, 2, 3, and 4 peptides attached to 
the dendron were calculated.  These concentrations were then compared with 
the concentration of amine determined by the assay.    As shown in Figure 3.12, 
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Figure 3.12.  Concentration of peaks A-D eluted from the SEC column as 
determined by the ninhydrin assay.
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peak A has the same amount of primary amine as the peptide, which was 
normalized to zero.  A steadily increasing amount of primary amine is found from 
peak A to peak C followed by the concentration dropping radically from peaks C 
to D.  Table 3.1 presents calculated concentrations of amine and presents the 
expected concentration for each anticipated coupling product (1, 2, 3 or 4 
peptides attached) as well as the concentrations of amine compared to the 
peptide.  All samples were normalized to the peptide.  As can be seen in Table 
3.1, peaks A and D have no primary amines indicating they are either peptide or 
4 peptides attached to the dendron, since these are the two possible products  
 
 
 
 
 
without any primary amines.  Peak B is 21 μM in amine, equivalent with 3 
peptides attached to the amine.  Peak C is 77 μM in amine, about half way 
between 2 and 1 peptides attached to the dendron.  Based on the SEC, NMR 
and quantitative ninhydrin data it was concluded that Peak A has 4 peptides 
Table 3.1.  Concentration of primary amine in the coupled product and the 
calculated concentration for each theoretical product. 
 
Compound Calculated 
Concentration 
Peak Concentration 
Fmoc-[Ahx]-AVRWLLTA-
[Ahx] 
0 uM   
4 peptides attached 0 uM A 0 uM 
3 Peptides Attached 21 uM B 21 uM 
2 Peptides Attached 59 uM C 77 uM 
1 Peptide Attached 147 uM D 0 uM
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attached to the dendron, peak B has 3 peptides attached; peak C is a mixture of 
1 and 2 peptides attached; and peak D is unreacted peptide. 
After several MALDI-TOF MS conditions were attempted, including 
varying the matrix, the concentration of matrix, the concentration of analyte, the 
matrix to analyte ratio and the settings on the instrument, only a peak at 1,471 
could be obtained.  The MW 1,471 was found to be consistent with breakage of 
the ester bond between the Gly and dendron, indicating coupling.  Occasionally, 
the breakage of an interior dendron ester bond was also observed.  These 
MALDI-TOF results gave no information about how many peptides were attached 
to each dendron.  Finally, MALDI-TOF conditions were discovered that provided 
the expected MW ion.  To obtain spectra of intact molecules, the samples were 
dissolved in 80 -90% Tricine Buffer and 10 - 20% methanol, then mixed 10:1 with 
alpha-cyano-4-hydroxycinnamic acid (CHCA) in 50:50 acetonitrile/water with 
0.05% TFA and spotted on the MALDI plate.  The MALID-TOF MS of peak A is 
shown in Figure 3.13.  The MW ion peak is at 6,167.  The peak at 4,733 is 
consistent with 1 peptide fragmenting between the Gly and the dendron.  Since 
the Gly was initially attached to the dendron, this indicates that it is a fragment 
and not incomplete coupling.  Also, SEC confirmed that only 1 peak (consistent 
with 4 peptides attached) was present.  The fragment at 2,735 is consistent with 
2 peptides fragmenting at the ester bond in the interior dendron portion and 1 
peptide fragmenting between the valine and arginine residues.  Finally, the peak 
at 1,471 correlates to the Fmoc-Pep-Gly peak that was seen in many of the 
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previously attempted MALDI spectra indicating coupling between the peptide and 
the dendron.  
 
 
 
MALDI-TOF MS of Fmoc-[Ahx]-AVRWLLTA-[Ahx]-Dendron
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Figure 3.13.  MALDI-TOF MS of Fmoc-Pep-Dendron (10).   
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3.4 Synthesis of DOX-Pep-Dendron 
In order to attach doxorubicin (DOX) to the peptide-dendron conjugate, the 
DOX first had to be modified to contain a carboxylic acid.  This was 
accomplished by reacting the DOX with glutaric anhydride (Scheme 3.3), 
producing 5-((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-((1S,3S)-3,5,12-trihydroxy-3-
(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-
yloxy)tetrahydro-2H-pyran-4-ylamino)-5-oxopentanoic acid (11, DOX-COOH), a 
DOX with a linker off the amine that terminates in a carboxylic acid.  Mass 
SEC Chromatogram of the Peptide-Dendron Conjugate Before &
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Figure 3.14.  SEC traces before and after treatment with piperidine to remove 
the Fmoc groups. 
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spectrometry confirmed the product with MW peaks of 680 (DOX-COOH+Na+) 
and 696 (DOX-COOH+K+).  The spectrum is shown in the experimental section.   
 
 
 
 
 
DOX-COOH (11) was attached to the H2N-Pep-Dendron via peptide coupling 
conditions as shown in Scheme 3.3.  The DOX-COOH (11) was activated with 
EDCI in DMF with DIEA prior to addition to H2N-Pep-Dendron in DMF.  Typically, 
6 - 8 equivalents of DOX-COOH were used per dendron to ensure complete 
coupling of all primary amines present.  The reaction was followed with SEC by 
running the reaction within 5 minutes of the activated DOX-COOH (11) being 
added to the dendron and then often 2 and 4 hours followed by at least every 24 
 
Scheme 3.3.  Synthesis of DOX-Pep-Dendron (13). 
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hours after the coupling reaction was started.  The reaction was followed at 280 
nm to track the H2N-Pep-Dendron (12) and 500 nm to track the DOX.  A new 
peak appeared at 18 minutes in both the 280 and 500 nm channels which is 
consistent with a coupling product.  Once the SEC remained consistent, the 
reaction was concentrated and purified by SEC. 
 
3.5 Characterization of DOX-Pep-Dendron 
The DOX-Pep-Dendron was characterized with both SEC, MALDI-TOF MS and 
ninhydrin.  Since DOX absorbs at 500 nm while the other components of the 
reaction do not, the product peak was located by monitoring the chromatogram at 
500 nm for DOX-COOH (11) and 280 nm for H2N-Pep-Dendron (12).  As can be 
seen in Figure 3.15, the DOX-COOH (11) coupled H2N-Pep-Dendron (12) elutes 
at 18 minutes while DOX-COOH (11) elutes at 24 minutes.  Furthermore, the 
DOX-Pep-Dendron (13) peak elutes earlier than the H2N-Pep-Dendron (12), 
indicating the creation of a larger molecule.  However, the DOX-Pep-Dendron 
(13) elutes later than H2N-Pep-Dendron (12).  This is possibly due to a 
conformational change in the molecule from going to a hydrophobic end groups 
(DOX) form hydrophilic (NH2) end groups.  Since the SEC column is designed for 
peptides and proteins, which have a defined shape, it is possible that the less 
defined structures of H2N-Pep-Dendron (12) and DOX-Pep-Dendron (13) could 
interact differently with the column packing beads and cause elution times to 
vary.   
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 To further show that the DOX-COOH attached to the H2N-Pep-Dendron 
(12), MALDI-TOF MS was performed on the isolated product (Figure 3.16).  
Unfortunately, the product ion peak could not be detected, but a quadruply 
charged (m/z = 4) product ion peak was observed at 1,981 amu.  Also, a peak at 
1,380 amu was detected which is the DOX-[Ahx]-AVRWL fragment, indicating 
coupling of the DOX to the H2N-Pep-Dendron scaffold.  Extensive spotting on a 
TLC plated followed by staining with ninhydrin elicited no color change, indicating 
no primary amines present in the molecule.  The culmination of these data 
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Figure 3.15.  SEC traces of DOX-Pep-Dendron (13) and DOX-COOH (11) 
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indicate that all four primary amines from H2N-[Ahx]- AVRWLLTA-[Ahx]-Dendron 
(12) reacted with the DOX-COOH (11) to give a single product with a DOX-
COOH (11) molecule attached to each amine on the H2N-Pep-Dendron scaffold.  
 
 
  
 
 
3.6 Toxicity studies of DOX-Pep-Dendron 
 Once the synthesis of the DOX-Pep-Dendron was complete, cellular 
toxicity studies were done using PyVT-R221A-luc cells.  These cells were 
developed from the MMTV-driven polyoma virus middle T antigen transgenic 
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Figure 3.16.  MALDI of DOX-Pep-Dendron.   
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mouse, developed by Muller and colleagues in 1992132, which is routinely used in 
the Matrisian laboratory for studies of breast cancer metastasis to the lung.  The 
MMTV-driven polyoma virus middle T antigen transgenic mouse is an improved 
model for studying breast to lung metastasis compared to previous models126.  
Furthermore, these tumors and the resulting cells express high levels of 
MMP9124. 
 
  
 
 
 
 The toxicity studies were done by plating 40,000 cells into 24 well plates 
and allowing them to equilibrate for 24 hours.  Three or four 24 well plates per 
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Figure 3.17.  Toxicity of DOX-Pep-Dendron (13) in PyVT-R221A-Luc cells.
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sample were prepared to obtain 3 - 4 time points.  Cells were then treated media 
containing compound to be tested (Dose 1) and were incubated another 24 
hours.  After 24 hours, three of the replicates were redosed (Dose 2) while one 
plate was treated with trypsin to detach the cells and counted using the trypan 
blue method.  This process was repeated until cells had 4 doses of drug over a 
96 hour period.  The first toxicity studies indicated the intact DOX-[Ahx]-
AVRWLLTA-[Ahx}-Dendron (13) was not toxic to the PyVT-R221A-luc cells.  
Since the molecule was designed as a prodrug, this lack of toxicity was  
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Figure 3.18.  Toxicity curves of Cleaved DOX-Pep-Dendron (13). 
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anticipated.  As seen in Figure 3.17, none of the concentrations of DOX-Pep-
Dendron (6 μM to 51 nM in DOX) were toxic towards the cells.  This was 
compared to a 4.5 μM solution of DOX, which is lethal to the cells.  
 Although the DOX-Pep-Dendron (13) digested with MMP9 to provide the 
cleaved product, DOX-[Ahx]-AVRW, was hypothesized to be toxic against PyVT-
R221A-Luc cells, the compound was found to be non-toxic.  As shown in Figure 
3.18, the cleaved compound had no toxicity at the same concentrations (6 μM to 
51 nM in DOX) as the intact DOX-Pep-Dendron (13), implying that the prodrug 
did not produce a toxic molecule when cleaved.  Although, the inactivation of 
DOX was accomplished with the prodrug approach, it was not possible to 
reactivate the drug’s activity.  Although, the cleaved product, DOX-[Ahx]-AVRW,   
did not produce toxicity, the reason for this lack of toxicity was not completely 
understood.  Any of a number of possible cleaved molecules could lead to the 
lack of toxicity of the cleaved prodrug.  To narrow down the possibilities, the 
DOX-COOH molecule was tested for toxicity against the PyVT-R221A-Luc cells. 
 Further experiments revealed that the DOX-COOH (11) was not toxic at 
concentrations as high as 152 μM while DOX is toxic at concentrations as low as 
184 nM in the PyVT-R221A-Luc cells.  As shown in Figure 3.19, the DOX-COOH  
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(11) did not produce a toxic effect over 96 hours and 4 doses.  With this data in 
hand, further investigation into the literature revealed that modification at the 
amine to form an amide and the specific glutaric acid modification used 
inactivates the toxic effects found in DOX182-183.  In fact most modifications that 
did not leave an amine within close proximity of the DOX amine inactivated the 
DOX131, 182-183.   
 
 
 
 
0 10 20 30 40 50 60 70 80 90 100 110
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
100 ug/mL DOX-COOH
6 ug/mL DOX
Time (Hours)
%
  S
ur
vi
va
l
 
 
Figure 3.19.  Toxicity of DOX-COOH (11) versus DOX.   
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3.7 Conclusions 
In the process of attempting to create an MMP9 prodrug, that can be 
attached to a modular system for delivery and monitoring the drug in vivo many 
lessons were learned.  The most important lesson that was learned was that not 
all coupling strategies produce the desired results.  This knowledge was then 
moved forward into redesigning molecules using a different peptide (AVRWLL) 
and different coupling strategy between the DOX and the peptide.  Major 
accomplishments highlighted in this chapter include, 1) the design and synthesis 
of the delivery system (H2N-Gly-Dendron, 9), 2) the conjugation of the dendron 
scaffold to MMP9 cleavable peptides and 3) cellular toxicity of the DOX 
conjugates.  The major challenge in preparing an MMP9 cleavable peptide 
system was in characterizing the final compounds.  First, attachment had to be 
proven and second how many groups attached needed to be determined.  The 
Fmoc-Pep-Dendron coupling was easily accomplished with standard peptide 
coupling reagents, but finding the appropriated HPLC conditions proved more 
difficult.  Ultimately this was accomplished by using a SEC column rather than a 
reverse phase C18 silica column.  The SEC column provided the added 
advantage of giving the relative size of the starting materials compared to what 
was being formed.  By seeing peaks elute earlier from the column compared to 
the peptide or the dendron it was possible to discern that coupling was taking 
place since larger molecules were being synthesized.  Further characterization 
was performed using NMR, a ninhydrin assay for amines and MALDI-TOF MS.  
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All the data show that the peptide and dendron couple to completion (four 
peptides attach to each dendron). 
 After coupling the dendron and peptide, the first DOX derivative was 
attached to the MMP9 cleavable Fmoc-Pep-Dendron.  This synthesis was 
accomplished by modifying the DOX with glutaric anhydride to provide a 
carboxylic acid off the amine and then coupling to the FmocPep-Dendron.  
Characterization was accomplished using SEC and MALDI-TOF MS.  While, the 
DOX-Pep-Dendron construct was successfully constructed and found to be non-
toxic when DOX was coupled to the scaffold it did not perform as a prodrug.  In 
other words, the toxic effect of DOX could not be re-initiated once DOX was 
released from the scaffold by MMP digestion.  After further investigation, it was 
found that the modified DOX (DOX-COOH, 11) was not toxic to the cells at high 
concentrations (up to 152 μM) concentrations.  Although some literature 
suggested that this modification was acceptable131, upon further investigation two 
papers were found stating that this specific modification eliminated the toxicity of 
DOX182-183.  Since the original strategy with DOX was unfruitful, the system was 
redesigned, based on the literature, to incorporate a new DOX coupling 
strategy184. 
 
3.8 Experimental Procedures 
 
General Methods: 
 MDA-MB-231 cells were purchased from ATCC and cultured in DMEM, 
10% FBS and gentamycin with 5% CO2.  PyVT-R221A-Luc cells were obtained 
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from the Matrisian laboratory and cultured in DMEM without L-glutamine, 10% 
FBS, gentamycin and puromycin with 5% CO2.  LLC-RSV and LLC-MMP9 cells 
were obtained from the Matrisian laboratory and cultured in DMEM, 10% FBS 
and gentamycin with 5% CO2.  The custom ordered peptides were purchased 
from Genscript™.  The enzymes were purchased from Calbiochem.  All other 
chemicals were purchased from Fisher Scientific or Aldrich Chemical companies 
and used as is unless otherwise indicated.   
 
Ninhydrin Assay: 
 A stock solution of leucine was made to be approximately 10 mM in water, 
using a volumetric flask.  A series of more dilute leucine standards were made 
from this original stock solution to cover the amine concentration range being 
examined.  The products to be tested were dissolved in water at 0.1 mg/mL and 
pipetted (100 μl per sample) into individual microcentrifuge tubes.  Next, 200 μl of 
ninhydrin reagent was added and the tubes were sealed and placed in boiling 
water for 10 minutes.  The solutions were cooled to room temperature, 600 μl of 
ethanol was added and the samples were analyzed by looking at the absorbance 
at 562 nm.  A graph of the absorbance intensity versus concentration was linear 
from mM to nM concentrations and used to determine the concentration of 
primary amine present in the sample.   
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5-(3-hydroxy-2-methyl-6-(3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-
6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)tetrahydro-2H-pyran-4-
ylamino)-5-oxopentanoic acid (DOX-COOH, 11) 
 
 Doxorubicin was stirred in DMF with glutaric anhydride overnight and 
purified by silica gel chromatography as synthesized previously131.  1H NMR 400 
MHz; δ 0.9779 (t, 2H), 1.55 (d, 2H), 1.69 (s, 4H), 1.76 (s,2H), 2.72 (s, 2H), 2.98 
(s, 6H), 3.41 (bs, 7H), 6.63 (s, 4H), 7.27 (s, 1H), 7.37 (s, 1H), 7.47 (s, 1H), and 
8.98 (s, 2H) ppm.  13C NMR 125 MHz. δ 15.7 (CH3), 21.7, 22.1, 25.2 (CH2), 32.8 
(CH2), 33.1 (CH2), 34.1 (CH2), 36.3 (CH2), 42.0, 43.5, 54.5 (C-N), 56.1 (CH3-O), 
60.2 (C-O), 65.5 (C-O), 68.3 (C-O), 69.8 (C-O), 72.3 (C-O), 90.3, 94.1 (Acetal), 
114.2 (Ar), 116.2 (Ar), 118.2 (Ar), 120.2 (Ar), 121.4 (Ar), 158.3 (Ar), 158.5 (Ar), 
158.7 (Ar), 158.8 (Ar), 159.0 (Ar), 171.4 (HNCO), 172.0 (COOH), and 174.7 
(C=O) ppm.  COSY correlations: 0.98 to 2.98, 1.55 to 1.76, 1.67 to 3.41, 1.67 to 
2.98, 2.98 to 8.98 ppm. 
 
2-(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-tert-
butoxycarbonylamino acetate)-2-((2-tert-butoxycarbonylamino acetate)-
methyl)-2-methylpropanoate) (Boc-Gly-Dendron): 
  
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for more than 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  First, 2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis(3-hydroxy-2-(hydroxymethyl)-
2-methylpropanoate) (1.1849g, 2.60 mmols), 2-(tert-butoxycarbonylamino)acetic 
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acid (Boc-Gly, 2.0277g, 11.6 mmols) and EDCI (2.4257g, 12.7 mmols) were 
dissolved in DMF individually and then mixed under Ag(g).  Next, DIEA was 
added via syringe and the reaction was stirred overnight (16 hours).  The 
reaction was concentrated under reduced pressure, dissolved in methylene 
chloride (100 mL) and washed with water (3 x 100 mL).  The aqueous layers 
were combined and extracted with methylene chloride (3 x 100 mL).  The organic 
layers were combined and TLC with 1:1 hexanes: ethyl acetate revealed 4 spots 
(Rf = 0.7, 0.38, 0.2, 0.12) after staining with potassium permanganate.  The 
organic layers was dried with magnesium sulphate, filted and concentrated onto 
silica gel at reduced pressure.   The product was purified on the Biotage SP1 
system with a 40i column using a gradiant (100% hexanes to 100% ethyl acetate 
over 700 mL).  The product was isolated as the second peak eluted (Rf = 0.38), 
and concentrated as a viscous yellow oil to yield 886.6 mg pure product (31%).  
MS (ESI)+: 1107.5 Dalton (M + Na)+; Calculated:  1107.48 Dalton 
(C50H76N4O22Na).  1H NMR 400 MHz (d6-DMSO) δ 8.00 (s, 2H), 7.35 (s, 5H), 
5.18 (s, 2H), 4.13 (m, 11H), 3.77 (dm, 12H), 2.96 (s, 6H), 2.88 (s, 7H), 2.05 (s, 
5H), 1.50 (s, 6H), 1.43 (s, 6H), 1.26 (s, 9H), 0.98 (s, 6H) ppm.   
 
2-(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-
((2-amino acetate)-methyl)-2-methylpropanoate) (H2N-Gly-Dendron): 
 
Boc-Gly-Dendron was dissolved in 1 mL of 1:1 methylene chloride to 
trifluoroacitic acid.  The reaction was stirred overnight then concentrated under 
vacuum to provide an oil with a very slight yellow color.  The product was used 
without further purification.  MS (ESI)+: 685.40 Dalton (M + H)+; Calculated:  
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685.29 Dalton (C30H45N4O14).   1H NMR 400 MHz (d6-DMSO) δ 8.05 (bs, 4H), 
7.36 (s, 5H), 5.14 (s, 2H), 4.25 (bs, 11H), 3.81 (bs, 9H), 1.22 (s, 3H), 1.13 (s, 6H) 
ppm.     
 
Fmoc-Pep-Gly-Dendron: 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for more than 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  The peptide of sequence 
Fmoc-Pep-COOH (35.12 mg, 0.026 mmols) was dissolved in 3.5 mL DMF with 
4Α molecular sieves).  Solutions of EDCI (20 mg/mL, 5.87 mg, 0.0306 mmols) 
and BOP (20 mg/mL, 13.5 mg, 0.0305 mmols) were made separately and added 
to the peptide solution followed by DIEA (10 μl. 0.109 mmols).  The peptide 
solution was stirred for 30 minutes at room temperature before H2N-Gly-Dendron 
(3.5 mg, 0.00511 mmols) was added to the reaction.  The reaction was stirred 
under Ar(g) for 69 hours with SEC being completed after 0.3, 1.5, 21, 24, 44, 49 
and 69 hours.  The reaction was filtered and the filter cake with molecular sieves 
was washed with DMF.  The filtrate was concentrated under reduced pressure to 
give a brown oil.  The oil was dissolved in actetonitrile/water and purified by SEC 
to elute 6 fractions, which were concentrated and characterized individually.  The 
first peak eluted provided 22.5 mg (72%) of (Fmoc-Pep)4-Gly-Dendron.  MADLI-
TOF MS (CHCA) Found 6,167 Dalton (M + K)+; calculated 6,162 Dalton 
(C314H453N60O66K).  SEC (55% 0.05% TFA in Acetonitrile/ 45% 0.065% TFA in 
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water) elution time 14 minutes.  Ninhydrin assay (see procedure above): no 
primary amines present.   
 
H2N-Pep-Gly-Dendron: 
 Fmoc-Pep-Gly-Dendron (4.01 mg) was dissolved in 1 mL of DMF and 
injected onto the SEC column.  Then 1 mL of piperidine was added followed by a 
second SEC injection (within 60 seconds).  The reaction was stirred overnight, 
injected onto the SEC column, concentrated under vacuum.  The oily product 
was dissolved in water and lyophilized overnight to give an extremely viscous 
yellow product.  .  MADLI-TOF MS (CHCA) Found 1,256 Dalton (Fragment: 
[Ahx]-AVRWLLTA-[Ahx]-Gly + K)+; calculated 1,251 Dalton (C58H97N15O13K).  
SEC (55% 0.05% TFA in Acetonitrile/ 45% 0.065% TFA in water) elution time 
21.5 minutes.  Ninhydrin assay (see procedure above): 4 primary amines 
present. 
 
5-((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-((1S,3S)-3,5,12-trihydroxy-3-(2-
hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-
yloxy)tetrahydro-2H-pyran-4-ylamino)-5-oxopentanoic acid (DOX-COOH): 
 
First, 2.33 mg (0.00402 mmols) of Doxorubicin ((8S,10S)-10-
((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-
trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-
dione) was dissolved in 0.5 mL of pyridine.  Then, glutaric anhydride (0.46 mg, 
0.00403 mmols) was added.  The reaction was covered with aluminum foil and 
stirred overnight.  Solvent was removed under vacuum and the product was 
purified on the Biotage SP1™ system with a gradient from 100% methylene 
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chloride to 25% methanol.  The product peak was concentrated to give 2.55 mg 
(96%).   MADLI-TOF MS (CHCA) Found 680.39 Dalton (M + Na)+ and 696.94 
(M+K)+ calculated 680.61 Dalton (C32H35NO14Na) and 696.72 Dalton 
(C32H35NO14K). 
 
 
DOX-Pep-Dendron: 
 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for more than 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  DOX-COOH (1.37 mg, 
0.00209 mmols) was dissolve in anhydrous DMF and EDCI (0.7 mg, 0.00365 
mmols) and DIEA (0.7 μl, 0.00765 mmols) were added.  The reaction was stirred 
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Figure 3.20.  Mass Spectrometry of DOX-COOH. 
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for 30 minutes prior to the addition of H2N-Pep-Gly-Dendron (1.37 mg, 0.000519 
mmols) in 0.5 mL DMF.  The reaction was stirred under Ar(g) until SEC indicated 
completion.  SEC was completed after 5 minutes, 2, 6, 24, 27 and 48 hours.  
After 48 hours, not change had occurred since the 27 minute chromatogram.  
The reaction was concentrated under vacuum and purified with SEC 
chromatography to give 25 mg (79%) of DOX4-Pep-Dendron.  MADLI-TOF MS 
(CHCA) Found 1981 Dalton (M+4K)+4; calculated 1,984 (C81H543N64O110K4)/4. 
 
Cleavage of Peptide compounds with Enzymes: 
 The compound to be cleaved or tested for ability to cleave was dissolved 
in methanol at 10 mg/mL.  Next, 100 μl of this solution was diluted with 900 μl of 
tricine buffer to make a 1 mg/mL solution.  The solution was injected into the 
HPLC (C18 silica with 55% 0.05% TFA in Acetonitrile/ 45% 0.065% TFA in 
water) for a zero time point.  Following HPLC, enzyme was added (either MMP9, 
MMP2 or Trypsin).  The vials were incubated at 37 οC overnight.  Again HPLC 
was used to determine what percentage of the sample had cleaved.  For 
samples which produced solid, the solid was collected, dissolved in 100% 
methanol and injected into the HPLC.  The samples were then characterized with 
ESI and MALDI-TOF MS to determine the cleavage products.  The solid usually 
contained the cleaved product. 
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Toxicity studies 
 PyVT-R221A-Luc cells were cultured in glutamine free DMEM media 
supplemented with 10% FBS, 500 μg/mL gentamycin and puromycin. Cells were 
plated at 40,000 – 60,000 cells/mL into 24 well plates (0.5 mL/well) in their 
culture medium.  A separate plated was used for each time point observed in the 
assay.  Thus 4 time points meant that 4 plates were used.  The cells were 
incubated overnight at 37 οC (usually 24 hours).  After examination under the 
microscope to ensure the cells were attached and looked healthy, the media was 
aspirated off each well (taking care to not disrupt the cells) and replaced with 
media containing the drug/ compound of interest or a control compound.  The 
drug and control solutions were made fresh just prior to use.  The cells were 
incubated 24 hours and then either redosed with fresh drug-media solutions or 
the cells were trypsinized and counted using trypan blue.  For typsinization, the 
media was removed by aspiration and each well was washed with 0.5 mL of 
DPBS.  The DPBS was removed and each well was treated with 200 μl of 
trypsin.  The plate was incubated for 10 - 15 minutes and then agitated, either 
with a shaker or by hand.  Finally, 40 μl of trypan blue was added to each well 
(typically 4 wells at a time) and the cells were counted with a hemocytometer.  
The dosing and counting was continued for the remaining time points so that the 
cells were given fresh drug every 24 hours until counted.      
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CHAPTER IV 
 
 
 
ALTERNATIVE STRATEGY FOR DOX DELIVERY THROUGH AN MMP9 
CLEAVABLE PEPTIDE 
 
 
 
4.1 Introduction 
 The modification of doxorubicin (DOX) at the amine to provide a carboxylic 
acid results in inactive drug.  With this knowledge, investigations into alternative 
strategies for DOX delivery were explored.  Since it was reported that Leu-DOX 
and Leu-Leu-DOX were toxic in HT1080 cells185, a new prodrug that gave LL-
DOX as the active drug was investigated.  This was attempted by shortening the 
peptide sequence from [Ahx]-AVRWLLTA-[Ahx] to AVRWLL.  Although AVRWLL 
has not been reported to be digested with MMP9, it is similar to the known 
cleavable sequence AVRWLLTA.  The sequence AVRWLLTA is cleaved by 
MMP9 between the tryptophan and leucine residues178.  The modified strategy 
leaves the [Ahx] groups off the peptide, shortening the sequence by two residues 
removing threonine and alanine (TA) attaches DOX to the carboxy terminus 
rather than the amine terminus of the peptide.   
In this chapter, the peptide sequence AVRWLL was investigated as a 
potential MMP9 activated prodrug for cancer therapy.  This was accomplished by 
1) synthesizing L-DOX and LL-DOX, 2) testing L-DOX and LL-DOX for toxicity in 
vitro, 3) investigating the digestion of AVRWLL by MMP9, 4) synthesizing 
AVRWLL-DOX and Dendron-AVRWLL-DOX and 5) investigating the digestion 
and cytotoxicity of AVRWLL-DOX and Dendron-AVRWLL-DOX.  It was 
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hypothesized that AVRWLL would be cleavage by MMP9 between the W and L 
residues because; the important recognition sequence was shown to be RWLL.  
It was anticipated that cleavage would not be as specific or rapid as the 
sequence AVRWLLTA but sill expected that the drug would be activated 
selectively in the tumor environment. 
 
4.2 Cleavage of the Fmoc-AVRWLL with Trypsin and MMP9 
 The peptide, Fmoc-AVRWLL was treated with trypsin and MMP9 in 
separate vials to determine digestion efficacy.  Trypsin was used as a positive 
control since it cleaves universally between arginine and tryptophan.  The 
peptide was incubated at 37 oC with either trypsin or MMP9 overnight in 10% 
methanol in tricine buffer.  Reverse phase HPLC (C18 silica with 0.065% TFA in 
water and 0.05% TFA in acetonitrile) was completed before the addition of 
enzyme and again after overnight incubation.  Figure 4.1 highlights the HPLC 
results obtained from the cleavage products.  As can be seen, the intact Fmoc-
AVRWLL peptide elutes at 31 minutes while samples treated with enzyme have 
more peaks at different elution times.  The sample treated with trypsin elutes four 
peaks at 25, 32, 34 and 36 minutes.  The sample treated with MMP9 elutes at 
32, 34 and 36 minutes with a small bump at 25 minutes.  Since the peak at 31 
minutes disappears after treatment with either enzyme digestion is occurring 
from trypsin and MMP9.  
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Figure 4.1.  Enzyme digestion of Fmoc-AVRWLL.  HPLC traces before 
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Figure 4.2.  ESI MS of Fmoc-AVRWLL cleaved with trypsin.  The peak at 
431 is from the WLL cleaved product. 
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 The cleavage of the Fmoc-AVRWLL peptide with trypsin and MMP9 was 
also characterized by collecting the peaks from the HPLC and performing ESI+ 
MS on the samples.  Trypsin treated Fmoc-AVRWLL provided the expected 
product, WLL, with a molecular weight of 431.07 amu at a 25 minute elution time 
from the column (Figure 4.2).  When Fmoc-AVRWLL was treated with MMP9, a 
cleavage product was detected, but not the expected product.  Peaks at 567 and 
589 were detected at an elution time of 32 minutes as shown in Figure 4.3.  This 
molecular weights are equivalent to protonated and sodiated RWLL-COOH.  This 
product could be further degraded in the cellular or tumor environment to LL-
DOX or L-DOX to become activated.  The expected cleavage product of LL-
COOH, with a molecular weight of 243, was barely detectable in the ESI+ MS 
spectrum of the crude cleavage product solution as shown in Figure 4.3.  Given 
that some cleavage is detected in the test tube and the microenvironment of a 
cell differs significantly from the test tube enough evidence was present to 
suggest that this peptide may cleave efficiently in vitro or in vivo to deliver a toxic 
dose of DOX selectively to cancerous tissue.   
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Figure 4.3.  ESI MS of Fmoc-AVRWLL after digestion with MMP9.  Top, 
product collected at 32 minutes.  The peak at 567 is from unexpected 
product RWLL.  Bottom: expected product LL (229) in the crude mixture. 
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4.3 Synthesis of Leu-DOX and Leu-Leu-DOX 
 Leu-DOX (14) and Leu-Leu-DOX (16) were synthesized using peptide 
coupling agents 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDCI) and 
Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate 
(BOP).  Leu-DOX was synthesized in two steps by first attaching DOX to BOC-
Leu using EDCI and diisopropylethyl amine (DIEA) in dimethyl formamide (DMF)  
 
 
 
 
 
under anhydrous conditions followed by purification on the Biotage SP1™ 
system using a hexane/ethyl acetate gradient to give Boc-Leu-DOX.  To 
complete the synthesis, the Boc-Leu-DOX was treated with TFA to remove the 
BOC protecting group and provide Leu-DOX (Scheme 4.1), which needed no 
further purification.   Nuclear Magnetic Resonance (NMR) and mass 
spectrometry (MS) match the reported data185. 
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Scheme 4.1.  Synthesis of Leu-DOX (14). 
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 Leu-Leu-DOX (16) was synthesized in three linear steps by first coupling 
BOC-Leu with Leu using BOP and DIEA in DMF under anhydrous conditions 
followed by purification on silica with the Biotage SP1™ system (methylene 
chloride to methanol gradient).  Pure product 15 was then reacted with DOX 
using EDCI and DIEA in DMF under anhydrous conditions to obtain Boc-Leu-
Leu-DOX after purification on the Biotage SP1™ system.  Purification was 
accomplished by first running a gradient with hexanes/ ethyl acetate and then  
 
 
 
 
 
 
 
Scheme 4.2.  Synthesis of LL-DOX (16). 
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rinsing the column with 0.1% ammonium hydroxide in methanol to elute the 
desired product.  Finally, pure Boc-Leu-Leu-DOX was treated with TFA to give 
the desired Leu-Leu-DOX (16, Scheme 4.2); which was used without further 
purification.  NMR and MS match the reported data185.  With these compounds in 
hand, toxicity against PyVT-R221A-Luc cells was tested to determine efficacy of 
the cleaved products. 
 
4.4 Cytotoxicity of L-DOX and LL-DOX 
Toxicity assays were performed on the DOX drugs and prodrugs against 
PyVT-R221A-Luc cells by means of the trypan blue assay.  Briefly, cells were 
plated into 24 well plates at a density of 50,000 cells/mL (0.5 mL/well).  The cells 
were incubated overnight (20 – 24 hours) before the media was replaced with 
fresh media that contained the compounds to be tested, controls or untreated 
media.  The cells were incubated another 24 hours prior to the first batch being 
detached, stained with trypan blue and counted with a hemocytometer.  Further 
plates of cells were retreated and incubated another 24 hours.  This process was 
repeated to obtain 3 or 4 time course points (24, 48, 72 and/or 96 hours) with 1 - 
4 doses of drug.  The number of total cells per well were calculated and then the 
percentage of live cells in the drug treated wells versus media (or DMSO) treated 
was calculated.   
 Over the dose course of DOX (Figure 4.4, top), the drug produces a toxic 
effect at all time points and concentrations. As expected, DOX becomes more 
toxic with increased dose concentration and incubation times.  At 24 hours there 
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is a 30 – 50% (depending on the drug dosing concentration) survival rate 
compared to control cells.  At other time points there are lower survival rates at 
all concentrations tested. The assay plateaus above 1.8 mM doses, with no 
difference at 72 and 96 hours.  Looking at the data from a different perspective, 
DOX has a toxic effect at all concentrations. This toxic affect increases over time 
(Figure 4.4 bottom) and the number of doses.  Also, the toxic effect is indeed 
dose dependent as over time the toxicity increases as the dose increases.  
L-DOX (14) compound, has been reported to have EC50 values of 6.7 μM 
in LNCa and 14.0 μM in DuPRO cells131. The cleavage product is also toxic to 
HT1080 cells185.  Testing for dose response toxicity at high concentrations in the 
PyVT-R221A-Luc cell line was completed and compared to the LNCa and 
DuPRO cell lines.  As with the DOX, the toxic effect increases over time, the 
number of doses and concentration.  The 24 and 48 hour time points are equally 
as toxic for the lower concentrations tested (0.15 – 7.5 μM).  As expected, two 
doses over 48 hours proves more toxic for concentrations of 15 and 23 μM, 
compared to the 24 hour (1 Dose) points.  After 72 hours, a greater therapeutic 
efficacy is noticeable compared to 48 hours and 2 doses, but not as good as 96 
hours and 4 doses.  From the survival versus time course graphs, it is obvious 
that toxicity is dose dependent with 0.15 μM producing a cell reduction of 75% 
over the 96 hour time course (4 Doses), and 23 μM eradicating all the cells over 
the same time and dose period.  The concentration tested is directly related to 
the efficacy of toxicity with higher concentrations producing greater cell death 
than lower concentrations.  Overall, the L-DOX toxicity supports the data 
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Figure 4.5.  Cytotoxicity of L-DOX (14) against the PyVT-R221A-Luc cell line.  
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Figure 4.6.  cytotoxicity of LL-DOX (16) against PyVT-R221A-Luc cell line.  
Top: Survival versus log concentration at 24, 48, 72 and 96 hours; Bottom: 
Survival versus time at different concentrations of drug. 
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Table 4.1.  IC50 values for DOX, L-
DOX and LL-DOX. 
 
Compound IC50 (μM)
DOX  
24 Hours 5.5
48 Hours NA
72 Hours NA
96 Hours NA
L-DOX  
24 Hours 17.4
48 Hours 12.0
72 Hours 7.1
96 Hours 3.1
LL-DOX 
24 Hours NA
48 Hours 166.7
72 Hours 1.1
96 Hours 5.8
demonstrated in the literature with the LNCa, DuPRO and HT1080 cell lines, but 
is not as effective against the PyVT-R221A-Luc cell line.  The IC50 values for L-
DOX in PyVT-R221A-Luc cells are 17.4, 12.0, 7.1 and 3.1 μM for 24, 48, 72 and 
96 hours or 1, 2, 3 and 4 doses respectively (Table 4.1).   
 Third, a dose response over time was completed for LL-DOX (16), the 
expected cleavage product.  Although not as pronounced as with the DOX and L-
DOX (14), the same general trends are observed; the more doses, the higher the 
therapeutic efficacy.  The 24 and 48 hour time points are less effective than the 
72 and 96 hour time points if the 1.3 μM concentration value is disregarded.  The 
the 72 and 96 hour treatments are approximately the same with the 72 hour time 
point being more effective at 0.13 and 1.3 μM, the 96 hour time point being better 
at 6.5 and 19 μM.  When looking at the 
data from the perspective of survival 
versus time, the results look a little more 
variable.  After 96 hours however, the 
anticipated order is maintained where 
the highest concentration (19 μM) is the 
most effective and the lowest 
concentration (0.13 μM) is the least 
effective with the remaining three 
concentrations falling into the expected 
order; the higher the concentration of 
drug, the higher the efficacy in vitro.  
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Using five concentrations for the toxicity curve allowed for initial IC50 
values to be calculated.  As shown in Table 4.1, the IC50 values are generally in 
the trend expected, however higher than optimal.  For DOX, only the 24 hour 
time point could be calculated due to the high doses used.  At more than 1 dose, 
the cells were completely wiped out, skewing the values to negative 
concentrations.  The L-DOX provides the expected trend with higher 
concentrations needed to eliminate half the cells after 1 dose (24 hours) and 
decreasing concentrations after additional doses.  The LL-DOX data does not fit 
the anticipated trend.  The 24 hour survival versus log concentration data (1 
dose) is not linear enough to calculate an IC50.  Furthermore, it appears that 3 
doses (72 hours) is more efficacious than 4 doses (96 hours).  Testing lower 
concentrations of DOX, L-DOX and LL-DOX would likely provide more consistent 
results.    
 
4.5 Synthesis and Characterization of AVRWLL-DOX 
First, AVRWLL-DOX was synthesized by coupling the DOX to the carboxyl 
termini of Fmoc-AVRWLL using EDCI and DIEA in DMF under anhydrous 
conditions for coupling (Scheme 4.3).  The peptide was activated with EDCI prior 
to addition of DOX.  The reaction was followed by reverse phase HPLC (C18 
silica with 0.065% TFA in water and 0.05% TFA in acetonitrile) with 
chromatograms being ran prior to DOX addition, within 5 minutes of DOX 
addition and after 2 and 24 hours of DOX addition.  Typically after 24 hours, the 
reaction was complete as shown by HPLC.  After purification with preparatory 
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HPLC, the product was characterized with ESI+ MS to give the product ion peak 
at 1531.87 amu (Figure 4.4).  The Fmoc protecting group was then removed 
using 50% piperidine in DMF.  Deprotection of the Fmoc groups was confirmed 
by ninhydrin TLC where ninhydrin stains for primary amines.  The starting 
material was not stained by ninhydrin, while the extensively concentrated and 
lyophilized product (removing all the piperidine) was stained, indicating that 
primary amines are present. 
 
 
 
 
 
 
Scheme 4.3.  Synthesis of AVRWLL-DOX (18). 
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4.6 Synthesis and Characterization of Dendron-AVRWLL-DOX 
To complete the synthesis of Dendron-AVRWLL-DOX (20), the H2N-
AVRWLL-DOX (18) was reacted with gultaric anhydride to provide a carboxylic 
acid for coupling to the dendron amines (Scheme 4.7).  The HOOC-AVRWLL-
DOX (19) product was purified with HPLC and coupling confirmation was 
completed with TLC using ninhydrin and bromo-cresol green stains.  Ninhydring, 
which selectively stains primary amines stained the starting material, H2N-
AVRWLL-DOX, and did not stain the product, HOOC-AVRWLL-DOX.  The 
product did stain with bromocresol green, a stain selective for carboxylic acids.  
 
 
 
  
Finally, the COOH-AVRWLL-DOX (19) was coupled to the dendron by EDCI 
coupling.  The HOOC-AVRWLL-DOX (19) was activated with EDCI in DIEA and 
 
 
Scheme 4.4.  Synthesis of Dendron-AVRWLL-DOX. 
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DMF and then added to a solution of dendron in DMF and stirred under 
anhydrous conditions until the reaction was complete as determined by HPLC.  
The reaction was purified with SEC to give a product with four peptide attached 
to each dendron.  The pure product was characterized with MADLI-TOF MS.  As 
seen in Figure 4.8, the MALDI-TOF spectrum does not provide an singularly  
 
 
 
 
 
charge molecular weight ion peak, but three key peaks that indicate coupling.  
The peak at 1,491 amu is from the dendron fragmenting at an interior ester bond, 
as seen in other peptide-dendron coupled products, and is equivalent to K+O-
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Figure 4.7.  ESI MS of Fmoc-AVRWLL-DOX.  The MW of 1531.87 indicates 
protonated Fmoc-AVRLL-DOX 
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(CH2)3-AVRWLL-DOX fragment.  This fragment indicates coupling between the 
peptides and the dendron, but does not indicate the number of AVRWLL-DOX 
attached.  The other two peaks are from m/z = 4 charged molecules.  Ordinarily, 
quadruply charged molecular ions would not be expected; however, since each 
peptide contains an arginine residue, which could be protonated, makes this 
mass is observable.  The peaks at 1,521 amu and 1,551 amu are both from 
quadruply charged product ion peaks.  The mass of 1,521 is equivalent to the 
dendron with four AVRWLL-DOX (18) molecules attached and  
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Figure 4.8.  MALDI-TOF MS of Dendron-AVRWLL-DOX. 
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the benzyl group cleaved and the mass of 1,551 is equivalent to the quadruply 
charged molecule with four AVRWLL-DOX molecules attached to the dendron.  
With the Dendron-AVRWLL-DOX (20) and AVRWLL-DOX molecules on hand, 
cleavage and toxicity studies were completed.   
 
4.7 Digestion of AVRWLL-DOX (18) and Dendron-AVRWLL-DOX (20) 
The AVRWLL-DOX (18) and Dendron-AVRWLL-DOX (20) molecules were 
treated with MMP9 in the same manor as the Fmoc-AVRWLL peptide to 
determine if cleavage occurred (described in section 4.2).  Unfortunately, no 
cleavage occurred.  As shown in Figure 4.12, there is no difference in the 
MALDI-TOF spectra before and after enzyme digestion.  Alternatively there was 
also no change in the HPLC chromatogram, which were low signal and 
resembled noise.  The environment of the cell differs from the test tube and may 
produce a toxic effect in PyVT-R221A-Luc cells.  To test this hypothesis, in vitro 
toxicity studies were performed.    
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Figure 4.9.  MMP9 digestion of Dendron-AVRWLL-DOX.  MALDI-TOF 
spectra of Dendron-AVRWLL-DOX (20) before and after MMP9 Cleavage.  
Top: Dendron-AVRWLL-DOX before treatment with MMP9; Bottom: 
Dendron-AVRWLL-DOX (20) after treatment with MMP9. 
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4.8 Cytoxicity of AVRWLL-DOX (18) and Dendron-AVRWLL-DOX (20) 
 Curves over several high concentrations of DOX, L-DOX (14) and LL-DOX 
(16) were obtained prior to testing AVRWLL-DOX (18) and Dendron-AVRWLL-
DOX (20), which were in limited quantities.  When testing the AVRWLL-DOX (18)  
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Figure 4.10.  Cytoxicity of 5 μM (in DOX) Dendron-AVRWLL-DOX, AVRWLL-
DOX, Leu-Leu-DOX, Leu-DOX and DOX against PyVT-R221A-Luc. 
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and Dendron-AVRWLL-DOX (20) compounds, DOX was used as a positive 
control while media and DMSO treated media were negative controls.  The cells 
were also treated with L-DOX (14) and LL-DOX (16) to test the therapeutic 
efficacy of the expected cleavage products.   
In the final toxicity experiment with the DOX prodrugs, the PyVT-R221A-
Luc cells were treated with AVRWLL-DOX (18), Dendron-AVRWLL-DOX (20), 
LL-DOX (16), L-DOX (14) and DOX at 5 μM and 50 nM concentrations.  The 5 
μM dose was to high to compare the prodrugs to the positive controls and DOX 
because the cells were completely wiped out after 48 hours (Figure 4.13).  The 
Leu-DOX (14) indicated a large amount of toxicity after 48 hours as well, but the 
cytotoxicity is lower after 72 and 96 hours.  The remaining three compounds, 
Dendron-AVRWLL-DOX (20), AVRWLL-DOX (18) and Leu-Leu-DOX (16) 
followed the same pattern.  After 48 hours, the toxicity of the drug was high 
compared to the DMSO controls; however, after 72 hours the toxic effect is only 
15%.  Once the cells were given four doses over 96 hours, the PyVT-R221A-Luc 
cells proliferate more than the media and DMSO treated controls.  Leu-Leu-DOX 
(16) also proliferated from 48 to 72 hours and 72 to 96 hours.  This pattern 
indicates that there is some toxicity initially of the drug(s), followed by loss of 
efficacy.  Since the DOX and Leu-DOX (14) were so toxic after 48 hours, 
comparison of these compounds to the LL-DOX, AVRWLL-DOX and Dendron-
AVRWLL-DOX was not possible at 5 μM concentrations.  Although the exact 
reason for the cells becoming viable in the presence of DOX and the other 
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compounds tested is not known, one possibility is that a sub-population of DOX 
resistant cells proliferate after the non-resistant cells die.   
In order to compare the effect of DOX and L-DOX with LL-DOX, AVRWLL-
DOX and Dendron-AVRWLL-DOX against the PyVT-R221A-Luc cells, the assay 
was repeated using 50 nM concentrations of DOX and looking at 48 and 96 hour 
time points.  The pattern of initial toxicity followed by recovery of the cells was 
more evident in the 50 nM assay.  The 48 and 96 hour time points, produce the 
same pattern at 50 nM doses (Figure 4.11) as the 5 μM doses did (Figure 4.10).   
In the 50 nM dosed cells, the Dendron-AVRWLL-DOX (20) compound knocked 
the survival of the cells down to 40% after 48 hours and then recovered to 110% 
after 96 hours.  The AVRWLL-DOX (18) had survival rates of 40 and 130% after 
48 and 96 hours respectively.  Leu-Leu-DOX (16), showed the same pattern but 
overall was more toxic, with survival rates of 30 and 80% after 48 and 96 hours 
respectively.  Leu-DOX (14), which could not be compared well at the 5 μM dose 
had survival rates of 15 and 160% after 48 and 96 hours.  This compound had 
the greatest change in survival between the two time points.  Finally, even DOX 
has an increase in survival between the 48 and 96 hour time points at 50 nM 
concentrations with a difference from 8 to 51% respectively.  One likely 
explanation is that there is a sub-population of cells growing that are resistant to 
DOX and DOX analogues.  This sub-population then experiences a faster growth 
rate in the PyVT-R221A-Luc cells than the non-resistant cells.  The assay was 
repeated to confirm the results.  The initial assay curves that did not produce this 
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effect were grown from a different vial of cells, which could explain the 
discrepancy. 
  
 
 
 
4.9 Conclusions 
 Since initial experiments with an MMP9 activatable DOX prodrug were 
unsuccessful; a new strategy was to used to reactivate DOX selectively in cancer 
cells.  This new strategy utilized a different peptide that is similar to the reported 
sequence known to be cleaved by MMP9.  The new sequence, AVRWLL, was 
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Figure 4.11.  Cytoxicity of Dendron-AVRWLL-DOX, AVRWLL-DOX, Leu-Leu-
DOX, Leu-DOX and DOX at against PyVT-R221A-Luc cells at 50 nM 
concentrations of DOX. 
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expected to be cleaved by MMP9 between the tryptophan and leucine residues 
like the original sequence, AVRWLLTA, is to provide cleavage product LL-DOX 
(16).  The literature reports that L-DOX (14) is toxic in HT-1080, LNCa and 
DuPRO cell lines and there are reports of other amino acid DOX conjugates that 
are toxic to cancer cells with up to four amino acids attached131, 185.  Construction 
of L-DOX (14) and LL-DOX (16) and the study of their toxicity in PyVT-R221A-
Luc cells proved the cleavage product is toxic indicating that the prodrug could 
be reactivated.  Even though the expected cleavage product did produce toxicity, 
there was little evidence that the new peptide was cleaved at a rate fast enough 
to produce toxic levels in vitro.  If any digestion occurred with MMP9 the majority 
of the product was WLL-DOX and not LL-DOX, since HPLC and MS analysis 
indicated cleavage primarily between the alanine and tryptophan residues.   
 Amino acids conjugated to DOX had been shown to produce toxic effects 
in other cell lines and cleavage by enzymes other than MMP9 could occur in 
vitro.  Two prodrugs, AVRWLL-DOX (18) and Dendron-AVRWLL-DOX (20), were 
synthesized and tested in PyVT-R221A-Luc cells.  At 5 μM concentrations (in 
DOX), the LL-DOX and AVRWLL-DOX compounds are toxic to PyVT-R221A-Luc 
cells after 48 hours but not after all 96 hours.  The L-DOX (14) and DOX controls 
are so toxic at 48 hours that all the cells are killed or no reproliferation is 
observed.  At 50 nM, all the compounds (Dendron-AVRWLL-DOX (20), 
AVRWLL-DOX (18), LL-DOX (16), L-DOX (14) and DOX) are toxic at 48 hours 
and regrow to 80 – 160% of the control by 96 hours.  The most likely explanation 
for this effect is that DOX sensitive cells are eliminated with the first two 
143 
treatments  (24 and 48 hours) and then DOX resistant cells rapidly proliferate.  
Growth rates between the PyVT-R221A-Luc and DOX resistant PyVT-R221A-
Luc cells may differ, resulting in the discrepancy between the number of cells in 
treated and untreated samples.  Interestingly, the LL-DOX (16), L-DOX (14) and 
DOX do not show the same trend in earlier toxicity curve studies (Figures 4.7, 4.8 
and 4.9).  This could be due to inconsistencies in the cells from two different 
frozen vials or a transformation of the cells between the initial assay and the 
assay testing with the AVRWLL-DOX (18) and Dendron-AVRWLL-DOX (20) 
prodrugs.   
  
4.10 Experimental Procedures 
 
General Methods: 
 MDA-MB-231 cells were purchased from ATCC and cultured in Dulbeco’s 
minimum essential medium (DMEM), 10% Fetal Bovine Serum (FBS) and 
gentamycin with 5% CO2 at 37 οC.  PyVT-R221A-Luc cells were obtained from 
the Matrisian laboratory and cultured in DMEM without L-glutamine, 10% FBS, 
gentamycin and puromycin with 5% CO2 at 37 οC.  LLC-RSV and LLC-MMP9 
cells were obtained from the Matrisian laboratory and cultured in DMEM, 10% 
FBS and gentamycin with 5% CO2.  The custom ordered peptides were 
purchased from Genscript™ and tested for purity then used as arrived.  The 
enzymes were purchased from Calbiochem.  All other chemicals were purchased 
from Fisher Scientific or Aldrich Chemical companies and used as is unless 
otherwise indicated.   
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2-amino-N-(3-hydroxy-2-methyl-6-((1S,3S)-3,5,12-trihydroxy-3-(2-
hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-
yloxy)tetrahydro-2H-pyran-4-yl)-4-methylpentanamide (Leu-DOX, 14): 
 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for at least 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  Boc-Leu (10.66 mg, 0.046 
mmoles) was stirred in DMF (2.5 mL) with EDCI (7.30 mg, 0.038 mmoles), BOP 
(20.54 mg, 0.046 mmoles) and DIEA (266 μL) for 30 minutes under Ag(g).  
Doxorubicin (10 mg, 0.017 mmols) in 0.5 mL DMF was added to the reaction.  
The reaction was stirred overnight then concentration in vacuo.  The product was 
purified on the Biotage SP1™ system with silica gel.  First a gradient from 100% 
hexanes to 100% ethyl acetate was used and then a second gradient of 100% 
ethyl acetate to 100% methanol was flushed through the column to elute pure 
Boc-Leu-DOX as the third product off the column.  MS (ESI)+: Found: 779.27 
Dalton (M + Na)+; Calculated:  779.78 Dalton (C38H48N2O14Na).  NMR and MS 
spectra are in Appendix B.   
 The Boc-Leu-DOX was then stirred in neat TFA for 2 hours at room 
temperature and concentrated to give pure Leu-DOX (14).  MS (ESI)+: Found: 
679.33 Dalton (M + Na)+; Calculated:  679.67 Dalton (C33H40N2O12Na).  NMR and 
MS spectra are in Appendix B. 
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2-amino-N-(1-(3-hydroxy-2-methyl-6-((1S,3S)-3,5,12-trihydroxy-3-(2-
hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-
yloxy)tetrahydro-2H-pyran-4-ylamino)-4-methyl-1-oxopentan-2-yl)-4-
methylpentanamide (Leu-Leu-DOX, 16): 
 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum at least 3 hours prior to use and exposed to anhydrous 
Ar(g) gas upon breaking the vacuum seal.  Boc-Leu (180.43 mg, 0.78 mmoles) 
was stirred with BOP (415.43 mg, 0.939 mmoles) and DIEA (250 μL) in DMF (5 
mL) for 30 minutes.  Leucine (124.61 mg, 0.950 mmols) in DMF (3 mL) was 
added to the reaction.  The reaction was stirred overnight and concentrated in 
vacuo.  The product was purified on the Biotage SP1™ system with a silica gel 
column and a gradient of 100% methylene chloride to 100% methanol to elute 4 
peaks.  The first peak eluted was 13.41 mg (5%) of Boc-Leu-Leu.  MS (ESI)+: 
Found: 367.13 Dalton (M + Na)+; Calculated:  367.44 Dalton (C17H32N2O5Na).  
NMR and MS spectra are in Appendix B. 
 Boc-Leu-Leu (6 mg, 0.017 mmoles) was stirred with BOP (12.39 mg, 
0.028 mmoles) and DIEA (5.6 μL, 0.61 mmoles) in  DMF (0.8 mL) for 10 minutes.  
Doxorubicin (5 mg, 0.0086 mmoles) in  DMF (0.3 mL) was added to the reaction.  
The reaction was stirred overnight and concentrated in vacuo.  The product was 
purified on the Biotage SP1™ system with a silica gel column and a gradient of 
100% methylene chloride to 100% methanol followed by rinsing with 1% 
ammonium hydroxide (3 column volumes) in methanol to elute 5 peaks.  The last 
peak eluted was 7.5 mg (99%) of Boc-Leu-Leu-DOX.  MS (ESI)+: Found: 869.47 
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Dalton (M + H)+; Calculated:  869.95 Dalton (C44H59N3O15Na).  NMR specta are 
in Appendix B. 
The Boc-Leu-Leu-DOX was then treated with neat TFA for 2 hours at 
room temperature and concentrated to give pure Leu-Leu-DOX (16).  MS (ESI)+: 
Found: 679.33 Dalton (M + Na)+; Calculated:  679.67 Dalton (C33H40N2O12Na).  
NMR spectra are in Appendix B.   
 
2-(2-(2-aminopropanamido)-3-methylbutanamido)-5-guanidino-N-(1-(1-(1-(3-
hydroxy-2-methyl-6-((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-
methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yloxy)tetrahydro-2H-
pyran-4-ylamino)-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-
ylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)pentanamide compound with 
methane (1:1) (AVRWLL-DOX, 18): 
 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for at least 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  Fmoc-AVRWLL (6.99 mg, 
0.0071 mmoles) was stirred with EDCI (1.5 mg, 0.0078 mmoles) and DIEA (50 
μL) in  DMF (1 mL) for 30 minutes.  Doxorubicin (4.55 mg, 0.0078 mmols) in  
DMF (0.5 mL) was added to the reaction.  The reaction was stirred overnight 
while being monitored with reverse phase HPLC (C18 silica with a gradient using 
0.065% water and 0.05% Acetonitrile) after 100 minutes and 24 hours.  The 
reaction was concentrated in vacuo and purified by prepatory (C18 silica with a 
gradient using 0.065% water and 0.05% Acetonitrile) HPLC to give pure Fmoc-
AVRWLL-DOX.  MS (ESI)+: Found: 1531.87 Dalton (M + Na)+; Calculated:  
1531.69 Dalton (C79H100N11O19Na). 
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 Fmoc-AVRWLL-DOX was treated with 1 mL piperidine in 1 mL DMF for 2 
hours.  The reaction was concentratated in vacuo and purified by prepatory 
HPLC (C18 silica with 0.065% water and 0.05% Acetonitrile) to give pure 
AVRWLL-DOX.  MS (MALDI-TOF)+: Found: 1283.31 Dalton (M + H)+; Calculated:  
1,284.45 Dalton (C64H89N11O11). 
 
Dendron-AVRWLL-DOX (20): 
 
 AVRWLL-DOX (7.0 mg, 0.0055 mmols) was stirred with succinic 
anhydride (0.94 mg, 0.0094 mmols) in  DMF (1.5 mL) overnight.  The reaction 
was spotted on TLC plates to show that it was negative for primary amines 
(ninhydrin stain) and positive for carboxylic acid functional groups (bromo-cresol 
green stain). MS (MALDI-TOF)+: Found: 1,384.32 Dalton (M + H)+; Calculated:  
1,384.53 Dalton (C68H93N11O20). 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for at least 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  The COOH-AVRWLL-DOX 
(3.85 mg, 0.0027 mmoles) product was stirred with EDCI (0.55 mg, 0.0029 
mmoles) and DIEA (2 μL) in DMF (0.5 mL) for 30 minutes.  Next, H2N-Gly-
Dendon (0.5 mg, 0.00073 mmoles) in DMF (0.5 mL) was added to the reaction.  
The reaction was stirred overnight while being monitored with SEC (0.065% 
water and 0.05% Acetonitrile).  The reaction concentrated in vacuo and purified 
by SEC to give Dendon-AVRWLL-DOX.  MS (MALDI-TOF)+: Found: 1,549 
Dalton (M+4H)4+; Calculated:  1,549 Dalton (C306H408N48O90Na). 
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Cleavage of Peptide compounds with Enzymes: 
 The compound to be tested for ability to cleave was dissolved in methanol 
at 10 mg/mL.  Next, 100 μl of this solution was diluted with 900 μl of tricine buffer 
to make a 1 mg/mL solution (10% methanol).  A 20 μl sample was injected into 
the HPLC (C18 reverse phase silica with 55% 0.05% TFA in Acetonitrile/ 45% 
0.065% TFA in water) for an undigested reference chromatogram.  Following 
HPLC, enzyme was added (either MMP9, MMP2 or Trypsin) and the samples 
were incubated at 37 οC overnight.  HPLC was repeated to determine the 
cleavage percentages (in any) of the sample.  For samples in which a solid was 
precipitate formed, the solid was collected by centrifugation, dissolved in 100% 
methanol and an aliquot was injected into the HPLC.  The samples were then 
characterized with ESI+ and MALDI-TOF MS to determine the cleavage products.  
The solid usually contained pure cleaved product. 
 
Toxicity studies 
 Cells were plated at 40,000 – 60,000 cells/mL into 24 well plates (0.5 
mL/well) in their culture medium.  A separate plate was used for each time point 
observed in the assay.  Thus 4 time points using 4 plates.  The cells were 
incubated overnight at 37 οC (20 - 24 hours, usually 24 hours).  After examination 
under the microscope to ensure the cells were attached and looked healthy, the 
media was aspirated off each well (taking care to not disrupt the cells) and 
replaced with media containing the drug, prodrug or a control compound.  The 
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drug prodrug and control solutions were made fresh just prior to use.  The cells 
were incubated 24 hours and then either redosed with fresh drug-media solutions 
or the cells were trypsinized and counted using trypan blue.  For typsinization, 
the media was removed by aspiration and each well was washed with 0.5 mL of 
DPBS.  The DPBS was removed by aspiration and each well was treated with 
200 μl of trypsin.  The plate was incubated at 37 oC and 5% CO2 for 10 - 15 
minutes and then agitated, either with a shaker or by hand.  Finally, 40 μl of 
trypan blue was added to each well (typically 4 wells at a time) and the live cells 
(cells that did not stain with trypan blue) were counted with a hemocytometer.  
The dosing and counting was continued for the remaining time points so that the 
cells were given fresh drug every 24 hours until counted (either 72 and 96 hours 
after the initial dose).      
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CHAPTER V 
 
 
 
FUNCTIONALIZATION OF PACLITAXEL TO A DENDRON THROUGH AN 
MMP-9 CLEAVABLE PEPTIDE 
 
 
 
5.1 Introduction 
Prodrugs as cancer therapeutics offer significant advantages over 
traditional chemotherapeutic drugs.  Traditional chemotherapeutics are non-
targeted and interact with all cells in the body.  Given that chemo drugs interact 
with both cancerous and non-cancerous tissues, near maximum tolerated doses 
need to be administered to ensure efficacy.  The systemic side effects of 
traditional chemotherapeutics include many minor symptoms such as vomiting 
and dizziness to potentially major problems such as increased myelotoxicity and 
cardiotoxicity.  A common strategy to overcome these side effects and improve 
efficacy is to deliver the chemotherapeutic agent directly to diseased tissue via a 
prodrug.  Prodrugs allow the therapeutic to remain latent until activated, which 
could be accomplished by a variety of chemical reactions which include 
enzymatic reactions such as proteolytic cleavage.  Targeting prodrugs to tumor 
cells reduces interactions between the drug and non-cancerous cells and allows 
for delivery of more active drugs to the diseased tissue, increasing efficacy and 
decreasing systemic toxicity.    
A variety of specific proteinases, including matrix metalloproteinases 
(MMPs), are found in the microenvironment of tumors and tumor metastases.  
MMPs present opportunities for prodrug therapy at the earliest stages of breast 
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cancer metastasis using nanotechnology rather than traditional pharmacological 
agent.  Previous results indicate that MMP9 expression influences the earliest 
stages of implantation of breast cancer cells in the lung.  There is epidemiological 
evidence that MMP9 is an indicator of poor prognosis for many cancers, 
including breast cancer125.  Targeting MMP9 expression provides the ability to 
specifically identify and target micrometastatic lesions that may be present in 
breast cancer patients but are undetectable by current imaging technology.   
Paclitaxel is an ideal drug for incorporation into a prodrug to treat breast 
cancer and micrometastatic lesions to the lung due to its current use for treating 
breast cancer.  Several cancers other than breast cancer are also sensitive to 
PXL including: lung, ovarian and head and neck malignancies.  Furthermore, the 
modification of PXL with succinic anhydride and subsequent conjugation to 
amine terminated dendrimers has been reported by Baker, et al100.  The specific 
modification was shown to not significantly effect the toxicity of the native drug101. 
To deliver the therapeutic, dendrimers offer multiple advantages for use as 
molecular scaffolds for prodrugs, including 1) the ability to conjugate multiple 
drugs to a single molecule, 2) the ability to incorporate multiple elements for 
therapy, imaging, tracking and targeting and 3) tunable size and functionality.  In 
the work presented here, a dendron is used as the scaffold for an MMP9 
activated paclitaxel (PXL prodrug).  The dendron can then be coupled to other 
dendrons of differing functionalities in a “mix and match” manner to synthesize 
multifunctional dendrimers.  These dendrimers can be used to deliver 
therapeutics, monitor the location and efficacy of delivery (with a fluorescence 
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sensor), target micrometastatic lesions, track the dendrimer location and tune the 
bioavailability for optimal delivery and excretion.  In this chapter, the conjugation 
of PXL to H2N-Pep-Dendron is described, followed by the in vitro testing of this 
new prodrug for cytotoxicity versus several cell lines. 
 
5.2 Synthesis and Characterization of PXL-Pep-Dendron (22) 
 To synthesize the MMP9 activated prodrug, paclitaxel was modified with 
succinic anhydride to provide a carboxylic acid linkage from the C2’OH as 
previously described by Baker, et. al.101.  Next, the H2N-Peptide-Dendron was  
 
 
 
 
 
 
Scheme 5.1.  Synthesis of PXLPep-Dendron. 
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coupled to PXL-COOH using (3-(dimethylamino)propyl)ethyl Carbodiimide 
Hydrochloride (EDCI) and diisopropyl-diethyl amine (DIEA) in anhydrous  
dimethyl formamide (DMF)  followed by purification with size exclusion 
chromatography (SEC)  as seen in Scheme 5.1.   
 
 
 
 
 
The reaction was followed using SEC to monitor the disappearance of 
H2N-Pep-Dendron and the appearance of a new peak.  As can be seen in Figure 
5.1, the H2N-Pep-Dendron (12) elutes at 21 minutes while after 25 hours of 
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Figure 5.1.  Reaction Progress of PXL coupling to the H2N-Peptide-Dendron.  
SEC of H2N-Pep-Dendron (12) and PXL-Pep-Dendron (22).
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Figure 5.2.  MALDI-TOF MS of PXL-Pep-Dendron. The 5,564 peak 
corresponds to the PXL-Pep-Dendron fragment after loss of two PXL-[Ahx]-
AVRWL groups. 
reacting, the H2N-Pep-Dendron peak disappears and a new peak at 7.7 minutes 
appears.  Since the new peak elutes earlier than the H2N-Pep-Dendron, indicates 
a larger molecule.  The peak at 28 minutes is from the coupling agents and the 
byproducts of coupling.  Thus its increased amplitude at 25 hours indicates the 
presence of more coupling byproducts.  Further characterization of the coupled 
product was accomplished with MALDI-TOF MS.  Among other MADLI-TOF 
fragments detected was the m/z = 4 mass at 4,409 amu for an intact PXL-Pep-
Dendron (22) (Figure 5.2).   
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5.3 Cleavage of Fmoc-Pep-Dendron (11) & PXL-Pep-Dendron (22) with MMP9 
 Although the sequence AVRWLLTA has been previously reported to be 
cleaved selectively by MMP9 178, cleavage of several copies of that sequence on 
a dendron has not been established.  The samples were treated with active 
MMP9 and analyzed for both the expected products and unreacted starting 
material using HPLC and MALDI-TOF-MS.  First, Fmoc-Pep-Dendron was 
digested with MMP9.  As seen in the HPLC spectra (reverse phase, C18 silica 
with a gradient from 0.065% water to 0.05% acetonitrile) in Figure 5.3, Fmoc-
Pep-Dendron is cleaved into two main components and at least one minor 
component.  Mass spectrometry (MALDI-TOF) further confirming the proteolytic 
cleavage shows expected cleavage peaks at 2,731 and 888 amu (Figure 5.3 
Bottom) of Fmoc-Pep-Dendron.  The peak at 2,731 amu is equivalent to (LLTA-
[Ahx])4-Dendron, one of the expected cleavage peak.  The peak at 888 amu is 
from the other expected product, Fmoc-[Ahx]-AVRW.  The remaining two 
identical peaks in the MS may result from further fragmentation of the digested 
dendron to (A-[Ahx])4-Dendron (1,469 amu) and Gly-Dendron (684 amu), likely 
arising from the analysis by MALDI-TOF MS.   
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Figure 5.3.  Digestion of Fmoc-Pep-Dendron (11) with MMP9. 
Chromatography before and after cleavage with MMP9 (Top) MALDI-TOF 
MS after cleavage with MMP9 (Bottom). 
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In Figure 5.4, the results of MMP9 treatment with PXL-Pep-Dendron are 
highlighted.  Before HPLC or MALDI-TOF MS it was evident that digestion 
occurred due to the formation of a significant amount of precipitate.  This 
precipitate was pelleted in the centrifuge, purified by washing twice with water 
followed by pelleting.  The precipitate was then dissolved in DMSO for HPLC and 
MALDI-TOF MS analysis.  The HPLC trace before and after treatment with 
MMP9 (reverse phase C18 column with 0.1% triethyl amine in acetonitrile and 
water; gradient from 45 – 100% acetonitrile) indicates digestion occurred.  The 
intact product elutes as a peak at 10.5 minutes while the cleaved product elutes 
at 8.5 minutes. Solubility likely plays a role in the shape of the chromatogram of 
the digested product.  The cleaved product provided the expected cleavage peak 
PXL-[Ahx]-AVRW (1,545 amu) as well as further fragmentation products at 1,319 
amu (PXL-[Ahx]-AVR) and 1,108 amu PXL-[Ahx]-A (Figure 5.3 Bottom) in the 
MALDI-TOF spectra.  From the MALDI-TOF MS data it can be concluded that 
MMP9 at least cleaves the peptide between the tryptophan and argenine 
residues are PXL-[Ahx]-AVR and PXL-[Ahx]-A or from further proteolytic 
cleavage of the initial PXL-[Ahx]-AVRW product.  The two smaller products 
detected in the MS, corresponding with PXL-[Ahx]-AVR and PXL-[Ahx]-A, could 
be a result of fragmenting in the MALDI-TOF MS instrument.   
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Figure 5.4.  Digestion of PXL-Peptide-Dendron (22) with MMP9. 
Chromatography before and after cleavage with MMP9 (Top) and MALDI-TOF 
MS after cleavage with MMP9 (Bottom).
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5.4 Cellular Toxicity Studies of PXL-Pep-Dendron (22) 
After the synthesis and confirmation of MMP9 cleavage, PXL-Pep-
Dendron (22) was tested for cytotoxicity against PyVT-R221A-Luc, MDA-MB-
231, LLC-RSV and LLC-MMP9 cells.  The PyVT-R221A-Luc and LLC-MMP9 
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Figure 5.5 Dose dependent cytotoxicity of paclitaxel compounds in PyVT-
R221A-Luc cells (high MMP9 expression) of Paclitaxel (PXL, triangles), 
modified Paclitaxel (PXL-COOH, squares), Paclitaxel Prodrug (PXL-Pep-
Dendron, diamonds) and cleaved Paclitaxel Prodrug (PXL-AVRW, circles) 
after 72 hours. 
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cells are MMP9 expressing cell lines, while MDA-MB-231 and LLC-RSV do not 
express detectable MMP9 in culture (MMP9 negative lines).  Initially, PyVT-
R221A-Luc cells were studied in preparation for in vivo studies in the MMTV-
PyVT mouse model, the parent model from which the PyVT-R221A-Luc cell line 
was derived.  Due to this pairing with the mouse model, the majority of 
cytotoxicity studies were performed with the PyVT-R221A-Luc cell line.  A human 
breast cancer cellular line, MDA-MB-231, was also investigated for confirmation 
of activity in a clinically relevant cell line.  Although, MDA-MB-231 cells express 
insignificant amounts of MMP9, the cytoxicity data provided insight into the 
prodrug efficacy in humans.  The remaining two cell lines, LLC-RSV and LLC-
MMP9, serve as MMP9 negative and positive cell lines respectively, but are 
otherwise identical124.  The MMP9 positive and negative cell lines were used to 
access the role of MMP9 for prodrug activation in vitro.   
 The results of the initial toxicity studies using PyVT-R221A-Luc cells were 
encouraging as the intact prodrug (PXL-Pep-Dendron) is significantly less toxic 
than the MMP9 cleaved product or paclitaxel (Figure 5.5) as determined by the t-
test (analysis is Appendix A).  As expected, all paclitaxel compounds produce 
concentration-dependent cytotoxicity (Figure 5.5). At the lower concentrations 
tested (1 and 5 nM in PXL), the number of viable cells after 3 days treatment is 
60% - 80%, with the prodrug and digested prodrug being slightly more toxic than 
PXL or PXL-COOH.  At higher concentrations, the drugs are more toxic to the 
PyVT-R221A-Luc cells, with the native PXL and modified (PXL-COOH) paclitaxel 
compounds being the most toxic. By definition, a prodrug should not produce 
161 
toxicity until activated. It was found that the cells are only 50 % viable at high 
concentrations of PXL-Pep-Dendron in the PyVT-R221A-Luc cells.  Given that 
the PyVT-R221A-Luc cells produce large concentrations of MMP9; peptide 
cleavage, releasing PXL-AVRW, likely occurs in vitro delivery a toxic dose of 
drug to the cells.   
Through the course of multiple doses over time, the cytotoxic effects are 
also increased.  For example, the MMP9 cleaved product (PXL-AVRW) is only 
slightly toxic after 1 or 2 doses (24 and 48 hours) while after 3 or 4 doses (72 and  
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Figure 5.6.  Cytotoxicity of PXL after 24 hours of treatment with: Paclitaxel 
(PXL, black), modified Paclitaxel (PXL-COOH, Red), Prodrug (Blue), Prodrug 
& GM6001 MMP inhibitor (Purple) in PyVT-R221A-Luc cells.  All trials were 
treated with an equivalent of 50 nM PXL.
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96 hours) it is about as toxic as PXL and PXL-COOH (Appendix A).  A dramatic 
change in toxicity between the prodrug (PXL-Pep-Dendron) and the digestion 
product (PXL-AVRW) occur between 24 and 48 hours after the first dose.  The 
cleaved product jumped from 109% survival to 44% survival between 24 hours (1 
dose) and 48 hours (2 doses) while the prodrug does not increase in toxicity on 
the second day.  Structural differences between PXL/PXL-COOH and PXL-
AVRW could account for the difference, possibly making cellular internalization or 
microtubular binding slower with the bulkier PXL-AVRW.  Alternatively, further 
enzymatic degradation of PXL-AVRW may be necessary prior to the onset of 
cytotoxic effects.     
 Next, toxicity data of the intact PXL-Pep-Dendron was obtained in which 
any MMPs released by the cells were blocked with GM6001, a general MMP 
inhibitor (Figure 5.6).  The uninhibited prodrug displays toxicity similar to PXL and 
PXL-COOH, while the cells treated with GM6001 (a general MMP inhibitor) are 
not significantly affected by the prodrug (PXL-Pep-Dendron).  The pre-cleaved 
prodrug (PXL-AVRW) produces similar cytotoxitiy as PXL and PXL-COOH in the 
PyVT-R221A-Luc cell line (Appendix A), again treating with 50 nM concentrations 
in PXL.  Furthermore, PyVT-R221A-Luc cells treated with only GM6001 did not 
produce significant changes in proliferation compared to media or DMSO treated 
controls.  Cytotoxicity experiments with multiple doses confirm the trend 
observed in Figure 5.6 (Appendix A).  Additional studies using 5 μM 
concentrations of PXL produce the same trends observed above (Appendix A).  
In summary, the cytotoxicity data indicates that the PyVT-R221A-Luc cells are 
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Table 5.1 IC50 toxicity values of Paclitaxel 
compounds in PyVT-R221A-Luc. 
Compound IC50 (μM) 
PXL-Pep-Dendron   
24 Hour 4.8±0.014
72 Hour 3.1 ±.0020
96 Hour 0.83±0.0033
PXL-AVRW 
24 Hour 3.0±0.0019
72 Hour 1.3±0.0022
96 Hour 0.79±0.0020
PXL-COOH 
24 Hour 4.2±0.0017
72 Hour 0.58±0.0019
96 Hour 0.85±0.0022
PXL 
24 Hour 3.6±0.0026
72 Hour 1.1±0.0017
96 Hour 1.2±0.0018
 
sensitive to PXL compounds and the proteolyzed prodrug (PXL-AVRW) has 
similar toxicity to the PyVT-R221A-Luc cell as PXL and PXL-COOH.  In addition, 
the data are consistent with the prodrug being cleaved in vitro by MMP9 present 
in the PyVT-R221A-Luc cells presumably by MMP9 expressed by these cells and 
with cleavage of the prodrug (and thus the cytotoxicity) being blocked by the 
addition of GM6001.  The above observations indicate that the PXL-Pep-
Dendron prodrug is not active until cleaved selectively by MMP9.    
 The measured cytotoxicity at five concentrations of the various PXL 
compounds, PXL-Pep-
Dendron (22), PXL-
AVRW, PXL-COOH and 
PXL, was used to 
calculate IC50 values.   
After 72 hours, the 
prodrug is significantly 
less toxic than the 
cleaved product, PXL-
COOH and PXL with an 
IC50 of 3.1 μM, compared 
to 1.3, 0.58 and 1.1 for 
PXL-AVRW, PXL-COOH and PXL respectively.  This 72 hour point indicates that 
the MMP9 activated prodrug has low toxicity to PyVT-R221A-Luc cells, while 
after 96 hours the prodrug toxicity is comparable with the active drugs.  Given 
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that the PyVT-R221A-Luc cells express MMP9, the difference in relative IC50 
values from 3 to 4 doses likely relates to the time it takes to activate the prodrug.   
To further examine the efficacy of the prodrug, its toxicity was studied in a 
human cell line (MDA-MB-231 breast cancer), PXL-Pep-Dendron (22), PXL-
AVRW (digestion product of the prodrug), PXL-COOH and PXL were tested at 5  
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Figure 5.7.  Cytotoxicity of paclitaxel compounds vs. MDA-MB-231 cells. Paclitaxel 
(PXL, solid), modified Paclitaxel (PXL-COOH, diagonal stripes), Prodrug (PXL-Pep-
Dendron, checker boxes), PXL-AVRW (vertical stripes).  The assays were 
performed at 50 nM drug concentration with 4 doses given over 96 hours.  Note, 
lower panels have expanded percent survival axis by 2x compared to the upper 
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μM and 50 nM concentrations (in PXL) over the course of 4 doses and 96 hours 
(Figure 5.7 for 50 nM and Appendix A for 5 μM).  Over the course of time, all 
compounds produced toxicity to the MDA-MB-231 cells; however, with the PXL-
Pep-Dendron being the least toxic.  The PXL-Pep-Dendron statistically differs 
from PXL after only 24 hours, PXL and PXL-COOH after 48 hours and PXL, PXL-
COOH and PXL-AVRW after 72 hours (for statistical analysis see Appendix A).    
As with the PyVT-R221A-Luc cell line, PXL-AVRW has the same toxicity as the 
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Figure 5.8.  Cytotoxicity of prodrug with and without an MMP inhibitor versus 
PyVT-R221A-Luc cells (high MMP9 expressing).  The data presented is the 
percent survival after 2 doses of compound over 48 hours.  All paclitaxel treated 
cells were treated with an equivalent of 50 nM paclitaxel.  The cytotoxicity is 
measured with respect to GM6001 and control.  GM6001 is a general MMP 
inhibitor.  (A) MMP9 negative cells (LLC-RSV) cytotoxicity of paclitaxel (PXL, 
solid), cleaved prodrug (PXL-AVRW, vertical stripes), prodrug (PXL-Pep-
Dendron, boxes) and Prodrug + GM6001 (horizontal stripes) in. GM6001 
enhanced the growth of cells by about 20% after 48 hours.  (B)  MMP9 positive 
cells (LLC-MMP9) cytotoxicity of paclitaxel (PXL, solid), cleaved prodrug (PXL-
AVRW, vertical stripes), prodrug (PXL-Pep-Dendron, boxes) and Prodrug + 
GM6001 (horizontal stripes) in. GM6001 reduce the growth of LLC-MMP9 cells 
by about 40% after 48 hours.   
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prodrug over the first 48 hours, however after 72 hours there is a significant 
change in the toxicity between the two compounds (see Appendix A for statistical 
analysis).  This supports the hypothesis that PXL-AVRW either needs extra time 
to enter the cell and interact with the microtubules or further cleavage from an 
unknown protease occurs in the cellular environment.  If the latter is true, then 
this requirement would be seen in different cell lines and should not be affected 
by the MMP9 concentration in the cell.  
 To further study the in vitro effects of the prodrug on MMP9, two cell lines; 
one that contains a naturally low concentration of MMP9 (LLC-RSV) and another 
transfected with a vector to express high amounts of MMP9 (LLC-MMP9) were 
studied.  As with the other two cell lines, prodrug (PXL-Pep-Dendron, 22) yielded 
the highest levels of survival (Figure 5.8).  In the MMP9 negative cell line, the 
prodrug proliferates statistically the same as the DMSO treated control cells, 
indicating no toxicity (Figure 5.8A).  In the MMP9 positive cell line, the prodrug 
has toxicity statistically equivalent to PXL and PXL-AVRW, the MMP9 digested 
product (Figure 5.8B, statistical data can be found in Appendix A).  When the 
MMP9 expressing cells are treated with GM6001 and prodrug, toxicity seen in 
cells treated with prodrug alone disappears.  This data demonstrates that 
GM6001 inhibited protease activity is necessary for the prodrug to produce 
toxicity.   
 As a further comparison, the toxicity of the prodrug with and without 
GM6001 in MMP9 expressing and non-expressing cells is shown in Figure 5.8.   
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The LLC-MMP9 cells treated with intact prodrug have an 80% reduction in cell 
growth compared to the same cell line treated coincidently with prodrug and an 
MMP inhibitor (GM6001).  The MMP9 negative cell line has the highest survival 
rate when treated with prodrug.  All indications are that PXLPep-Dendron (22) is 
non-toxic until cleaved by MMP9 and therefore should interact preferentially with 
MMP9 expressing tissues such as in tumor rather than healthy tissues (which 
generally contain low levels of MMP9). 
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Figure 5.9.  Cytotoxicity of prodrug with and without an MMP inhibitor versus 
PyVT-R221A-Luc cells (MMP9 expressing).  The data presented is the percent 
survival after 2 doses of compound over 48 hours.  All paclitaxel treated cells 
were treated with an equivalent of 50 nM paclitaxel.  The cytotoxicity is 
measured with respect to GM6001 and control.  GM6001 is a general MMP 
inhibitor.  Cytotoxicity of prodrug (solid), Prodrug + GM6001 (horizontal 
stripes) and GM6001 (Diagonal checkers) in MMP9 positive cells (LLC-MMP9) 
and prodrug (white dots), Prodrug + GM6001 (diagonal stripes) and GM6001 
(boxes) in MMP9 negative cells (LLC-RSV).  
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5.5 Conclusions 
 The MMP9 activated prodrug was synthesized by attaching a modified 
paclitaxel to the terminal amines on the H2N-Pep-Dendron scaffold and MMP9 
digestion to PXL-AVRW was confirmed.  Using prodrug (PXL-Pep-Dendron) and 
digested prodrug (PXL-AVRW) cellular toxicity studies were completed to 
demonstrate the utility of the prodrug.  The intact prodrug was shown to be toxic 
in cell lines that express MMP9 and have reduced toxicity in cell lines that are 
MMP9 negative.  The broad spectrum MMP inhibitor, GM6001, diminished the 
cytotoxicity of PXL-Pep-Dendron versus the MMP9 expressing cell line PyVT-
R221A-Luc and LLC-MMP9.  The compound was significantly less effective 
versus LLC-RSV as compared with LLC-MMP9 cells (e.g. blocking the MMP9 in 
PyVT-R221A-Luc and LLC-MMP9 cells significantly reduced the toxicity of the 
prodrug).  These data are consistent with the interpreted data, showing that 
MMP9 expression is necessary for toxicity and the drug has limited toxicity under 
the conditions tested until activated by MMP9.  The progress described in this 
dissertation places the project in a position to test the in vivo efficacy of the 
prodrug in animals, leading to the eventual translation into use in humans. 
 
5.7 Experimental Procedures 
 
General Methods: 
 MDA-MB-231 cells were purchased from ATCC and cultured in DMEM, 
10% FBS and gentamycin with 5% CO2.  PyVT-R221A-Luc cells were obtained 
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from the Matrisian laboratory and cultured in DMEM without L-glutamine, 10% 
FBS, gentamycin and puromycin with 5% CO2.  LLC-RSV and LLC-MMP9 cells 
were obtained from the Matrisian laboratory and cultured in DMEM, 10% FBS 
and gentamycin with 5% CO2.  The custom ordered peptides were purchased 
from Genscript™.  The enzymes were purchased from Calbiochem.  All other 
chemicals were purchased from Fisher Scientific or Aldrich Chemical companies 
and used as is unless otherwise indicated.   
 
(2a,4a,5ß,7ß,10ß,13a)-4,10-bis(acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-
oxobutanoic acid-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-
epoxytax-11-en-2-yl benzoate (PXL-COOH): 
  
 This compound was made as described in 101.  Briefly, paclitaxel (77.61 
mg, 0.091 mmols) was dissolved in methylene chloride (6 mL).  Succinic 
anhydride (13.1 mg, 0.131 mmols) in 0.8 mL of methylene chloride was added 
followed by pyridine (27 μl).  The reaction was stirred for 4 days.  TLC (1:1 
hexanes: ethyl acetate on silica gel) indicated 4 spots under a UV lamp and with 
potassium permanganate staining.  Staining with bromo-cresol green indicated 
that the carboxylic acid was the last spot.  The reaction was concentrated onto 
silica gel and purified with the Biotage™ SP1 system using a hexane/ 
ethylacetate gradiant followed by flushing with methanol to elute the product.  
After concentration the last peak eluted was 84.5 mg (97%) of desired product as 
confirmed by MS.  MS (ESI)+ Found: 954.30 Dalton (M + H)+; calculated: 954.99 
Da. (C51H56NO17). 
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PXL-Pep-Dendron (22): 
 All glassware used in the reaction was flame dried and cooled in a 
desiccator prior to use.  The solvents were anhydrous and all solid materials 
were dried under vacuum for more than 3 hours prior to use and exposed to 
anhydrous Ar(g) gas upon breaking the vacuum seal.  First, PXL-COOH (8.51 
mg, 0.0091 mmols) was dissolved in 0.5 mL DMF.  Next, EDCI (5.00 mg, 0.026 
mmols) and BOP (5 mg, 0.011 mmols) were added to the PXL-COOH solution 
followed by DIEA (180 μl).  The reaction was stirred for 30 minutes prior to 
adding H2N-Pep-Gly-Dendron (3.56 mg, 0.00068 mmols), dissolved in 0.5 mL 
DMF.  The reaction was stirred under Ar(g) overnight with SEC spectra taken 5 
minutes after H2N-Pep-Gly-Dendron addition and after 15 hours.  A notable 
change in the elution time of the first peak indicated coupling occurred.  The 
reaction was concentrated under vacuum, and dissolved in DMSO.  The product 
was purified by first using Amicon Centrifugation Diafiltration tubes (3,000 
MWCO) to concentrate the high molecular weight compounds followed by three 
washings with DMSO to remove all the low molecular weight compounds.  The 
remaining high molecular weight compounds were separated using SEC to 
provide 5.13 mg (85%) of pure (PXL-Pep)4-Gly-Dendron.  MADLI-TOF MS 
(CHCA) Found 2,121 Dalton (Fragment: PXL-[Ahx]-AVRWLLTA-[Ahx]-Gly + H)+; 
calculated 2,119 Dalton (C108H148N16O28); Found 4,409 Dalton (Fragment: (PXL-
[Ahx]-AVRWLLTA-[Ahx]-Gly)4-Dendron/4 + H)+; calculated 4,408 Dalton 
(C447H609N64O121).  SEC (55% 0.05% TFA in Acetonitrile/ 45% 0.065% TFA in 
water) elution time 7.7 minutes. 
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Cleavage of Peptide compounds with Enzymes: 
 The compound to be cleaved or tested for ability to cleave was dissolved 
in methanol at 10 mg/mL.  Next, 100 μl of this solution was diluted with 900 μl of 
tricine buffer to make a 1 mg/mL solution.  A 10 μL aliquot of solution was 
injected into the HPLC (C18 silica with 55% 0.05% TFA in Acetonitrile/ 45% 
0.065% TFA in water) for a zero time point.  Following HPLC, enzyme (either 
MMP9, MMP2 or Trypsin) was added to the reagent solution and the reaction 
mixture was incubated at 37 οC overnight.  Again, analytical HPLC was used to 
determine what percentage of the sample had cleaved.  For samples which 
produced solid, the solid was collected, dissolved in 100% methanol and injected 
into the HPLC.  The samples were then characterized with ESI and MALDI-TOF 
MS to determine the cleavage products.  The solid usually contained the cleaved 
product. 
 
 
 
Toxicity studies 
 Cells were plated at 40,000 – 60,000 cells/mL into 24 well plates (0.5 
mL/well) in appropriate culture medium.  A separate plated was used for each 
time point measured in the assay (i.e. four plates were used to measure 4 time 
points).  The cells were incubated overnight at 37 οC (usually 24 hours).  After 
examination under the microscope to ensure the cells were attached and looked 
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healthy, the media was aspirated off each well (taking care to not disrupt the 
cells) and replaced with media containing the drug/ compound of interest or a 
control compound.  The drug and control solutions were made fresh just prior to 
use.  The cells were incubated 24 hours and then either redosed with fresh drug-
media solutions or the cells were trypsinized and counted using trypan blue.  For 
typsinization, the media was removed by aspiration and each well was washed 
with 0.5 mL of DPBS.  The DPBS was removed and each well was treated with 
200 μl of trypsin.  The plate was incubated for 10 - 15 minutes and then agitated, 
either with a shaker or by hand.  Finally, 40 μl of trypan blue was added to each 
well (typically 4 wells at a time) and the cells were counted with a 
hemocytometer.  The dosing and counting was continued for the remaining time 
points so that the cells were given fresh drug every 24 hours until counted.      
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CHAPTER VI 
 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 The research presented in this dissertation was intended to aid in 
advancing medical research by improving on molecular imaging and therapeutic 
delivery through the use of functionalized dendrimeric particles.  Two projects: 
one developing TSPO targeted imaging agents and the other an MMP9 
activatable prodrug was developed simultaneously that have several 
commonalities.  These commonalities include: 1) the development of dendrimeric 
particles for biological purposes, 2) the functionalization of a dendrimer or 
dendron and 3) the use of targeting biomarkers to specifically delivery the 
dendrimeric particles to diseased cells.  
The work in Chapter 2 was an expansion of previous work performed in 
the Bornhop laboratory that focused on developing new imaging agents for 
targeting TSPO.   The project was transitioned from small molecules that can 
incorporate only a single imaging agent (and thus only a single imaging modality) 
per targeting ligand to a multifunctional, polyvalent species that incorporates 
multiple imaging/targeting modalities.  Here, a G(4)-PAMAM dendrimer scaffold 
was modified to target TSPO and produce fluorescence and MRI signals on 
mitochondria of high TSPO expressing cells.  Due to the desity of the gadolinium 
metal, EM imaging was investigated.  Although the treated cells produced 
increased contrast compared to controls, the contrast was due to osmium 
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staining of the dendrimers post fixation.  Regardless, the increase contrast on 
mitochondria in treated versus control cells shows that the dendrimers are 
targeting the mitochondria.   Furthermore, this is proof-of-principle that EM can 
be used to study cellular processes at the molecular level. The EM studies are 
being further explored by Madeline Dukes in Dr. Niels De Jonge’s laboratory 
along with the development of liquid STEM for live cell imaging.     
Potential clinical uses of the TSPO targeted agents go beyond diagnostic 
agents to include applications as surgical tools and therapeutic efficacy 
monitoring.  The most common cancers in which diagnostic imaging of TSPO 
expression would be useful are brain, breast, colorectal and prostate tumors 
since these cancers have been shown to have extremely high concentrations of 
the protein.  As diagnostic agents, the MR signature is useful since it can be 
detected in deep tissue and is inherently sensitive; while the fluorescence agent 
has limited use.  As surgical tools, the dual-modality of the agent is advantages 
because the fluorescence and MRI signatures can be used in conjunction.  In 
particular, brain gliomas often need to be surgically removed and it is up to the 
surgeon’s discretion as to which excised.  Removing more tissue than necessary 
can lead to un-necessary loss of brain function; while leaving cancerous tissue 
can lead to tumor regrowth.  Since gliomas (brain cancer) have high expression 
of TSPO, these dual-modal imaging dendrimers provide a method for in surgery 
cancer labeling.  The dendrimer can be administered via pre-surgical injection or 
“splashed on” the exposed tissue during surgery.  If injection is the method of 
delivery, then a pre-surgical MRI scan will reveal the location size and shape of 
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the tumor.  The sensitive fluorescence signal then differentiates which tissue (or 
cells if surgical techniques become that accurate) needs to be removed.  Post 
surgical success/failure can be monitored with the MRI agent on the dendrimer.  
The targeted MR agent is improved over the typical profusion agents for post 
surgical applications, since scar and other highly vascularized tissues produce 
increased contrast in the MRI are difficult to differentiate from re-emergence of 
the diseased tissue.  The dendrimer imaging agents can be further applied to 
progression monitoring of therapeutics in TSPO associated diseases.  During 
treatment imaging a patient’s effected tissues provides insight into whether the 
cancer is spreading (therapy completely failing), maintaining size (therapy 
stopping or slowing growth) or disappearing (therapy is being successful).  
Targeted and sensitive imaging techniques, including better imaging agents, can 
also be used to detect early signs of metastases, which can be treated promptly 
for better patient outcome.  
Although imaging to detect and follow the progression of disease and 
therapy is useful in minimizing the invasiveness of treatments.  Nanoparticles can 
also be utilized to further reduce invasiveness by incorporating therapeutics.  
Chemical therapeutics limit invasive procedures such as surgical retraction while 
targeted clinical therapeutics reduce systemic toxicity and maximize positive 
patient outcomes.  In the second project presented here, a series of MMP9 
activated therapeutic dendrons were developed, which can then be coupled with 
other dendrons to form tailor made dendrimers with the desired properties.  
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Specifically, these MMP9 activated therapeutic dendrons are designed to target 
early tumor progression and the establishment of micro-metastatic lesions.   
Rational design was implemented in developing the prodrug.  Proteolytic 
cleavage of a peptide by MMP9 was incorporated as the method for delivering 
the active drug.  Not only is MMP9 associated with early stages of tumor 
development of micro-metastatic lesions, but the peptide sequence AVRWLLTA 
has been shown to be specifically cleaved by the enzyme186.  Incorporating this 
peptide into a dendron was intended to create a molecular carrying system that 
releases drug or imaging agent upon cleavage by MMP9.  The focus of the work 
presented here was to incorporate a therapeutic molecule that would be released 
and produce toxicity to MMP9 associated cells.  Initially doxorubicin (DOX) was 
investigated; however the attachment chemistry inactivated the drug.  Following 
attempts with modified DOX conjugation, paclitaxel was attached to the scaffold 
and found to be more efficacious than DOX for this system. 
Synthesizing an MMP9 cleavable therapeutic proved more of a challenge 
than initially anticipated.  First, the coupling of the cleavable peptide to the 
dendron scaffold was difficult to characterize, both in determining that attachment 
had occurred and in determining the number of peptides per dendron that 
attached.  After employing a variety of techniques including nuclear magnetic 
resonance (NMR), size exclusion chromatography (SEC) and a ninhydrin assay 
for primary amines, a matrix assisted laser desorption ionization time-of-flight 
mass spectrum (MALDI-TOF MS) of the product was finally obtained, the MALDI-
TOF spectrum definitively confirmed that four peptides had attached to the 
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dendron.  Attaching DOX to the H2N-Pep-Dendron was an easier synthetic 
expedition, but unfortunately the drug was permanently inactivated due to 
unforeseen structural changes.   
Two strategies were investigated to produce a working MMP9 activated 
prodrug molecule: a new peptide sequence that released LL-DOX (a toxic 
analogue of DOX) and attaching paclitaxel to the scaffold.  The modified peptide, 
AVRWLL, was found to not be digested by MMP9.  Nonetheless, preliminary 
cellular toxicity studies were performed on this compound with results indicating 
that these agents have some therapeutic efficacy.  During the experiments to test 
therapeutic efficacy, a sub-population of DOX resistant, rapidly proliferating cells 
formed.  More extensive investigation of these agents need to be performed to 
determine the usefulness of these agents. 
Incorporating paclitaxel (PXL) onto the H2N-Pep-Dendron in place of DOX 
was the most successful strategy for producing an MMP9 activated prodrug.  The 
attachment of PXL was simple and accomplished quickly.  The final product, 
PXL-Pep-Dendron, was tested in cells as both the intact prodrug and MMP9 
cleaved products.  The intact compound was also tested with inhibitors and in 
MMP9 positive and negative cell lines.  The inhibitors increased survival in the 
MMP9 positive cell lines, indicating that the prodrug is cleaved in vitro, leading to 
the toxic effect observed.  The combination of all the cell studies demonstrates 
that the MMP9 activated prodrug is non-toxic until activated by the protease.   
Along with an MMP9 activable prodrug, other modules are necessary to 
produce a multifunctional dendrimer.  The idea is that individual dendrons with 
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different functionalities will be coupled together to give “mix and match” 
dendrimers.  Any number of dendrons can be synthesized to give optimal 
functionality for the desired effect in treating and/or imaging any disease.  A 
complimentary dendron for the MMP9 prodrug, MMP9 activated molecular 
sensor, is being developed that produces fluorescence upon MMP9 cleavage.  
The prodrug dendron coupled with the molecular sensor dendron provides a dual 
matched MMP9 activatible dendrimers; where the sensor visualizes drug 
delivery.   Other modules that can be incorporated include: (a) an imaging agent 
to track the dendrimer location before and after delivery, (b) a targeting ligand to 
specifically bind the disease site and (c) ADME agents to tune administration, 
distribution, metabolism and excretion properties of the dendrimers.  The “mix 
and match” concept can be expanded to include a variety of drugs, imaging 
agents, sensors and ADME agents as well as to target any protease or receptor 
and treat and/or image any disease. 
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APPENDIX A 
 
 
BIOLOGICAL DATA OF MMP9 ACTIVATED PRODRUGS 
 
 
 
A.1  MMP9 Expression in Cells 
 
 To estimate the MMP9 expression of the four cell lines being used in 
toxicity studies, zymography was performed on the cell lysates and the  media.  
Briefly, zymography was performed by taking the cell media and lysates from 
confluent T75 flasks were concentrating the solutions with 3,000 MWCO 
diafiltration tubes and tested the concentrated samples with a bicinchoninic acid 
assay for total protein content.  Next, an acrylamide gel was ran using 10 μg of 
protein per well and HT1080 as a positive control.  The results of the assay were 
quantified by detection of the Pro and active MMP9 bands on the gel as 
determined by the MW marker and HT1080 positive control (Table 5.1).  As 
expected, the MMP9 content of the LLC-RSV cells was not detectable with this 
assay, indicating no enzyme present.  The LLC-MMP9 cells have a high level of 
MMP9 in the media and low levels of MMP9 in the cell lysates.  Since the 
enzyme is secreted from the cell into the surrounding area (cell media), it is 
expected to see more MMP9 in the media than the lysates.  The media 
associated with PyVT-R221A-Luc cells also contained high levels of MMP9 with 
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none being detected in the lysates.  Media from the MDA-MB-231 cells 
 
 
had only a very slight band in the gel and none was detected in the lysates.  
Overall, two cell lines, LLC-MMP9 and PyVT-R221A-Luc, were found to contain 
significant levels of MMP9.    
 
A.2 Toxicity Studies 
The results of the initial toxicity study using PyVT-R221A-Luc cells were 
encouraging with the intact molecule being less toxic than the MMP9 cleaved 
product (Figure 5.4).  The MMP9 cleaved compound also displayed toxicity 
similar to PXL-COOH and PXL after 72 and 96 hours (3 and 4 doses). One dose 
Table A.1 MMP9 expression levels in the cells lines of interest. 
Cell Line MMP9 Detection Level 
LLC-RSV Lysates Not Detectable 
LLC-RSV Media Not Detectable 
LLC-MMP9 Lysates Low Levels 
LLC-MMP9 Media High Levels 
PyVT-R221A-Luf Lysates Not Detectable 
PyVT-R221A-Luf Media High Levels 
MDA-MB-231 Lysates Not Detectable 
MDA-MB-231 Media Barely Detectable 
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Figure A.1 Survival of Paclitaxel (PXL).  Top % Survival versus Time at 5 μM, 
1 υM, 500 nM, 50 nM, 5 nM and 1 nM .  Bottom: % Survival versus Time at 
24, 48, 72 and 96 hours in PyVT-R221A-Luf cells.   
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of PXL-Pep-Dendron (22) did not produce much toxicity in either the cleaved or 
intact molecules (Figure 5.4).  A dramatic change in toxicity between the intact 
and cleaved PXL-Pep-Dendron (22) was seen between 24 and 48 hours after the 
first dose, when the cleaved molecule went from 109% of cells surviving 
compared to control at 24 hours (1 dose) to 44% at 48 hours (2 doses).  Further 
studies were performed to 1) determine the difference in survival between the 
intact and cleaved PXL-Pep-Dendrons (22), 2) optimize the dosing range and 
time, 3) study the effect of an MMP inhibitor on the survival of cells treated with 
the intact prodrug, 4) study the affect of the prodrug in a human cell line and 5) 
study the effect of the drug (cleaved and intact) in MMP9 positive and null cell 
lines.   
 The complete toxicity studies included testing PXL, PXL-COOH and intact 
and cleaved PXL-Pep-Dendron (22) with 4 doses (over 96 hours) at 
concentrations from 1 nM to 5 μM in PXL.  As shown in Figure A.1, PXL is toxic 
at the higher concentrations tested: 5 μM, 1 μM, 500 nM and 50 nM after 96 
hours; but the 5 and 1 nM doses were effective against the PyVT-R221A-Luc 
cells only after 48 hours followed by proliferation at 72 and 96 hours.  The 
proliferation at later doses (72 & 96 hour) could be due to ineffective technique 
when running the assay or to the development of PXL resistant cells.  One dose 
of drug has the least effect on the cells, but still culminates in 50% survival of the 
cells treated with 5 μM.        
As illustrated in Figure A.2, after two doses it is evident that there is an 
overall lower survival than the other time points.  Possibilities for this observation 
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Figure A.2 Survival of Paclitaxel (PXL-COOH).  Top % Survival versus Time at 
5 υM, 1 υM, 500 nM, 50 nM, 5 nM and 1 nM .  Bottom: % Survival versus 
Time at 24, 48, 72 and 96 hours in PyVT-R221A-Luf cells. 
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are that there was a technique error at this point or the cells have some PXL 
resistance that is overcome after 48 hours and the sub-culture of cells begins to 
proliferate.  Repeating this experiment and trying to culture the potential sub-
culture would conclude which possibility is occurring here.  Doses 3 and 4 look 
promising, with only three doses, of drug needed to produce a toxic effect equal 
to PXL.   At high concentrations 3 or 4 doses are equally as toxic. 
 The PXL-COOH toxicity indicate that there is little difference between the 
native drug (PXL) and the modified drug (PXL-COOH) when comparing Figure 
5.5 to 5.6.  Again, the cells dosed with the lower concentrations (5 and 1 nM) 
have a low survival rate at 48 hours and promptly make a come back after 72 
and 96 hours.  The highest three concentrations (5 μM, 1 μM and 500 nM) all 
produce a survival rate of 10% or below after 72 hours, which continues to the 96 
hour (4 Doses) data.  Over the number of doses given, the results follow a basic 
trend.  When only one dose is given, there is a 60 – 80 % survival rate of cells, 
depending on the concentration given to the cells.  Once 2 doses are given, that 
survival rate drops to 20 – 30 % of cells.  At 3 and 4 doses the survival rate is 
more concentration dependent, with 1 and 5 nM concentrations having a survival 
rate of 80 – 110%.  These points reflect the increased survival after 48 hours in 
the other graph (Figure 5.5 Top).  After the two low concentrations, the 50 nM 
dose has a survival of 25 and 40 % for 3 and 4 doses respectively.  Then, the 
higher concentrations of drug behave as expected and produce a mere 10% 
survival rate of cells after either 72 or 96 hours.    
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After looking at the toxicity data for PXL and PXL-COOH in PyVT-R221A-
Luc cells, the data of the prodrug was analyzed (Figures A.1 and A.2).  First, the 
intact PXL-Pep-Dendron (22) was graphed.  From the percent survival versus 
time graph (Figure A.3, Top), the intact PXL-Pep-Dendron (22) has a 30 – 40 % 
survival after 96 hours (4 Doses) at higher concentrations of drug (5 μM, 1 μM, 
500 nM and 50 nM).  Compared to the approximate 10% survival that was 
observed after 72 and 96 hours for PXL and PXL-COOH at these concentrations, 
it appears that the intact PXL-Pep-Dendron (22) is less toxic, as desired for the 
development of the prodrug.  
 Analyzing that data from the percent survival versus concentration graph 
(Figure A.3, Bottom), it is clear that at high concentrations of intact PXL-Pep-
Dendron (22) more doses is more efficacious.  At a 500 nM concentration, 1 and 
2 doses appear to have the same or better efficacy as subsequent doses.  At 
lower concentrations, the survival rate ranges from 80 % for one dose to 35 % for 
4 doses, indicating that the cells can tolerate a low dose of the intact prodrug 
without much effect.  Since there are detectable levels of MMP9 in the cell line, 
there could be some cleavage that occurs in vitro.  Overall, the intact PXL-Pep-
Dendron (22) is not as toxic as the native PXL or the modified PXL-COOH.  The 
toxicity of PXL has been reduced, although not completely inactivated.  
Inactivation was also observed with DOX-Pep-Dendron (13), so next, the toxicity 
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Figure A.3 Survival of Intact PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron (22).  Top 
% Survival versus Time at 5 υM, 1 υM, 500 nM, 50 nM, 5 nM and 1 nM .  
Bottom: % Survival versus Time at 24, 48, 72 and 96 hours in PyVT-R221A-
Luf Cells. 
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Table A.2 96 Hour toxicity data of PXL, PXL-COOH, Cleaved and Intact in 
PXLPep-Dendron. 
Compound 5 μM 1 μM 500 
nM 
50 
nM 
5 nM 1 nM
PXL 8 14 18 26 89 113 
PXL-COOH 8 9 9 40 175 118 
Cleaved PXL-[Ahx]-
AVRWLLTA-[Axh]-
Dendron 
13 14 38 26 65 83 
Intact PXL-[Ahx]-
AVRWLLTA-[Axh]-
Dendron 
29 33 37 35 244 233 
 
of the cleaved PXL- Pep-Dendron (22) was studied.   
 Ideally, the cleaved PXL-Pep-Dendron (22) would have the same or better 
efficacy as PXL and PXL-COOH or at least perform better than intact PXL-Pep-
Dendron (22).  At the lower concentrations, cleaved PXL-Pep-Dendron (22) 
performs better than intact PXL-Pep-Dendron (22) with survival rates of 83 and 
65% at concentrations of 1 and 5 nM compared with 233 and 244% respectively 
for intact PXL-Pep-Dendron (22).  The PXL-COOH has survival rates of 175 and 
118 % for 5 and 1 nM concentration dosages while PXL has 113 and 89 % 
survival after 4 doses with 1 and 5 nM respectively.  As seen in all the toxicity 
data, the 1 and 5 nM counts are off due to the cells becoming immune at low 
concentrations or errors in running the assay.  Thus, the intact PXL-Pep-Dendron 
(22) compares well with that of PXL-COOH and PXL, however none of the drugs 
are efficacious at these concentrations.  Looking at higher concentrations (500 
nM and above), where PXL and PXL-COOH had survival rates of 8 -15% and 
intact PXL-Pep-Dendron (22) has survival rates of 22 – 35 %; the PXL-Pep-
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Dendron (22) had survival rates between 11 and 25 %.  Disregarding the 500 nM 
point for the cleaved dendron reduces the toxicity of the cleaved PXL-[Axh]-
AVRWLLTA-[Ahx]-Dendron to approximately that observed for the PXL and PXL-
COOH compounds.  This indicates that the cleaved prodrug is more efficient at 
killing PyVT-R221A-Luc cells than the intact.  Over the first three time points, 
intact PXL-Pep-Dendron (22) has a survival range of 27 – 89 %, cleaved PXL-
Pep-Dendron (22) a range of 18 – 95 %, PXL-COOH a range of 2 – 111 % and 
PXL a range of 5 – 111 %.  The lack of significant difference in the survival rates 
reflects the zymography results, which show PyVT-R221A-Luc cells express 
MMP9.  Therefore, even intact molecule can be cleaved by the enzyme and 
produce toxicity to the cell through the expected mechanism.  In looking at the 
data graphed as percent survival versus concentration, it’s apparent that the 
more doses given of cleaved PXL-Pep-Dendron (22), the lower the survival rate.  
Furthermore, as the concentration of dose increases, the survival rate decreases 
as desired for the activated prodrug.   
 Next, toxicity data of the intact PXL-Pep-Dendron was obtained in which 
any MMPs produced by the cells were blocked with GM6001, a general MMP 
inhibitor (Figure A.4).  Only 2 concentrations were tested for each molecule.  As 
observed in Figure A.4, treatment of GM6001 not only improves the cell survival 
for intact prodrug, but also for the cleaved prodrug.  The 
reason
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Figure A.4 Survival of Intact PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron (22).  Top 
% Survival versus Time at 5 υM, 1 υM, 500 nM, 50 nM, 5 nM and 1 nM .  
Bottom: % Survival versus Time at 24, 48, 72 and 96 hours in PyVT-R221A-
Luf Cells. 
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 for this remains a mystery and needs further investigation; however it is possible 
that since GM6001 is a general MMP9 inhibitor some other mechanism could be 
blocked that is necessary for the cleaved product to be toxic.  The other 
mechanism could include further cleavage by a different MMP or another enzyme  
(non-MMP) which is also blocked with GM6001.   
 
 
 
 
 
 Finally, endpoint analysis for the cells dosed with 5 μM of drug or prodrug 
(cleaved and intact) are graphed as a bar graph for comparison (Figure A.6).  
Although the different doses and time points show the same general trend, the 
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Figure A.5 Survival of Intact and Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx]-
Dendron (22) with 10 μM GM6001.  
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96 hour (5 μM) time point is the most pronounced.  The trends are as follows: 1) 
Intact PXL-Pep-Dendron (22) is less toxic than cleaved PXL-Pep-Dendron (22) 
by a factor of two; 2) GM6001 does not inhibit the activity of Intact PXL-Pep-
Dendron (22), but does inhibit cleaved PXL-Pep-Dendron (22); and 3) PXL-
COOH and PXL are slightly more toxic that cleaved PXL-Pep-Dendron (22).  
Overall the GM6001 inhibition data shows that PXL-Pep-Dendron (22) is working 
to some extent as a prodrug in the PyVT-R221A-Luc cells.   
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Figure A.6 Survival of Intact and Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx]-
Dendron (22) with and without 10 μM GM6001 as well as PXL-COOH and 
PXL after 4 doses (96 hours) at 5 μM concentration of compound in PyVT-
R221A-Luf Cells.   
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To further examine the potential for these prodrugs, their toxicity was 
determined in a human cell line (MDA-MB-231 breast cancer).  The studies were 
completed as described above, using both intact and cleaved PXL-Pep-Dendron 
(22), intact PXL-Pep-Dendron (22) with 10 μM GM6001 (a general MMP 
inhibitor), PXL-COOH and PXL at 5 μM and 50 nM concentrations.  For both 
concentrations interrogated, the intact PXL-Pep-Dendron (22) is the least toxic 
followed by compound 22 with GM6001.  Although it was not expected that 
GM6001 would be toxic to the cells, a follow-up experiment indicated that after 
48 hours (2 Doses) the survival rate was 90% while after 96 hours (4 Doses) the 
survival rate dropped to 68%.  As seen in Figure A.6, after 48 hours there is an 
11% difference at 5 μM and a 10% difference at 50 nM between PXL-Pep-
Dendron (22) and compound 22 co-incubated with GM6001.  Not only does it 
appear that GM6001 is moderately toxic to the cells, but it also does not block 
activity of the intact prodrug.  Possibilities for this observation include the prodrug 
being toxic or there is another mechanism of cleavage occurring that is not 
related to MMPs is therefore not blocked by GM6001.  Since there was barely a 
detectable level of MMP9 in the cell media and none in the lysates, the prodrug is 
most likely not being cleaved by MMP9 to form the active cleavage product.  
Thus, the toxicity is likely due to the GM6001 or proteolytic activity by an enzyme 
other than MMP9. 
 Cleaved PXL-Pep-Dendron (22) is more toxic than intact 22 in a 
concentration dependent fashion.  At 5 μM concentrations, cleaved PXL-Pep-
Dendron (22) is 60% more toxic after 24 hours of treatment, before converging at 
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Figure A.7.  Survival of Intact PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron (22) with 
and without10 μM GM6001, Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron 
(22), PXL-COOH and PXL in MDA-MB-231 human breast cancer cells at 5 μM 
(Top) and 50 nM (Bottom) doses.   
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Figure A.8.  Survival of Intact PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron (22) 
with and without10 μM GM6001, Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx]-
Dendron (22), PXL-COOH and PXL in LLC-RSV Lewis Lung Cancer cells at 
5 μM (Top) and 50 nM (Bottom) doses.   
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about the same toxicity level after 96 hours.  At 50 nM concentration, the cleaved 
product only kills about 17% more cells than intact 22 and again by 96 hours the 
two curves merge at 5 – 10% survival.   Although this difference is not ideal, it 
provides the same trend as the PyVT-R221A-Luc cells.   
 Finally, the PXL-COOH and PXL have about the same toxicity at both 
concentrations tested and are the most toxic compounds tested in this study.  
The only exception is the 24 hour point at 50 nM dosing concentration where the 
PXL has a much lower survival rate.  This could be due to reduced toxicity with 
the modification to paclitaxel or an error in the first dosing cycle.  Overall, the 
MDA-MB-231 cells have the expected trend in which the prodrug is less toxic in 
the “inactive” form than in the “active” form.   
 To study the in vitro effect of MMP9, two last cell lines were studied: LLC-
RSV and LLC-MMP9 which contain naturally low and transfected with high 
amounts of MMP9 respectively. As with the other two cell lines, intact PXL-Pep-
Dendron (22) has the highest levels of survival (Figure A.7).  Also, again 
including GM6001 with intact 22 lowered the survival of the cells at 48 and 72 
hours.  At 24 and 96 hours 22 and 22 + GM6001 were the same for both 
concentrations, indicating that there may be some increased toxicity due to 
GM6001.  This observation was further confirmed with a follow-up study that 
showed that after 48 hours the percent survival of LLC-RSV cells treated with 
only GM6001 at 77%.  Cleaved PXL-Pep-Dendron (22) proved to be more 
efficient at killing cells after 48 and 72 hours than the intact 22 at both 
concentrations (Figure A.9).  The cleaved and intact 22 had a greater survival 
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difference with the 5 μM concentration with the 24 hour time point also offering a 
greater kill rate.  Finally, the PXL-COOH and PXL were both more efficacious at 
killing the cells than either the intact or cleaved prodrug, but not by too much for 
some time points.  Overall, intact prodrug, 22, has little effect on the cells, while 
cleaved prodrug, 22, has some effect, but not as much as native PXL or modified 
PXL-COOH.  
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Figure A.9 Survival of Intact and Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx]-
Dendron (22) with and without 10 μM GM6001 as well as PXL-COOH and 
PXL after 2 doses (48 hours) at 50 nM concentration of compound in LLC-
RSV cells.   
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Figure A.10.  Survival of Intact PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron (22) 
with and without10 μM GM6001, Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx]-
Dendron (22), PXL-COOH and PXL in LLC-MMP9 Lewis Lung Cancer cells at 
5 μM (Top) and 50 nM (Bottom) doses.  
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 Next, I studied the LLC-MMP9 cell line, which has been transfected with 
the gene for producing the enzyme and therefore has a high concentration of 
MMP9 (confirmed by the zymography).  In the LLC-MMP9 cell line, the toxicity  
 
 
 
 
 
studies reflect this high level of MMP9 and that the enzyme is necessary for 
toxicity of the prodrug.  For both concentrations tested, the least toxic (highest 
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Figure A.11 Survival of Intact and Cleaved PXL-[Ahx]-AVRWLLTA-[Ahx}-Dendron 
(22) with and without 10 μM GM6001 as well as PXL-COOH and PXL after 2 
doses (48 hours) at 50 nM concentration of compound in LLC-MMP9 cells.   
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survival rate) is intact PXL-Pep-Dendron (22) with GM6001.  Peculiarly, the PXL-
COOH also has a high survival rate in this cell line.  However, cleaved 22 
appears to have the most cell death over both concentrations tested followed by 
the native PXL.  Just slightly less toxic than the PXL is the intact PXLPep  
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Figure A.12.  Comparison of PXL-[Ahx]-AVRWLLTA-[Ahx]-Dendron (22) 
treated cells in MMP9 positive, MMP9 positive with GM6001 and MMP9 null 
cells.   
200 
Dendron (22), which presumably undergoes cleavage by MMP9 prior to inducing 
cell death.  
As a further comparison, the toxicity of the cleaved and intact prodrugs in 
the LLC-RSV and LLC-MMP9 cell lines is graphed in Figure A.11.  The LLC-
MMP9 cells treated with intact prodrug have an 80% reduction in cell grown 
compared to the same cell line treated coincidently with intact prodrug and an 
MMP inhibitor.  Finally, the MMP9 null cell line has the highest survival rate when 
treated with intact prodrug.  All indications are that PXL-Pep-Dendron (22) is 
inactive until cleaved by MMP9.   
 
A.3 Raw Data from Toxicity Studies 
 
Table A.3.  Cell count raw data from cytotoxicity experiments with DOX, Leu-
DOX, Leu-Leu-DOX, and Paclitaxel after 24 hours in PyVT-R221A-Luc cells. 
Compound & 
Concentration Well 1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average 
# Cells 
10 ug/mL DOX 1 2 0 0 0.75 1800 432
3 ug/mL DOX 4 0 0 1 1.25 3000 720
1 ug/mL DOX 1 3 0 1 1.25 3000 720
0.3 ug/mL DOX 2 1 2 1 1.5 3600 864
0.1 ug/mL DOX 2 3 2 0 1.75 4200 1008
0.3% DMSO   6 8 7 16800 4032
Media 3 2   2.5 6000 1440
15 ug/mL Leu-DOX 1 0 2 2 1.25 3000 720
10 ug/mL Leu-DOX 4 2 2 0 2 4800 1152
5 ug/mL Leu-DOX 2 2 0 0 1 2400 576
1 ug/mL Leu-DOX 4 3 2 3 3 7200 1728
0.1 ug/mL Leu DOX 1 5 1 6 3.25 7800 1872
0.3% DMSO   6 4 5 12000 2880
Media 2 5   3.5 8400 2016
15 ug/mL Leu-Leu-
DOX 0 3 3 8 3.5 8400 2016
10 ug/mL Leu-Leu-
DOX 5 4 1 1 2.75 6600 1584
201 
5 ug/mL Leu-Leu-
DOX 3 3 9 6 5.25 12600 3024
1 ug/mL Leu-Leu-
DOX 0 0 0 3 0.75 1800 432
0.1 ug/mL Leu-Leu-
DOX 3 4 1 5 3.25 7800 1872
0.3% DMSO   4 4 4 9600 2304
Media 4 4   4 9600 2304
10 ug/mL PXL 
EtOH 0 2 1 0 0.75 1800 432
10 ug/mL PXL -
COOH 
EtOH/DMSO 0 0 0 1 0.25 600 144
10 ug/mL PXL 
DMSO 1 0 1 2 1 2400 576
10 ug/mL PXL-
COOH DMSO 1 0 1 0 0.5 1200 288
0.3% EtOH 1 0 5 2 2 4800 1152
0.3% DMSO   4 3 3.5 8400 2016
Media 6 2   4 9600 2304
15 ug/mL PXL 0 1 0 1 0.5 1200 288
15 ug/mL PXL-
COOH 0 2 1 0 0.75 1800 432
0.3% DMSO 4 9 4 4 5.25 12600 3024
0.3% DMSO 2 6 6 2 4 9600 2304
Media 3 1 3 3 2.5 6000 1440
Media 4 2 3 1 2.5 6000 1440
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Table A.4 Cell count raw data from cytotoxicity experiments with DOX, Leu-DOX, 
Leu-Leu-DOX, and Paclitaxel after 48 hours in PyVT-R221A-Luc cells. 
 
 
Compound and 
Concentration 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average 
# Cells 
10 ug/mL DOX 0 0 0 0 0 0 0
3 ug/mL DOX 0 0 1 0 0.25 600 144
1 ug/mL DOX 0 0 0 1 0.25 600 144
0.3 ug/mL DOX 0 1 1 0 0.5 1200 288
0.1 ug/mL DOX 2 0 0 0 0.5 1200 288
0.3% DMSO   6 9 7.5 18000 4320
Media 9 5   7 16800 4032
15 ug/mL Leu-DOX 1 0 0 2 0.75 1800 432
10 ug/mL Leu-DOX 2 1 1 2 1.5 3600 864
5 ug/mL Leu-DOX 3 0 2 1 1.5 3600 864
1 ug/mL Leu-DOX 7 3 3 3 4 9600 2304
0.1 ug/mL Leu DOX 8 3 1 7 4.75 11400 2736
0.3% DMSO   2 1 1.5 3600 864
Media 2 2   2 4800 1152
15 ug/mL Leu-Leu-DOX 2 4 1 1 2 4800 1152
10 ug/mL Leu-Leu-DOX 1 2 5 9 4.25 10200 2448
5 ug/mL Leu-Leu-DOX 6 3 2 2 3.25 7800 1872
1 ug/mL Leu-Leu-DOX 2 1 0 1 1 2400 576
0.1 ug/mL Leu-Leu-DOX 1 7 4 0 3 7200 1728
0.3% DMSO   7 5 6 14400 3456
Media 4 8   6 14400 3456
10 ug/mL PXL EtOH 0 0 3 0 0.75 1800 432
10 ug/mL PXL -COOH 
EtOH/DMSO 1 0 3 0 1 2400 576
10 ug/mL PXL DMSO 0 1 1 0 0.5 1200 288
10 ug/mL PXL-COOH 
DMSO 2 1 2 2 1.75 4200 1008
0.3% EtOH 6 2 4 5 4.25 10200 2448
0.3% DMSO   1 3 2 4800 1152
Media 0 4   2 4800 1152
15 ug/mL PXL 1 0 1 1 0.75 1800 432
15 ug/mL PXL-COOH 0 1 0 0 0.25 600 144
0.3% DMSO 4 2 3 2 2.75 6600 1584
0.3% DMSO 6 8 1 1 4 9600 2304
Media 9 6 6 4 6.25 15000 3600
Media 2 4 2 0 2 4800 1152
203 
 
 
 
 
Table A.5 Cell count raw data from cytotoxicity experiments with DOX, Leu-DOX, 
Leu-Leu-DOX, and Paclitaxel after 72 hours in PyVT-R221A-Luc cells. 
Compound & 
Concentration 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average 
# Cells 
10 ug/mL DOX 0 0 0 0 0 0 0
3 ug/mL DOX 0 0 0 0 0 0 0
1 ug/mL DOX 0 0 0 0 0 0 0
0.3 ug/mL DOX 1 0 0 0 0.25 600 144
0.1 ug/mL DOX 0 1 0 1 0.5 1200 288
0.3% DMSO   5 3 4 9600 2304
Media 6 16   11 26400 6336
15 ug/mL Leu-DOX 0 2 0 0 0.5 1200 288
10 ug/mL Leu-DOX 1 1 1 0 0.75 1800 432
5 ug/mL Leu-DOX 1 0 3 0 1 2400 576
1 ug/mL Leu-DOX 3 4 3 3 3.25 7800 1872
0.1 ug/mL Leu DOX 4 13 3 3 5.75 13800 3312
0.3% DMSO   10 6 8 19200 4608
Media 14 9   11.5 27600 6624
15 ug/mL Leu-Leu-DOX 1 0 5 0 1.5 3600 864
10 ug/mL Leu-Leu-DOX 3 0 2 1 1.5 3600 864
5 ug/mL Leu-Leu-DOX 4 4 1 1 2.5 6000 1440
1 ug/mL Leu-Leu-DOX 3 3 0 0 1.5 3600 864
0.1 ug/mL Leu-Leu-DOX 4 3 0 0 1.75 4200 1008
0.3% DMSO   5 5 5 12000 2880
Media 6 3   4.5 10800 2592
10 ug/mL PXL EtOH 0 0 0 1 0.25 600 144
10 ug/mL PXL -COOH 
EtOH/DMSO 0 1 0 0 0.25 600 144
10 ug/mL PXL DMSO 0 0 0 0 0 0 0
10 ug/mL PXL-COOH 
DMSO 0 0 0 1 0.25 600 144
0.3% EtOH 5 3 6 4 4.5 10800 2592
0.3% DMSO   8 7 7.5 18000 4320
Media 3 4   3.5 8400 2016
15 ug/mL PXL 0 0 0 1 0.25 600 144
15 ug/mL PXL-COOH 0 0 1 0 0.25 600 144
0.3% DMSO 1 4 4 0 2.25 5400 1296
0.3% DMSO 3 4 3 2 3 7200 1728
Media 5 3 6 7 5.25 12600 3024
Media 5 3 2 6 4 9600 2304
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Table A.6 Cell count raw data from cytotoxicity experiments with DOX, Leu-DOX, 
Leu-Leu-DOX, and Paclitaxel after 96 hours in PyVT-R221A-Luc cells. 
Compound & Concentration 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL Average # Cells 
10 ug/mL DOX 0 0 0 0 0 0 0
3 ug/mL DOX 0 0 0 0 0 0 0
1 ug/mL DOX 0 0 0 0 0 0 0
0.3 ug/mL DOX 0 0 0 0 0 0 0
0.1 ug/mL DOX 0 1 0 0 0.25 600 144
0.3% DMSO   65 20 42.5 102000 24480
Media 10 34   22 52800 12672
15 ug/mL Leu-DOX 1 0 0 0 0.25 600 144
10 ug/mL Leu-DOX 1 0 0 0 0.25 600 144
5 ug/mL Leu-DOX 1 1 0 1 0.75 1800 432
1 ug/mL Leu-DOX 9 2 3 1 3.75 9000 2160
0.1 ug/mL Leu DOX 7 6 10 24 11.75 28200 6768
0.3% DMSO   21 7 14 33600 8064
Media 11 19   15 36000 8640
15 ug/mL Leu-Leu-DOX 3 5 0 1 2.25 5400 1296
10 ug/mL Leu-Leu-DOX 6 4 6 3 4.75 11400 2736
5 ug/mL Leu-Leu-DOX 5 6 5 4 5 12000 2880
1 ug/mL Leu-Leu-DOX 8 10 5 12 8.75 21000 5040
0.1 ug/mL Leu-Leu-DOX 13 8 10 4 8.75 21000 5040
0.3% DMSO   64 14 39 93600 22464
Media 24 47   35.5 85200 20448
10 ug/mL PXL EtOH 1 1 0 0 0.5 1200 288
10 ug/mL PXL -COOH 
EtOH/DMSO 0 0 1 0 0.25 600 144
10 ug/mL PXL DMSO 0 0 0 0 0 0 0
10 ug/mL PXL-COOH 
DMSO 0 0 0 0 0 0 0
0.3% EtOH 4 3 6 5 4.5 10800 2592
0.3% DMSO   21 22 21.5 51600 12384
Media 10 28   19 45600 10944
15 ug/mL PXL 1 1 0 0 0.5 1200 288
15 ug/mL PXL-COOH 0 0 0 0 0 0 0
0.3% DMSO 19 5 8 3 8.75 21000 5040
0.3% DMSO 10 8 22 1 10.25 24600 5904
Media 5 7 14 3 7.25 17400 4176
Media 13 7 17 7 11 26400 6336
 
 
 
Table A.7 Cell count raw data from cytotoxicity experiments with DOX, PXL and 
PXL-COOH after 24 hours in PyVT-R221A-Luc cells. 
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Compound & 
Concentration 
Well 
1 
Well 
2 
Well 
3 
Well 
4 
Well 
5 
Well 
6 Average 
Average 
Cells/mL 
Average 
# Cells 
Media 5 7     6 14400 3456
0.1% DMSO   14 5   9.5 22800 5472
0.1 ng/mL DOX 20 8 4 7   9.75 23400 5616
1 ng/mL DOX 12 7 4 4   6.75 16200 3888
10 ng/mL DOX 6 16 8 0.3   7.575 18180 4363.2
100 ng/mL DOX 11 7 3 2   5.75 13800 3312
1000 ng/mL DOX 3 0 1 5   2.25 5400 1296
Media 29 22     25.5 61200 14688
0.1% DMSO   25 20   22.5 54000 12960
1 ng/mL PXL 17 14 13 17   15.25 36600 8784
10 ng/mL PXL 7 8 6 7   7 16800 4032
100 ng/mL PXL 8 5 4 7   6 14400 3456
1000 ng/mL PXL 8 1 2 1   3 7200 1728
10 ug/mL PXT 4 6 0 0   2.5 6000 1440
Media 20 36     28 67200 16128
0.1% DMSO   25 6   15.5 37200 8928
1 ng/mL PXL-
COOH 44 11 17 13   21.25 51000 12240
10 ng/mL PXL-
COOH 18 17 12 24   17.75 42600 10224
100 ng/mL PXL-
COOH 4 5 4 2   3.75 9000 2160
1000 ng/mL PXL-
COOH 6 4 2 2   3.5 8400 2016
10 ug/mL PXL-
COOH 7 1 1 0   2.25 5400 1296
Media 13 29 18 14 15 14 17.16667 41200 9888
Media 16 13 24 12 22 34 20.16667 48400 11616
0.1% DMSO 19 19 11 9 6 10 12.33333 29600 7104
0.1% DMSO 6 8 8 6 9 9 7.666667 18400 4416
 
 
 
Table A.8 Cell count raw data from cytotoxicity experiments with DOX, PXL and 
PXL-COOH after 48 hours in PyVT-R221A-Luc cells. 
Compound & 
Concentration 
Well 
1 
Well 
2 
Well 
3 
Well 
4 
Well 
5 
Well 
6 Average 
Average 
Cells/mL
Average 
# Cells 
Media 39 19     29 69600 16704
0.1% DMSO   30 53   41.5 99600 23904
0.1 ng/mL DOX 31 41 22 53   36.75 88200 21168
1 ng/mL DOX 26 18 33 38   28.75 69000 16560
10 ng/mL DOX 39 12 15 17   20.75 49800 11952
100 ng/mL DOX 6 5 7 6   6 14400 3456
1000 ng/mL DOX 0 0 0 1   0.25 600 144
Media 30 29     29.5 70800 16992
0.1% DMSO   58 13   35.5 85200 20448
1 ng/mL PXL 54 17 40 8   29.75 71400 17136
10 ng/mL PXL 19 35 19 3   19 45600 10944
206 
100 ng/mL PXL 4 6 5 2   4.25 10200 2448
1000 ng/mL PXL 6 5 1 1   3.25 7800 1872
10 ug/mL PXT 6 3 4 3   4 9600 2304
Media 29 38     33.5 80400 19296
0.1% DMSO   54 22   38 91200 21888
1 ng/mL PXL-COOH 36 38 43 46   40.75 97800 23472
10 ng/mL PXL-COOH 20 19 26 20   21.25 51000 12240
100 ng/mL PXL-
COOH 11 7 4 2   6 14400 3456
1000 ng/mL PXL-
COOH 8 7 1 6   5.5 13200 3168
10 ug/mL PXL-COOH 1 2 5 1   2.25 5400 1296
Media 27 31 24 21 12 20 22.5 54000 12960
Media 28 33 50 25 24 13 28.83333 69200 16608
0.1% DMSO 36 44 44 26 20 15 30.83333 74000 17760
0.1% DMSO 25 55 21 10 13 6 21.66667 52000 12480
 
 
 
Table A.9 Cell count raw data from cytotoxicity experiments with DOX, PXL and 
PXL-COOH after 72 hours in PyVT-R221A-Luc cells. 
Compound & 
Concentration 
Well 
1 
Well 
2 
Well 
3 
Well 
4 
Well 
5 
Well 
6 Average 
Average 
Cells/mL
Average 
# Cells 
Media 99 194     146.5 351600 84384
0.1% DMSO   97 43   70 168000 40320
0.1 ng/mL DOX 86 57 23 48   53.5 128400 30816
1 ng/mL DOX 44 81 36 18   44.75 107400 25776
10 ng/mL DOX 26 13 22 4   16.25 39000 9360
100 ng/mL DOX 3 3 2 2   2.5 6000 1440
1000 ng/mL DOX 0 0 0 0   0 0 0
Media 97 99     98 235200 56448
0.1% DMSO   70 13   41.5 99600 23904
1 ng/mL PXL 57 50 22 25   38.5 92400 22176
10 ng/mL PXL 2 12 7 1   5.5 13200 3168
100 ng/mL PXL 1 4 4 0   2.25 5400 1296
1000 ng/mL PXL 1 4 2 3   2.5 6000 1440
10 ug/mL PXT 1 3 0 1   1.25 3000 720
Media 88 249     168.5 404400 97056
0.1% DMSO   49 93   71 170400 40896
1 ng/mL PXL-COOH 57 69 38 27   47.75 114600 27504
10 ng/mL PXL-COOH 37 32 25 21   28.75 69000 16560
100 ng/mL PXL-
COOH 2 1 1 2   1.5 3600 864
1000 ng/mL PXL-
COOH 6 1 5 8   5 12000 2880
10 ug/mL PXL-COOH 4 1 5 4   3.5 8400 2016
Media 136 80 259 92 247 203 169.5 406800 97632
Media 42 79 34 18 18 9 33.33333 80000 19200
0.1% DMSO 15 34 45 78 124 17 52.16667 125200 30048
207 
0.1% DMSO 22 43 27 68 13 23 32.66667 78400 18816
 
 
 
 
 
 
 
Table A.10 Cell count raw data from cytotoxicity experiments with DOX, PXL and 
PXL-COOH after 96 hours in PyVT-R221A-Luc cells. 
Compound & 
Concentration 
Well 
1
Well 
2
Well 
3 
We
ll 4 
Well 
5 
Well 
6 
Averag
e Average Cells/mL 
Media 36 25     30.5 73200 
0.1% DMSO   42 21   31.5 75600 
0.1 ng/mL DOX 72 52 116 9   62.25 149400 
1 ng/mL DOX 56 102 36 2   49 117600 
10 ng/mL DOX 18 15 14 0   11.75 28200 
100 ng/mL DOX 3 2 1 0   1.5 3600 
1000 ng/mL DOX 0 0 0 0   0 0 
Media 61 69     65 156000 
0.1% DMSO   40 27   33.5 80400 
1 ng/mL PXL 36 24 28 17   26.25 63000 
10 ng/mL PXL 16 12 5 3   9 21600 
100 ng/mL PXL 7 0 1 2   2.5 6000 
1000 ng/mL PXL 2 1 0 0   0.75 1800 
10 ug/mL PXT 1 1 0 0   0.5 1200 
Media 33 45     39 93600 
0.1% DMSO   31 13   22 52800 
1 ng/mL PXL-COOH 21 23 14 11   17.25 41400 
10 ng/mL PXL-COOH 65 24 11 11   27.75 66600 
100 ng/mL PXL-
COOH 1 4 0 1   1.5 3600 
1000 ng/mL PXL-
COOH 5 1 1 0   1.75 4200 
10 ug/mL PXL-COOH 0 0 0 0   0 0 
Media 21 11 16 7 16 33
17.333
33 41600 
Media 32 22 27 18 14 12
20.833
33 50000 
0.1% DMSO 49 19 30 16 27 15 26 62400 
0.1% DMSO 23 32 26 11 22 17
21.833
33 52400 
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Table A.11 Cell count raw data from cytotoxicity experiments with preliminary 
PXL Prodrug compounds. 
 
 
 
 
 
 
 
 
Table A.12 Cell count raw data from cytotoxicity experiments with PXL Prodrug 
compounds after 24 hours in PyVT-R221A-Luc cells.. 
24 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average 
# Cells 
24 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average 
# Cells 
PXL-AVRW 7 12 9 10 9.5 114000 57000 
PXL-Pep-Dendron 14 9 6 13 10.5 126000 63000 
PXL-COOH 6 2 6 7 5.25 63000 31500 
PXL 4 5 4 5 4.5 54000 27000 
0.1% DMSO/ 1% MeOH 11 5 11 8 8.75 105000 52500 
Media 3 11 11 7 8 96000 48000 
48 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4    
PXL-AVRW 7 5 3 5 5 60000 30000 
PXL-Pep-Dendron 11 8 9 15 10.75 129000 64500 
PXL-COOH 0 6 5 4 3.75 45000 22500 
PXL 3 2 2 5 3 36000 18000 
0.1% DMSO/ 1% MeOH 15 13 7 11 11.5 138000 69000 
Media 6 17 18 18 14.75 177000 88500 
72 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4    
PXL-AVRW 2 5 5 5 4.25 51000 25500 
PXL-Pep-Dendron 7 6 15 13 10.25 123000 61500 
PXL-COOH 3 3 1 3 2.5 30000 15000 
PXL 2 0 1 4 1.75 21000 10500 
0.1% DMSO/ 1% MeOH 9 15 31 36 22.75 273000 136500 
Media 27 14 18 21 20 240000 120000 
209 
5 μM PXL-Pep-Dendron  14 29 13 11 16.75 40200 20100
1 μM PXL-Pep-Dendron  17 14 26 3 15 36000 18000
500 nM PXL-Pep-Dendron  9 6 6 15 9 21600 10800
50 nM PXL-Pep-Dendron 24 9 15 14 15.5 37200 18600
5 nM PXL-Pep-Dendron  16 13 23 24 19 45600 22800
1 nM PXL-Pep-Dendron  11 9 17 4 10.25 24600 12300
5 μM PXL-AVRW 10 15 5 7 9.25 22200 11100
1 μM PXL-AVRW 12 9 6 12 9.75 23400 11700
500 nM PXL-AVRW 19 18 22 6 16.25 39000 19500
50 nM PXL-AVRW 16 25 22 15 19.5 46800 23400
5 nM PXL-AVRW 30 25 20 10 21.25 51000 25500
1 nM PXL-AVRW 4 19 17 4 11 26400 13200
5 μM PXL-Pep -Dendron & GM6001 21 19 14 24 19.5 46800 23400
50 nM PXL-Pep-Dendron & GM6001 24 31 20 21 24 57600 28800
5 μM PXL-AVRW & GM6001 20 27 10 12 17.25 41400 20700
50 nM PXL-AVRW & GM6001 32 27 17 30 26.5 63600 31800
DMSO/ Media 30 42 23 17 28 67200 33600
Media 14 34 27 6 20.25 48600 24300
5 μM PXL-COOH 22 12 12 11 14.25 34200 17100
1 μM PXL-COOH 23 21 16 14 18.5 44400 22200
500 nM PXL-COOH 23 15 14 12 16 38400 19200
50 nM PXL-COOH 20 22 15 15 18 43200 21600
5 nM PXL-COOH 21 19 18 28 21.5 51600 25800
1 nM PXL-COOH 26 28 31 25 27.5 66000 33000
5 μM PXL 18 13 13 12 14 33600 16800
1 μM PXL 13 5 8 9 8.75 21000 10500
500 nM PXL 11 15 15 16 14.25 34200 17100
50 nM PXL 14 11 12 14 12.75 30600 15300
5 nM PXL 20 31 34 26 27.75 66600 33300
1 nM PXL 31 24 23 24 25.5 61200 30600
DMSO/Media 39 29 20 18 26.5 63600 31800
Media 32 42 35 37 36.5 87600 43800
DMSO/Media 24 14 23 19 28.16667 67600 33800
DMSO/Media 27 29 41 30    
DMSO/Media 24 22 34 17    
Media 36 34 33 24 31.83333 76400 38200
Media 31 33 35 34    
Media 29 28 34 31    
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Table A.13 Cell count raw data from cytotoxicity experiments with PXL Prodrug 
compounds after 48 hours in PyVT-R221A-Luc cells.. 
48 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average 
# Cells 
5 μM PXL-Pep-Dendron  22 21 13 13 17.25 41400 20700
1 μM PXL-Pep-Dendron  23 19 22 17 20.25 48600 24300
500 nM PXL-Pep-Dendron  11 5 7 9 8 19200 9600
50 nM PXL-Pep-Dendron 20 26 18 14 19.5 46800 23400
5 nM PXL-Pep-Dendron  23 16 7 18 16 38400 19200
1 nM PXL-Pep-Dendron  12 11 15 10 12 28800 14400
5 μM PXL-AVRW        
1 μM PXL-AVRW        
500 nM PXL-AVRW 17 13 16 17 15.75 37800 18900
50 nM PXL-AVRW 14 11 9 12 11.5 27600 13800
5 nM PXL-AVRW 10 10 11 13 11 26400 13200
1 nM PXL-AVRW 17 18 23 19 19.25 46200 23100
5 μM PXL-Pep -Dendron & GM6001 36 37 32 16 30.25 72600 36300
50 nM PXL-Pep-Dendron & GM6001 23 22 22 21 22 52800 26400
5 μM PXL-AVRW & GM6001        
50 nM PXL-AVRW & GM6001        
DMSO/ Media 21  18 24 15.75 37800 18900
Media 23 17 36 19 23.75 57000 28500
5 μM PXL-COOH 27 27 23 37 28.5 68400 34200
1 μM PXL-COOH 30 35 25 16 26.5 63600 31800
500 nM PXL-COOH 38 34 44 26 35.5 85200 42600
50 nM PXL-COOH 49 29 32 34 36 86400 43200
5 nM PXL-COOH        
1 nM PXL-COOH        
5 μM PXL 11 7 9 10 9.25 22200 11100
1 μM PXL 7 5 1 8 5.25 12600 6300
500 nM PXL 9 8 11 8 9 21600 10800
50 nM PXL 10 7 6 6 7.25 17400 8700
5 nM PXL 6 9 10 13 9.5 22800 11400
1 nM PXL 10 12 13 8 10.75 25800 12900
DMSO/Media        
Media        
DMSO/Media 5 6 4 2 4.25 10200 5100
DMSO/Media 4 0 3 1 2 4800 2400
DMSO/Media 3 4 2 3 3 7200 3600
211 
Media 8 8 8 6 7.5 18000 9000
Media 11 9 10 10 10 24000 12000
Media 11 7 9 8 8.75 21000 10500
 
 
 
Table A.14 Cell count raw data from cytotoxicity experiments with PXL Prodrug 
compounds after 72 hours in PyVT-R221A-Luc cells. 
72 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average 
# Cells 
5 μM PXL-Pep-Dendron  17 14 13 15 14.75 35400 17700
1 μM PXL-Pep-Dendron  17 14 20 15 16.5 39600 19800
500 nM PXL-Pep-Dendron  22 20 20 19 20.25 48600 24300
50 nM PXL-Pep-Dendron 20 18 23 21 20.5 49200 24600
5 nM PXL-Pep-Dendron  36 9.75 23 23 22.9375 55050 27525
1 nM PXL-Pep-Dendron  27 21 24 25 24.25 58200 29100
5 μM PXL-AVRW        
1 μM PXL-AVRW        
500 nM PXL-AVRW 12 10 11 8 10.25 24600 12300
50 nM PXL-AVRW 13 6 7 6 8 19200 9600
5 nM PXL-AVRW 11 10 14 5 10 24000 12000
1 nM PXL-AVRW 19 18 15 17 17.25 41400 20700
5 μM PXL-Pep -Dendron & GM6001 30 28 21 11 22.5 54000 27000
50 nM PXL-Pep-Dendron & 
GM6001 
25 17 22 7
17.75 42600 21300
5 μM PXL-AVRW & GM6001        
50 nM PXL-AVRW & GM6001        
DMSO/ Media 14 14 17 15 15 36000 18000
Media 22 23 21 20 21.5 51600 25800
5 μM PXL-COOH 13 16 14 14 14.25 34200 17100
1 μM PXL-COOH 23 17 18 22 20 48000 24000
500 nM PXL-COOH 51 42 55 13 40.25 96600 48300
50 nM PXL-COOH 31 26 35 2 23.5 56400 28200
5 nM PXL-COOH        
1 nM PXL-COOH        
5 μM PXL 4 2 4 4 3.5 8400 4200
1 μM PXL 5 4 6 2 4.25 10200 5100
500 nM PXL 2 1 1 1 1.25 3000 1500
50 nM PXL 11 12 6 9 9.5 22800 11400
5 nM PXL 35 32 29 20 29 69600 34800
1 nM PXL 32 33 30 25 30 72000 36000
DMSO/Media        
Media        
212 
DMSO/Media 4 5 3 2 3.5 8400 4200
DMSO/Media 3 2 3 6 3.5 8400 4200
DMSO/Media 2 5 5 8 5 12000 6000
Media 24 27 18 12 20.25 48600 24300
Media 34 34 20 24 28 67200 33600
Media 30 28 28 21 26.75 64200 32100
 
 
 
 
 
 
Table A.15 Cell count raw data from cytotoxicity experiments with PXL Prodrug 
compounds after 96 hours in PyVT-R221A-Luc cells. 
96 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average 
# Cells 
5 μM PXL-Pep-Dendron  11 10 9 8 9.5 22800 11400
1 μM PXL-Pep-Dendron  12 7 14 11 11 26400 13200
500 nM PXL-Pep-Dendron  12 10 14 9 11.25 27000 13500
50 nM PXL-Pep-Dendron 9 11 9 13 10.5 25200 12600
5 nM PXL-Pep-Dendron  72 72 81 28 63.25 151800 75900
1 nM PXL-Pep-Dendron  71 78 70 16 58.75 141000 70500
5 μM PXL-AVRW        
1 μM PXL-AVRW        
500 nM PXL-AVRW 6 5 2 3 4 9600 4800
50 nM PXL-AVRW 5 3 6 4 4.5 10800 5400
5 nM PXL-AVRW 12 6 9 5 8 19200 9600
1 nM PXL-AVRW 16 13 10 7 11.5 27600 13800
5 μM PXL-Pep -Dendron & GM6001 22 21 20 18 20.25 48600 24300
50 nM PXL-Pep-Dendron & 
GM6001 
29 25 26 23
25.75 61800 30900
5 μM PXL-AVRW & GM6001        
50 nM PXL-AVRW & GM6001        
DMSO/ Media 9 12 10 9 10 24000 12000
Media 10 8 11 6 8.75 21000 10500
5 μM PXL-COOH 5 9 7 5 6.5 15600 7800
1 μM PXL-COOH 14 10 10 9 10.75 25800 12900
500 nM PXL-COOH 105 33 50 37 56.25 135000 67500
50 nM PXL-COOH 52 37 48 29 41.5 99600 49800
5 nM PXL-COOH        
1 nM PXL-COOH        
5 μM PXL 3 4 0 2 2.25 5400 2700
1 μM PXL 4 3 2 2 2.75 6600 3300
213 
500 nM PXL 8 4 2 4 4.5 10800 5400
50 nM PXL 7 11 15 18 12.75 30600 15300
5 nM PXL 36 52 38 35 40.25 96600 48300
1 nM PXL 142 67 52 44 76.25 183000 91500
DMSO/Media        
Media        
DMSO/Media 3 3 2 2 2.5 6000 3000
DMSO/Media 6 3 5 1 3.75 9000 4500
DMSO/Media 6 6 4 7 5.75 13800 6900
Media 6 10 8 9 8.25 19800 9900
Media 31 32 26 20 27.25 65400 32700
Media 39 35 33 34 35.25 84600 42300
 
 
 
Table A.16 Cell count raw data from cytotoxicity experiments with DOX Prodrug 
compounds after 24 hours in PyVT-R221A-Luc cells. 
24 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average # 
Cells 
5 uM AVRWLL-DOX 15 12 16 16 14.75 35400 17700
50 nM AVRWLL-DOX 20 14 21 17 18 43200 21600
5 uM Dendron-AVRWLL-DOX 7 13 7 15 10.5 25200 12600
50 nM Dendron-AVRWLL-DOX 17 11 15 13 14 33600 16800
5 uM Leu-Leu-DOX 5 9 7 7 7 16800 8400
50 nM Leu-Leu-DOX 5 24 15 19 15.75 37800 18900
5 uM Leu-DOX 28 22 22 15 21.75 52200 26100
50 nM Leu-DOX 40 38 19 42 34.75 83400 41700
5 uM DOX 11 12 10 5 9.5 22800 11400
50 nM DOX 33 29 17 31 27.5 66000 33000
DMSO/Media 39 29 20 18 26.5 63600 31800
Media 32 42 35 37 36.5 87600 43800
DMSO/Media 24 14 23 19 28.16667 67600 33800
DMSO/Media 27 29 41 30    
DMSO/Media 24 22 34 17    
Media 36 34 33 24 31.83333 76400 38200
Media 31 33 35 34    
Media 29 28 34 31    
 
 
 
Table A.17 Cell count raw data from cytotoxicity experiments with DOX Prodrug 
compounds after 48 hours in PyVT-R221A-Luc cells. 
214 
48 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average # 
Cells 
5 uM AVRWLL-DOX 17 19 20 12 17 40800 20400
50 nM AVRWLL-DOX 18 16 12 16 15.5 37200 18600
5 uM Dendron-AVRWLL-DOX 7 4 12 9 8 19200 9600
50 nM Dendron-AVRWLL-DOX 19 12 16 10 14.25 34200 17100
5 uM Leu-Leu-DOX 5 5 7 9 6.5 15600 7800
50 nM Leu-Leu-DOX 7 6 8 8 7.25 17400 8700
5 uM Leu-DOX 3 5 4 3 3.75 9000 4500
50 nM Leu-DOX 8 6 5 5 6 14400 7200
5 uM DOX 0 0 0 0 0 0 0
50 nM DOX 3 2 6 2 3.25 7800 3900
DMSO/Media 46 40 41 28 38.75 93000 46500
Media 38 45 32 11 31.5 75600 37800
DMSO/Media 45 39 38 32 36.58333 87800 43900
DMSO/Media 39 44 31 32    
DMSO/Media 49 31 32 27    
Media 34 32 37 41 35.25 84600 42300
Media 40 33 31 31    
Media 30 43 35 36    
 
 
 
Table A.18 Cell count raw data from cytotoxicity experiments with DOX Prodrug 
compounds after 72 hours in PyVT-R221A-Luc cells. 
72 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average # 
Cells 
5 uM AVRWLL-DOX 28 26 26 16 24 57600 28800
50 nM AVRWLL-DOX 39 32 40 17 32 76800 38400
5 uM Dendron-AVRWLL-DOX 22 30 28 32 28 67200 33600
50 nM Dendron-AVRWLL-DOX 35 33 38 37 35.75 85800 42900
5 uM Leu-Leu-DOX 11 9 9 3 8 19200 9600
50 nM Leu-Leu-DOX 10 5 6 10 7.75 18600 9300
5 uM Leu-DOX 4 7 8 8 6.75 16200 8100
50 nM Leu-DOX 32 30 34 35 32.75 78600 39300
5 uM DOX 0 0 0 0 0 0 0
50 nM DOX 7 6 5 1 4.75 11400 5700
DMSO/Media 37 38 57 36 42 100800 50400
Media 45 46 36 33 40 96000 48000
DMSO/Media 25 52 40 41 34.66667 83200 41600
DMSO/Media 28 34 33 36    
DMSO/Media 28 30 39 30    
215 
Media 41 46 28 38 32.58333 78200 39100
Media 34 24 45 22    
Media 50 28 16 19    
 
 
 
Table A.19 Cell count raw data from cytotoxicity experiments with DOX Prodrug 
compounds after 96 hours in PyVT-R221A-Luc cells. 
96 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average # 
Cells 
5 uM AVRWLL-DOX 31 37 35 29 33 79200 39600
50 nM AVRWLL-DOX 43 43 45 35 41.5 99600 49800
5 uM Dendron-AVRWLL-DOX 35 41 41 42 39.75 95400 47700
50 nM Dendron-AVRWLL-DOX 38 32 30 36 34 81600 40800
5 uM Leu-Leu-DOX 27 25 29 23 26 62400 31200
50 nM Leu-Leu-DOX 24 22 26 26 24.5 58800 29400
        
Plate 7        
5 uM Leu-DOX 7 1 5 1 3.5 8400 4200
50 nM Leu-DOX 49 51 43 50 48.25 115800 57900
5 uM DOX 0 0 0 0 0 0 0
50 nM DOX 20 22 15 13 17.5 42000 21000
DMSO/Media 141 80 98 60 94.75 227400 113700
Media 102 76 99 42 79.75 191400 95700
        
Plate 8        
DMSO/Media 29 32 34 27 28.5 68400 34200
DMSO/Media 21 29 31 29    
DMSO/Media 39 18 25 28    
Media 33 36 28 30 28.5 68400 34200
Media 25 30 31 27    
Media 16 27 32 27    
 
 
 
Table A.20 Cell count raw data from cytotoxicity experiments with Paclitaxel 
Prodrug compounds after 24 hours in MDA-MB-231, LLC-RSV and LLC-MMP9 
cells. 
24 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average 
# Cells 
MDA-MB-231        
5 μM PXL-Pep-Dendron 11 4 10 11 9 21600 10800
50 nM PXL-Pep-Dendron 12 12 11 6 10.25 24600 12300
216 
5 μM PXL-AVRW 6 6 1 4 4.25 10200 5100
50 nM PXL-AVRW 12 11 9 9 10.25 24600 12300
5 μM PXL-Pep-Dendron & GM6001 7 7 7 8 7.25 17400 8700
50 nM PXL-Pep-Dendron & GM6001 3 3 3 1 2.5 6000 3000
5 μM PXL-COOH 8 7 4 3 5.5 13200 6600
50 nM PXL-COOH 11 9 9 5 8.5 20400 10200
5 μM PXL 6 4 5 5 5 12000 6000
50 nM PXL 3 6 3 4 4 9600 4800
0.5 % DMSO 20 13 11 10 13.5 32400 16200
Media 8 6 10 6 7.5 18000 9000
0.5% DMSO 5 5 12 7 8 19200 9600
0.5% DMSO 10 4 3 5  0 0
0.5% DMSO 11 9 12 13  0 0
Media 12 10 12 9 11.66667 28000 14000
Media 12 9 10 9  0 0
Media 16 12 13 16  0 0
LLC-RSV        
5 μM PXL-Pep-Dendron 10 8 7 5 7.5 18000 9000
50 nM PXL-Pep-Dendron 14 8 7 8 9.25 22200 11100
5 μM PXL-AVRW 5 4 2 2 3.25 7800 3900
50 nM PXL-AVRW 7 8 6 9 7.5 18000 9000
5 μM PXL-Pep-Dendron & GM6001 8 9 8 6 7.75 18600 9300
50 nM PXL-Pep-Dendron & GM6001 10 8 6 5 7.25 17400 8700
5 μM PXL-COOH 6 2 4 5 4.25 10200 5100
50 nM PXL-COOH 5 7 4  5.333333 12800 6400
5 μM PXL 6 2 2 4 3.5 8400 4200
50 nM PXL 5 6 3 2 4 9600 4800
0.5 % DMSO 11 9 8 8 9 21600 10800
Media 2 2 0 1 1.25 3000 1500
0.5% DMSO 4 3 4 4 3.333333 8000 4000
0.5% DMSO 1 3 3 0  0 0
0.5% DMSO 7 5 4 2  0 0
Media 3 2 0 4 2.666667 6400 3200
Media 6 3 8 1  0 0
Media 0 4 1 0  0 0
LLC-MMP9        
5 μM PXL-Pep-Dendron 7 9 5 3 6 14400 7200
50 nM PXL-Pep-Dendron 5 2 4 4 3.75 9000 4500
5 μM PXL-AVRW 2 4 2 2 2.5 6000 3000
50 nM PXL-AVRW 3 1 3 2 2.25 5400 2700
217 
5 μM PXL-Pep-Dendron & GM6001 13 5 9 3 7.5 18000 9000
50 nM PXL-Pep-Dendron & GM6001 3 2 5 8 4.5 10800 5400
5 μM PXL-COOH 5 6 3 2 4 9600 4800
50 nM PXL-COOH 4 6 5 4 4.75 11400 5700
5 μM PXL 6 3 6 5 5 12000 6000
50 nM PXL 5 4 5 2 4 9600 4800
0.5% DMSO 14 7 3 7 7.75 18600 9300
Media 1 3 7 1 3 7200 3600
0.5% DMSO 4 3 4 3 3.5 8400 4200
0.5% DMSO 6 2 3 3  0 0
0.5% DMSO 5 4 2 3  0 0
Media 4 4 2 3 4.916667 11800 5900
Media 5 4 4 3  0 0
Media 10 6 6 8  0 0
 
 
 
 
Table A.21 Cell count raw data from cytotoxicity experiments with Paclitaxel 
Prodrug compounds after 48 hours in MDA-MB-231, LLC-RSV and LLC-MMP9 
cells. 
48 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average 
# Cells 
MDA-MB-231        
5 μM PXL-Pep-Dendron 9 14 8 12 10.75 25800 12900
50 nM PXL-Pep-Dendron 12 15 14 9 12.5 30000 15000
5 μM PXL-AVRW 7 4 6 3 5 12000 6000
50 nM PXL-AVRW 14 8 11 10 10.75 25800 12900
5 μM PXL-Pep-Dendron & GM6001 13 9 9 4 8.75 21000 10500
50 nM PXL-Pep-Dendron & 
GM6001 
20 13 10 11
13.5 32400 16200
5 μM PXL-COOH 4 2 3 1 2.5 6000 3000
50 nM PXL-COOH 5 6 6 3 5 12000 6000
5 μM PXL 1 0 1 0 0.5 1200 600
50 nM PXL 4 3 3 3 3.25 7800 3900
0.5 % DMSO 20 21 19 18 19.5 46800 23400
Media 12 18 16 12 14.5 34800 17400
0.5% DMSO 20 22 14 18 18.83333 45200 22600
0.5% DMSO 40 18 17 3  0 0
0.5% DMSO 24 14 24 12  0 0
Media 21 11 21 12 13.66667 32800 16400
218 
Media 21 11 12 5  0 0
Media 20 12 6 12  0 0
LLC-RSV        
5 μM PXL-Pep-Dendron 13 10 10 11 11 26400 13200
50 nM PXL-Pep-Dendron 16 13 14 17 15 36000 18000
5 μM PXL-AVRW 6 4 2 3 3.75 9000 4500
50 nM PXL-AVRW 7 11 9 6 8.25 19800 9900
5 μM PXL-Pep-Dendron & GM6001 7 5 4 4 5 12000 6000
50 nM PXL-Pep-Dendron & 
GM6001 
14 9 8 9
10 24000 12000
5 μM PXL-COOH 2 2 2 3 2.25 5400 2700
50 nM PXL-COOH 0 4 4 2 2.5 6000 3000
5 μM PXL 3 3 1 1 2 4800 2400
50 nM PXL 3 1 3 2 2.25 5400 2700
0.5 % DMSO 19 8 6 2 8.75 21000 10500
Media 4 4 9 7 6 14400 7200
0.5% DMSO 20 9 14 12 13.08333 31400 15700
0.5% DMSO 14 21 4 1  0 0
0.5% DMSO 28 22 8 4  0 0
Media 6 5 7 9 6.5 15600 7800
Media 4 4 10 3  0 0
Media 11 9 5 5  0 0
LLC-MMP9        
5 μM PXL-Pep-Dendron 4 2 2 1 2.25 5400 2700
50 nM PXL-Pep-Dendron 2 0 1 1 1 2400 1200
5 μM PXL-AVRW 3 0 1 2 1.5 3600 1800
50 nM PXL-AVRW 2 2 2 3 2.25 5400 2700
5 μM PXL-Pep-Dendron & GM6001 10 5 5 4 6 14400 7200
50 nM PXL-Pep-Dendron & 
GM6001 
11 6 7 3
6.75 16200 8100
5 μM PXL-COOH 4 3 1 0 2 4800 2400
50 nM PXL-COOH 9 9 5 3 6.5 15600 7800
5 μM PXL 1 4 2 0 1.75 4200 2100
50 nM PXL 3 0 2 0 1.25 3000 1500
0.5% DMSO 2 0 0 13 3.75 9000 4500
Media 9 1 3 8 5.25 12600 6300
0.5% DMSO 5 12 5 4 7.416667 17800 8900
0.5% DMSO 12 10 7 6  0 0
0.5% DMSO 12 5 6 5  0 0
Media 8 3 4 1 3.833333 9200 4600
Media 5 2 2 5  0 0
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Media 1 2 10 3  0 0
 
 
 
Table A.22 Cell count raw data from cytotoxicity experiments with Paclitaxel 
Prodrug compounds after 72 hours in MDA-MB-231, LLC-RSV and LLC-MMP9 
cells. 
72 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL
Average 
# Cells 
MDA-MB-231        
5 μM PXL-Pep-Dendron 12 10 11 7 10 24000 12000
50 nM PXL-Pep-Dendron 19 17 16 15 16.75 40200 20100
5 μM PXL-AVRW 6 5 4 3 4.5 10800 5400
50 nM PXL-AVRW 8 8 6 5 6.75 16200 8100
5 μM PXL-Pep-Dendron & GM6001 6 7 8 7 7 16800 8400
50 nM PXL-Pep-Dendron & GM6001 7 5 7 9 7 16800 8400
5 μM PXL-COOH 2 0 1 3 1.5 3600 1800
50 nM PXL-COOH 7 5 5 6 5.75 13800 6900
5 μM PXL 2 3 1 4 2.5 6000 3000
50 nM PXL 2 6 2 1 2.75 6600 3300
0.5 % DMSO 39 31 23 25 29.5 70800 35400
Media 34 27 24 21 26.5 63600 31800
0.5% DMSO 35 38 31 14 30.08333 72200 36100
0.5% DMSO 40 39 29 10  0 0
0.5% DMSO 49 39 31 6  0 0
Media 31 9 5 7 16.5 39600 19800
Media 34 11 11 15  0 0
Media 26 29 15 5  0 0
LLC-RSV        
5 μM PXL-Pep-Dendron 3 4 4 3 3.5 8400 4200
50 nM PXL-Pep-Dendron 14 11 13 11 12.25 29400 14700
5 μM PXL-AVRW 1 1 1 1 1 2400 1200
50 nM PXL-AVRW 5 2 2 2 2.75 6600 3300
5 μM PXL-Pep-Dendron & GM6001 0 0 2 2 1 2400 1200
50 nM PXL-Pep-Dendron & GM6001 6 2 5 5 4.5 10800 5400
5 μM PXL-COOH 0 0 0 0 0 0 0
50 nM PXL-COOH 2 2 3 1 2 4800 2400
5 μM PXL 0 2 0 0 0.5 1200 600
50 nM PXL 1 1 1 1 1 2400 1200
0.5 % DMSO 29 22 26 23 25 60000 30000
Media 25 28 26 27 26.5 63600 31800
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0.5% DMSO 50 51 50 13 39.66667 95200 47600
0.5% DMSO 53 45 46 4  0 0
0.5% DMSO 58 54 41 11  0 0
Media 20 2 11 12 11.91667 28600 14300
Media 22 9 9 9  0 0
Media 15 15 10 9  0 0
LLC-MMP9        
5 μM PXL-Pep-Dendron 1 0 0 1 0.5 1200 600
50 nM PXL-Pep-Dendron 3 0 0 0 0.75 1800 900
5 μM PXL-AVRW 0 0 0 0 0 0 0
50 nM PXL-AVRW 1 1 0 1 0.75 1800 900
5 μM PXL-Pep-Dendron & GM6001 0 3 2 0 1.25 3000 1500
50 nM PXL-Pep-Dendron & GM6001 2 1 0 2 1.25 3000 1500
5 μM PXL-COOH 0 0 1 0 0.25 600 300
50 nM PXL-COOH 3 4 3 2 3 7200 3600
5 μM PXL 1 1 0 0 0.5 1200 600
50 nM PXL 2 0 0 0 0.5 1200 600
0.5% DMSO 21 9 5 4 9.75 23400 11700
Media 5 5 0 3 3.25 7800 3900
0.5% DMSO 28 24 7 3 17.91667 43000 21500
0.5% DMSO 30 21 25 1  0 0
0.5% DMSO 29 46 1 0  0 0
Media 7 7 3 1 4.833333 11600 5800
Media 25 3 0 4  0 0
Media 3 3 2 0  0 0
 
 
 
Table A.23 Cell count raw data from cytotoxicity experiments with Paclitaxel 
Prodrug compounds after 96 hours in MDA-MB-231, LLC-RSV and LLC-MMP9 
cells. 
96 Hours 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL 
Average 
# Cells 
MDA-MB-231        
5 μM PXL-Pep-Dendron 3 2 0 2 1.75 4200 2100
50 nM PXL-Pep-Dendron 5 6 7 4 5.5 13200 6600
5 μM PXL-AVRW 3 5 5 1 3.5 8400 4200
50 nM PXL-AVRW 6 3 2 1 3 7200 3600
5 μM PXL-Pep-Dendron & GM6001 3 5 2 3 3.25 7800 3900
50 nM PXL-Pep-Dendron & 
GM6001 
6 5 8 3
5.5 13200 6600
5 μM PXL-COOH 0 1 1 0 0.5 1200 600
221 
50 nM PXL-COOH 0 2 0 1 0.75 1800 900
5 μM PXL 1 0 0 1 0.5 1200 600
50 nM PXL 1 2 1 2 1.5 3600 1800
0.5 % DMSO 49 48 27 40 41 98400 49200
Media 32 29 13 12 21.5 51600 25800
0.5% DMSO 58 42 52 19 48.41667 116200 58100
0.5% DMSO 50 66 31 26  0 0
0.5% DMSO 61 65 69 42  0 0
Media 63 66 18 12 28.75 69000 34500
Media 57 18 10 18  0 0
Media 32 18 16 17  0 0
LLC-RSV        
5 μM PXL-Pep-Dendron 2 1 0 2 1.25 3000 1500
50 nM PXL-Pep-Dendron 16 12 16 17 15.25 36600 18300
5 μM PXL-AVRW 2 2 0 0 1 2400 1200
50 nM PXL-AVRW 12 10 10 10 10.5 25200 12600
5 μM PXL-Pep-Dendron & GM6001 1 0 0 0 0.25 600 300
50 nM PXL-Pep-Dendron & 
GM6001 
12 13 11 9
11.25 27000 13500
5 μM PXL-COOH 0 0 0 0 0 0 0
50 nM PXL-COOH 1 2 0 1 1 2400 1200
5 μM PXL 0 2 3 0 1.25 3000 1500
50 nM PXL 2 2 0 0 1 2400 1200
0.5 % DMSO 114 29 38 23 51 122400 61200
Media 48 54 42 29 43.25 103800 51900
0.5% DMSO 117 127 107 103 111.9167 268600 134300
0.5% DMSO 109 90 125 116  0 0
0.5% DMSO 112 140 99 98  0 0
Media 60 64 55 7 39.75 95400 47700
Media 60 64 12 9  0 0
Media 55 36 44 11  0 0
LLC-MMP9        
5 μM PXL-Pep-Dendron 0 1 0 1 0.5 1200 600
50 nM PXL-Pep-Dendron 0 0 1 2 0.75 1800 900
5 μM PXL-AVRW 0 1 0 0 0.25 600 300
50 nM PXL-AVRW 1 1 0 1 0.75 1800 900
5 μM PXL-Pep-Dendron & GM6001 0 0 0 0 0 0 0
50 nM PXL-Pep-Dendron & 
GM6001 
1 2 1 0
1 2400 1200
5 μM PXL-COOH 0 0 1 0 0.25 600 300
50 nM PXL-COOH 3 3 2 2 2.5 6000 3000
222 
5 μM PXL 0 0 0 0 0 0 0
50 nM PXL 0 0 0 0 0 0 0
0.5% DMSO 14 9 3 11 9.25 22200 11100
Media 15 6 18 11 12.5 30000 15000
0.5% DMSO 69 31 50 38 60.5 145200 72600
0.5% DMSO 78 66 63 76  0 0
0.5% DMSO 67 59 64 65  0 0
Media 38 29 9 8 20.66667 49600 24800
Media 25 14 15 13  0 0
Media 26 31 22 18  0 0
 
 
Table A.24 Cell count raw data from cytotoxicity experiments with GM6001 after 
48 and 96 hours in PyVT-R221A-Luc, MDA-MB-231, LLC-RSV and LLC-MMP9 
cells. 
PyVT 48 Hour 
Well 
1 
Well 
2 
Well 
3 
Well 
4 Average 
Average 
Cells/mL Average # Cells 
5 uM GM6001  21 38 66 41.66667 100000 50000
50 nM GM6001 64 50  30 48 115200 57600
DMSO 69 59 30 25 45.75 109800 54900
Media 51 41 44  45.33333 108800 54400
PyVT 96 Hour        
5 uM GM6001 71 74 69 74 72 172800 86400
50 nM GM6001 58 49 55 48 52.5 126000 63000
DMSO 82 75 72  76.33333 183200 91600
Media 62 83 32  59 141600 70800
MDA 48 Hour        
5 uM GM6001 40 31 24 26 30.25 72600 36300
50 nM GM6001 23 24 17 16 20 48000 24000
DMSO 42 42 30 20 33.5 80400 40200
Media 32 21 19 42 28.5 68400 34200
MDA 96 Hour        
5 uM GM6001 33 30 29 27 29.75 71400 35700
50 nM GM6001 33 32 33 31 32.25 77400 38700
DMSO 45 50 41 37 43.25 103800 51900
Media 47 40 44 39 42.5 102000 51000
LLC-RSV 48 Hour        
5 uM GM6001  38 38 26 34 81600 40800
50 nM GM6001  29 55 26 36.66667 88000 44000
DMSO  59 44 30 44.33333 106400 53200
Media 45 62  32 46.33333 111200 55600
LLC-RSV 96 Hour        
5 uM GM6001 115 133 142 141 132.75 318600 159300
50 nM GM6001  189 183 170 180.6667 433600 216800
DMSO 75 74 88 76 78.25 187800 93900
Media  165 173 139 159 381600 190800
223 
LLC-MMP9 48 Hour        
5 uM GM6001 23 17 18  19.33333 46400 23200
50 nM GM6001 44 37 43 32 39 93600 46800
DMSO 36  30 20 28.66667 68800 34400
Media 32 29 25  28.66667 68800 34400
LLC-MMP9 96 Hour        
5 uM GM6001 74 73 74 69 72.5 174000 87000
50 nM GM6001 65 62 72 65 66 158400 79200
DMSO 59 61 64 59 60.75 145800 72900
Media 85 88 81  84.66667 203200 101600
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A.4 Cytotoxicity Graphs of Cellular Data 
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Figure A.13.  Cytotoxicity versus Log Concentration (M) in PyVT-R221A-Luc 
Cells 
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Figure A.14 Cytotoxicity versus Log Concentration (M) in PyVT-R221A-Luc 
Cells after 24 Hours 
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Figure A.15 Cytotoxicity versus Log Concentration (M) in PyVT-R221A-Luc 
Cells after 48 Hours 
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Figure A.16 Cytotoxicity versus Log Concentration (M) in PyVT-R221A-Luc 
Cells after 72 Hours 
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Figure A.17 Cytotoxicity versus Log Concentration (M) in PyVT-R221A-Luc 
Cells after 96 Hours 
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Figure A.18. Bar graph of cellular cytotoxicity versus Log Concentration in 
PyVT-R221A-Luc cells after (A) 24 Hours, (B) 48 Hours, (C) 72 Hours and (D) 
96 Hours.
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Figure A.19. Bar graph of cellular cytotoxicity versus Concentration in PyVT-
R221A-Luc cells. 
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Figure A.20. Bar graph of cellular cytotoxicity versus Concentration MB-MDA-
231 cells after 48 hours. 
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Figure A.21. Bar graph of cellular cytotoxicity versus Concentration MB-MDA-
231 cells after 96 hours. 
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Figure A.22. Bar graph of cellular cytotoxicity at 5 μM in PXL MB-MDA-231 
cells over 4 time points after 96 hours 
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Figure A.23. Bar graph of cellular cytotoxicity at 5 μM in PXL LLC-RSV cells 
over 4 time points after 96 hours 
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Figure A.24. Bar graph of cellular cytotoxicity at 50 nM in PXL LLC-RSV cells 
over 4 time points over 96 hours 
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Figure A.25. Bar graph of cellular cytotoxicity at 5 μM in PXL LLC-MMP9 cells 
over 4 time points over 96 hours 
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Figure A.26. Bar graph of cellular cytotoxicity at 50 nM in PXL LLC-MMP9 
cells over 4 time points over 96 hours 
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APPENDIX B 
 
 
 
SELECTED NMR SPECTRA 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1 NMR or Acetonide-Bis-MPA (2,2,5-trimethyl-1,3-dioxane-5-
carboxylic acid). 
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Figure B.2. Expanded NMR of Acetonide-Bis-MPA (2,2,5-trimethyl-1,3-
dioxane-5-carboxylic acid).
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Figure B.3 NMR of Bis-MPA-Bn (benzyl 3-hydroxy-2-(hydroxymethyl)-2-
methylpropanoate) 
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Figure B.4. NMR of Acetonide-G(1)-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis(2,2,5-trimethyl-1,3-
dioxane-5-carboxylate). 
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Figure B.5. Expanded NMR of Acetonide-G(1)-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis(2,2,5-trimethyl-1,3-
dioxane-5-carboxylate). 
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Figure B.6. Expanded NMR of Acetonide-G(1)-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis(2,2,5-trimethyl-1,3-
dioxane-5-carboxylate). 
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Figure B.7. NMR of G(1)-Dendron-Bn (2-(benzyloxycarbonyl)-2-
methylpropane-bis(2,2,5-trimethyl-1,3-dioxane-5-carboxylate). 
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Figure B.8. NMR of G(1)-Dendron-Bn (2-(benzyloxycarbonyl)-2-
methylpropane-bis(2,2,5-trimethyl-1,3-dioxane-5-carboxylate). 
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Figure B.9.  NMR of Boc-Gly-Dendron-Bn (2-(benzyloxycarbonyl)-2-
methylpropane-1,3-diyl bis[3-(2-tert-butoxycarbonylamino acetate)-2-((2-tert-
butoxycarbonylamino acetate)-methyl)-2-methylpropanoate). 
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Figure B.10.  Expanded NMR of Boc-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-tert-
butoxycarbonylamino acetate)-2-((2-tert-butoxycarbonylamino acetate)-
methyl)-2-methylpropanoate). 
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Figure B.11.  Expanded NMR of Boc-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-tert-
butoxycarbonylamino acetate)-2-((2-tert-butoxycarbonylamino acetate)-
methyl)-2-methylpropanoate). 
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.  
 
Figure B.12.  NMR spectra of H2N-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-
((2-amino acetate)-methyl)-2-methylpropanoate).
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Figure B.13.  Expanded NMR spectra of H2N-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-
((2-amino acetate)-methyl)-2-methylpropanoate). 
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Figure B.14.  Expanded NMR spectra of H2N-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-
((2-amino acetate)-methyl)-2-methylpropanoate). 
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Figure B.15.  HSQC NMR spectra of H2N-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-((2-
amino acetate)-methyl)-2-methylpropanoate). 
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Figure B.16.  HMBC NMR spectra of H2N-Gly-Dendron-Bn (2-
(benzyloxycarbonyl)-2-methylpropane-1,3-diyl bis[3-(2-amino acetate)-2-((2-
amino acetate)-methyl)-2-methylpropanoate). 
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Figure B.17.  1H NMR of Fmoc-AVRWLLTA.  
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Figure B.18. Expanded 1H NMR of Fmoc-AVRWLLTA.  
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Figure B.19. Expanded 1H NMR of Fmoc-AVRWLLTA.  
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Figure B.20. Expanded 1H NMR of Fmoc-AVRWLLTA.  
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Figure B.21. HSQC NMR of Fmoc-AVRWLLTA.  
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Figure B.22. Expanded HSQC NMR of Fmoc-AVRWLLTA. 
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Figure B.23. Expanded HSQC NMR of Fmoc-AVRWLLTA. 
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Figure B.24. Expanded HSQC NMR of Fmoc-AVRWLLTA 
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Figure B.25. Expanded HMBC NMR of Fmoc-AVRWLLTA 
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Figure B.26. HMBC NMR of Fmoc-AVRWLLTA 
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Figure B.27. Expanded HMBC NMR of Fmoc-AVRWLLTA 
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Figure B.28. Expanded HMBC NMR of Fmoc-AVRWLLTA 
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Figure B.29. Expanded HMBC NMR of Fmoc-AVRWLLTA 
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Figure B.30 HSQC of Fmoc-Peptide-Dendron. 
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Figure B.31 Expanded HSQC of Fmoc-Peptide-Dendron 
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Figure B.32 Expanded HSQC of Fmoc-Peptide-Dendron 
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Figure B.33 HMBC of Fmoc-Peptide-Dendron 
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Figure B.34 Expanded HMBC of Fmoc-Peptide-Dendron 
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Figure B.35 Expanded HMBC of Fmoc-Peptide-Dendron 
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Figure B.36 Expanded HMBC of Fmoc-Peptide-Dendron 
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Figure B.37 Expanded HMBC of Fmoc-Peptide-Dendron 
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Figure B.38 Expanded HMBC of Fmoc-Peptide-Dendron 
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Figure B.39 HMBC & HSQC overlay of Fmoc-Peptide-Dendron. 
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Figure B.40 Expanded HMBC & HSQC overlay of Fmoc-Peptide-Dendron. 
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Figure B.41 Expanded HMBC & HSQC overlay of Fmoc-Peptide-Dendron. 
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Figure B.42 Expanded HMBC & HSQC overlay of Fmoc-Peptide-Dendron. 
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Figure B.43 Expanded HMBC & HSQC overlay of Fmoc-Peptide-Dendron. 
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Figure B.44 1H NMR of DOX-COOH (5-(3-hydroxy-2-methyl-6-(3,5,12-
trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-
hexahydrotetracen-1-yl)tetrahydro-2H-pyran-4-ylamino)-5-oxopentanoic acid). 
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Figure B.45. 13C NMR of DOX-COOH (5-(3-hydroxy-2-methyl-6-(3,5,12-
trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-
hexahydrotetracen-1-yl)tetrahydro-2H-pyran-4-ylamino)-5-oxopentanoic acid). 
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Figure B.46. 1H NMR of Leu-DOX (2-amino-N-((2S,3S,4S)-3-hydroxy-2-methyl-
6-((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-
1,2,3,4,6,11-hexahydrotetracen-1-yloxy)tetrahydro-2H-pyran-4-yl)-4-
methylpentanamide). 
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Figure B.47. 1H NMR of Leu-DOX (2-amino-N-(1-((2S,3S,4S)-3-hydroxy-2-
methyl-6-((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-
dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yloxy)tetrahydro-2H-pyran-4-
ylamino)-4-methyl-1-oxopentan-2-yl)-4-methylpentanamide) 
285 
 
Figure B.48. 1H NMR of Leu-Leu-DOX (tert-butyl 1-(1-((2S,3S,4S)-3-hydroxy-2-
methyl-6-((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-
1,2,3,4,6,11-hexahydrotetracen-1-yloxy)tetrahydro-2H-pyran-4-ylamino)-4-
methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate). 
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